<HTML><HEAD><TITLE>Gene Ontology Results</TITLE></HEAD><BODY>
<H1>Gene Ontology Enrichment Results</H1>
<A HREF="homerResults.html">Homer <i>de novo</i> Motif Enrichment Results</A><BR/>
<A HREF="knownResults.html">Known Motif Enrichment Results</A><BR/>
<H4>Text file version of complete results (i.e. open with Excel)
<UL>
<LI><A HREF="biological_process.txt">biological process</A>: Functional groupings of proteins (<A HREF="http://www.geneontology.org">Gene Ontology</A>)</LI>
<LI><A HREF="molecular_function.txt">molecular function</A>: Mechanistic actions of proteins (<A HREF="http://www.geneontology.org">Gene Ontology</A>)</LI>
<LI><A HREF="cellular_component.txt">cellular component</A>: Protein localization (<A HREF="http://www.geneontology.org">Gene Ontology</A>)</LI>
<LI><A HREF="chromosome.txt">chromosome location</A>: Genes with similar chromosome localization (<A HREF="http://www.ncbi.nlm.nih.gov/gene">NCBI Gene</A>)</LI>
<LI><A HREF="kegg.txt">KEGG pathways</A>: Groups of proteins in the same pathways (<A HREF="http://www.genome.jp/kegg/pathway.html">KEGG</A>)</LI>
<LI><A HREF="interactions.txt">protein interactions</A>: "Proteins interacting with a common protein (BIND, EcoCyc, HPRD)" (<A HREF="http://www.ncbi.nlm.nih.gov/gene">NCBI Gene</A>)</LI>
<LI><A HREF="interpro.txt">interpro domains</A>: Proteins with similar domains and features (<A HREF="http://www.ebi.ac.uk/interpro/">Interpro</A>)</LI>
<LI><A HREF="pfam.txt">pfam domains</A>: Proteins with similar domains and features (<A HREF="http://www.sanger.ac.uk/Software/Pfam/">Pfam</A>)</LI>
<LI><A HREF="smart.txt">smart domains</A>: Proteins with similar domains and features (<A HREF="http://smart.embl-heidelberg.de/">SMART</A>)</LI>
<LI><A HREF="gene3d.txt">gene3d domains</A>: Proteins with similar domains and features (<A HREF="http://cathwww.biochem.ucl.ac.uk:8080/Gene3D">Gene3D</A>)</LI>
<LI><A HREF="prosite.txt">prosite domains</A>: Proteins with similar domains and features (<A HREF="http://ca.expasy.org/prosite/">Prosite</A>)</LI>
<LI><A HREF="prints.txt">prints domains</A>: Proteins with similar domains and features (<A HREF="http://www.bioinf.manchester.ac.uk/dbbrowser/PRINTS/">PRINTS</A>)</LI>
<LI><A HREF="msigdb.txt">MSigDB lists</A>: "Genes sets for pathways, factor/miRNA target predictions, expression patterns, etc." (<A HREF="http://www.broadinstitute.org/gsea/msigdb/index.jsp">MSigDB</A>)</LI>
<LI><A HREF="biocyc.txt">BIOCYC pathways</A>: Groups of proteins in the same pathways (<A HREF="http://biocyc.org/">BIOCYC</A>)</LI>
<LI><A HREF="cosmic.txt">COSMIC cancer mutations</A>: Genes mutated in similar cancers (<A HREF="http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/">COSMIC</A>)</LI>
<LI><A HREF="gwas.txt">GWAS genes</A>: Genes mutated in similar diseases (<A HREF="http://www.genome.gov/26525384">GWAS Catalog</A>)</LI>
<LI><A HREF="lipidmaps.txt">Lipid Maps pathways</A>: Groups of proteins in the same lipid pathways (<A HREF="http://www.ncbi.nlm.nih.gov/biosystems/">Lipid Maps/Biosystems</A>)</LI>
<LI><A HREF="pathwayInteractionDB.txt">Pathway Interaction DB</A>: Groups of proteins in the same pathways (<A HREF="http://pid.nci.nih.gov/">Pathway Interaction Database</A>)</LI>
<LI><A HREF="reactome.txt">REACTOME pathways</A>: Groups of proteins in the same pathways (<A HREF="http://www.reactome.org/PathwayBrowser/">REACTOME</A>)</LI>
<LI><A HREF="smpdb.txt">SMPDB pathways</A>: Groups of proteins in the same pathways (<A HREF="http://www.smpdb.ca/">SMPDB</A>)</LI>
<LI><A HREF="wikipathways.txt">WikiPathways</A>: Groups of proteins in the same pathways (<A HREF="http://www.wikipathways.org/index.php/Special:BrowsePathwaysPage">Wikipathways</A>)</LI>
</UL>
<H2>Enriched Categories</H2>
<TABLE border="1" cellpading="0" cellspacing="0">
<TR><TH>P-value</TH><TD>ln(P)</TD><TD>Term</TD><TD>GO Tree</TD><TD>GO ID</TD><TD># of Genes in Term</TD><TD># of Target Genes in Term</TD><TD># of Total Genes</TD><TD># of Target Genes</TD><TD>Common Genes</TD></TR>
<TR><TD>4.122e-05</TD><TD>-10.10</TD><TD>Rab_BD</TD><TD>interpro domains</TD><TD>IPR010911</TD><TD>12</TD><TD>2</TD><TD>18293</TD><TD>15</TD>
<TD>MYRIP,SYTL2</TD></TR>
<TR><TD>7.227e-05</TD><TD>-9.54</TD><TD>Deregulation of Rab and Rab Effector Genes in Bladder Cancer</TD><TD>WikiPathways</TD><TD>WP2291</TD><TD>16</TD><TD>2</TD><TD>4455</TD><TD>4</TD>
<TD>MYRIP,SYTL2</TD></TR>
<TR><TD>8.474e-05</TD><TD>-9.38</TD><TD>RABBD</TD><TD>prosite domains</TD><TD>PS50916</TD><TD>12</TD><TD>2</TD><TD>11866</TD><TD>14</TD>
<TD>MYRIP,SYTL2</TD></TR>
<TR><TD>1.841e-04</TD><TD>-8.60</TD><TD>RAB27A (RAB27A, member RAS oncogene family)</TD><TD>protein interactions</TD><TD>5873</TD><TD>30</TD><TD>2</TD><TD>16036</TD><TD>11</TD>
<TD>MYRIP,SYTL2</TD></TR>
<TR><TD>2.800e-04</TD><TD>-8.18</TD><TD>PETROVA_ENDOTHELIUM_LYMPHATIC_VS_BLOOD_DN</TD><TD>MSigDB lists</TD><TD>PETROVA_ENDOTHELIUM_LYMPHATIC_VS_BLOOD_DN</TD><TD>156</TD><TD>3</TD><TD>17758</TD><TD>15</TD>
<TD>ALDH2,PLOD2,MECOM</TD></TR>
<TR><TD>3.149e-04</TD><TD>-8.06</TD><TD>AACTTT_UNKNOWN</TD><TD>MSigDB lists</TD><TD>AACTTT_UNKNOWN</TD><TD>1782</TD><TD>7</TD><TD>17758</TD><TD>15</TD>
<TD>COL4A5,FAM198B,CNTNAP2,TOX2,SYTL2,MECOM,NETO2</TD></TR>
<TR><TD>3.604e-04</TD><TD>-7.93</TD><TD>YAMAZAKI_TCEB3_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>YAMAZAKI_TCEB3_TARGETS_UP</TD><TD>170</TD><TD>3</TD><TD>17758</TD><TD>15</TD>
<TD>COL4A5,PLOD2,NR4A1</TD></TR>
<TR><TD>4.203e-04</TD><TD>-7.77</TD><TD>HMRNUCRECPTR</TD><TD>prints domains</TD><TD>PR01285</TD><TD>1</TD><TD>1</TD><TD>4759</TD><TD>2</TD>
<TD>NR4A1</TD></TR>
<TR><TD>4.763e-04</TD><TD>-7.65</TD><TD>GSE31082_CD4_VS_CD8_SP_THYMOCYTE_UP</TD><TD>MSigDB lists</TD><TD>GSE31082_CD4_VS_CD8_SP_THYMOCYTE_UP</TD><TD>187</TD><TD>3</TD><TD>17758</TD><TD>15</TD>
<TD>ALDH2,NR4A1,SYTL2</TD></TR>
<TR><TD>5.358e-04</TD><TD>-7.53</TD><TD>KEGG_LYSINE_DEGRADATION</TD><TD>MSigDB lists</TD><TD>KEGG_LYSINE_DEGRADATION</TD><TD>41</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>ALDH2,PLOD2</TD></TR>
<TR><TD>5.382e-04</TD><TD>-7.53</TD><TD>GSE17721_POLYIC_VS_PAM3CSK4_1H_BMDM_DN</TD><TD>MSigDB lists</TD><TD>GSE17721_POLYIC_VS_PAM3CSK4_1H_BMDM_DN</TD><TD>195</TD><TD>3</TD><TD>17758</TD><TD>15</TD>
<TD>COL4A5,CNTNAP2,MECOM</TD></TR>
<TR><TD>5.714e-04</TD><TD>-7.47</TD><TD>human chr16q11</TD><TD>chromosome location</TD><TD>human chr16q11</TD><TD>1</TD><TD>1</TD><TD>26250</TD><TD>15</TD>
<TD>NETO2</TD></TR>
<TR><TD>5.795e-04</TD><TD>-7.45</TD><TD>V$STAT5A_04</TD><TD>MSigDB lists</TD><TD>V$STAT5A_04</TD><TD>200</TD><TD>3</TD><TD>17758</TD><TD>15</TD>
<TD>NR4A1,SYTL2,MECOM</TD></TR>
<TR><TD>6.860e-04</TD><TD>-7.28</TD><TD>NLRP14 (NLR family, pyrin domain containing 14)</TD><TD>protein interactions</TD><TD>338323</TD><TD>1</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>MECOM</TD></TR>
<TR><TD>6.860e-04</TD><TD>-7.28</TD><TD>ABCC13 (ATP binding cassette subfamily C member 13, pseudogene)</TD><TD>protein interactions</TD><TD>150000</TD><TD>1</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>NR4A1</TD></TR>
<TR><TD>7.346e-04</TD><TD>-7.22</TD><TD>LINDGREN_BLADDER_CANCER_CLUSTER_3_DN</TD><TD>MSigDB lists</TD><TD>LINDGREN_BLADDER_CANCER_CLUSTER_3_DN</TD><TD>217</TD><TD>3</TD><TD>17758</TD><TD>15</TD>
<TD>COL4A5,SYTL2,MECOM</TD></TR>
<TR><TD>8.178e-04</TD><TD>-7.11</TD><TD>Lysine degradation</TD><TD>KEGG pathways</TD><TD>hsa00310</TD><TD>52</TD><TD>2</TD><TD>6908</TD><TD>6</TD>
<TD>ALDH2,PLOD2</TD></TR>
<TR><TD>8.178e-04</TD><TD>-7.11</TD><TD>Lysine degradation</TD><TD>KEGG pathways</TD><TD>ko00310</TD><TD>52</TD><TD>2</TD><TD>6908</TD><TD>6</TD>
<TD>ALDH2,PLOD2</TD></TR>
<TR><TD>8.200e-04</TD><TD>-7.11</TD><TD>SUN3</TD><TD>interpro domains</TD><TD>IPR030274</TD><TD>1</TD><TD>1</TD><TD>18293</TD><TD>15</TD>
<TD>SUN3</TD></TR>
<TR><TD>8.200e-04</TD><TD>-7.11</TD><TD>MDS1</TD><TD>interpro domains</TD><TD>IPR026710</TD><TD>1</TD><TD>1</TD><TD>18293</TD><TD>15</TD>
<TD>MECOM</TD></TR>
<TR><TD>8.200e-04</TD><TD>-7.11</TD><TD>Caspr2</TD><TD>interpro domains</TD><TD>IPR029831</TD><TD>1</TD><TD>1</TD><TD>18293</TD><TD>15</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>8.200e-04</TD><TD>-7.11</TD><TD>Nuc_orp_HMR_rcpt</TD><TD>interpro domains</TD><TD>IPR003071</TD><TD>1</TD><TD>1</TD><TD>18293</TD><TD>15</TD>
<TD>NR4A1</TD></TR>
<TR><TD>8.200e-04</TD><TD>-7.11</TD><TD>SYTL2</TD><TD>interpro domains</TD><TD>IPR027006</TD><TD>1</TD><TD>1</TD><TD>18293</TD><TD>15</TD>
<TD>SYTL2</TD></TR>
<TR><TD>8.200e-04</TD><TD>-7.11</TD><TD>NETO2</TD><TD>interpro domains</TD><TD>IPR028868</TD><TD>1</TD><TD>1</TD><TD>18293</TD><TD>15</TD>
<TD>NETO2</TD></TR>
<TR><TD>8.246e-04</TD><TD>-7.10</TD><TD>VHL (von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase)</TD><TD>protein interactions</TD><TD>7428</TD><TD>285</TD><TD>3</TD><TD>16036</TD><TD>11</TD>
<TD>COL4A5,PLOD2,NR4A1</TD></TR>
<TR><TD>8.807e-04</TD><TD>-7.03</TD><TD>WINTER_HYPOXIA_METAGENE</TD><TD>MSigDB lists</TD><TD>WINTER_HYPOXIA_METAGENE</TD><TD>231</TD><TD>3</TD><TD>17758</TD><TD>15</TD>
<TD>COL4A5,PLOD2,NR4A1</TD></TR>
<TR><TD>8.812e-04</TD><TD>-7.03</TD><TD>Collagen biosynthesis and modifying enzymes</TD><TD>REACTOME pathways</TD><TD>R-HSA-1650814</TD><TD>64</TD><TD>2</TD><TD>8202</TD><TD>6</TD>
<TD>COL4A5,PLOD2</TD></TR>
<TR><TD>9.291e-04</TD><TD>-6.98</TD><TD>REACTOME_COLLAGEN_FORMATION</TD><TD>MSigDB lists</TD><TD>REACTOME_COLLAGEN_FORMATION</TD><TD>54</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>COL4A5,PLOD2</TD></TR>
<TR><TD>1.063e-03</TD><TD>-6.85</TD><TD>endomembrane system</TD><TD>cellular component</TD><TD>GO:0012505</TD><TD>3658</TD><TD>9</TD><TD>17570</TD><TD>15</TD>
<TD>PLOD2,NR4A1,COL4A5,SUN3,CNTNAP2,FAM198B,MYRIP,SYTL2,MECOM</TD></TR>
<TR><TD>1.261e-03</TD><TD>-6.68</TD><TD>NUCLEARECPTR</TD><TD>prints domains</TD><TD>PR01284</TD><TD>3</TD><TD>1</TD><TD>4759</TD><TD>2</TD>
<TD>NR4A1</TD></TR>
<TR><TD>1.261e-03</TD><TD>-6.68</TD><TD>TRANSFERRIN</TD><TD>prints domains</TD><TD>PR00422</TD><TD>3</TD><TD>1</TD><TD>4759</TD><TD>2</TD>
<TD>MFI2</TD></TR>
<TR><TD>1.371e-03</TD><TD>-6.59</TD><TD>IGHG4 (immunoglobulin heavy constant gamma 4 (G4m marker))</TD><TD>protein interactions</TD><TD>3503</TD><TD>2</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>ALDH2</TD></TR>
<TR><TD>1.371e-03</TD><TD>-6.59</TD><TD>ABCA5 (ATP binding cassette subfamily A member 5)</TD><TD>protein interactions</TD><TD>23461</TD><TD>2</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>NR4A1</TD></TR>
<TR><TD>1.426e-03</TD><TD>-6.55</TD><TD>GEORGANTAS_HSC_MARKERS</TD><TD>MSigDB lists</TD><TD>GEORGANTAS_HSC_MARKERS</TD><TD>67</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>FAM198B,MECOM</TD></TR>
<TR><TD>1.463e-03</TD><TD>-6.53</TD><TD>Metabolism of serotonin</TD><TD>REACTOME pathways</TD><TD>R-HSA-380612</TD><TD>2</TD><TD>1</TD><TD>8202</TD><TD>6</TD>
<TD>ALDH2</TD></TR>
<TR><TD>1.463e-03</TD><TD>-6.53</TD><TD>Serotonin clearance from the synaptic cleft</TD><TD>REACTOME pathways</TD><TD>R-HSA-380615</TD><TD>2</TD><TD>1</TD><TD>8202</TD><TD>6</TD>
<TD>ALDH2</TD></TR>
<TR><TD>1.586e-03</TD><TD>-6.45</TD><TD>Collagen formation</TD><TD>REACTOME pathways</TD><TD>R-HSA-1474290</TD><TD>86</TD><TD>2</TD><TD>8202</TD><TD>6</TD>
<TD>COL4A5,PLOD2</TD></TR>
<TR><TD>1.639e-03</TD><TD>-6.41</TD><TD>FAM198</TD><TD>interpro domains</TD><TD>IPR029207</TD><TD>2</TD><TD>1</TD><TD>18293</TD><TD>15</TD>
<TD>FAM198B</TD></TR>
<TR><TD>1.639e-03</TD><TD>-6.41</TD><TD>Myrip/Melanophilin</TD><TD>interpro domains</TD><TD>IPR006788</TD><TD>2</TD><TD>1</TD><TD>18293</TD><TD>15</TD>
<TD>MYRIP</TD></TR>
<TR><TD>1.639e-03</TD><TD>-6.41</TD><TD>Evi1/Prdm16</TD><TD>interpro domains</TD><TD>IPR030413</TD><TD>2</TD><TD>1</TD><TD>18293</TD><TD>15</TD>
<TD>MECOM</TD></TR>
<TR><TD>1.702e-03</TD><TD>-6.38</TD><TD>regulation of kainate selective glutamate receptor activity</TD><TD>biological process</TD><TD>GO:2000312</TD><TD>2</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>NETO2</TD></TR>
<TR><TD>1.702e-03</TD><TD>-6.38</TD><TD>superior temporal gyrus development</TD><TD>biological process</TD><TD>GO:0071109</TD><TD>2</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>1.713e-03</TD><TD>-6.37</TD><TD>human chr3q28-q29</TD><TD>chromosome location</TD><TD>human chr3q28-q29</TD><TD>3</TD><TD>1</TD><TD>26250</TD><TD>15</TD>
<TD>MFI2</TD></TR>
<TR><TD>1.783e-03</TD><TD>-6.33</TD><TD>HADDAD_T_LYMPHOCYTE_AND_NK_PROGENITOR_UP</TD><TD>MSigDB lists</TD><TD>HADDAD_T_LYMPHOCYTE_AND_NK_PROGENITOR_UP</TD><TD>75</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>PLOD2,MECOM</TD></TR>
<TR><TD>1.788e-03</TD><TD>-6.33</TD><TD>SMID_BREAST_CANCER_BASAL_DN</TD><TD>MSigDB lists</TD><TD>SMID_BREAST_CANCER_BASAL_DN</TD><TD>653</TD><TD>4</TD><TD>17758</TD><TD>15</TD>
<TD>COL4A5,FAM198B,CNTNAP2,SYTL2</TD></TR>
<TR><TD>1.803e-03</TD><TD>-6.32</TD><TD>Rab_eff_C</TD><TD>pfam domains</TD><TD>PF04698</TD><TD>2</TD><TD>1</TD><TD>16629</TD><TD>15</TD>
<TD>MYRIP</TD></TR>
<TR><TD>1.803e-03</TD><TD>-6.32</TD><TD>FAM198</TD><TD>pfam domains</TD><TD>PF15051</TD><TD>2</TD><TD>1</TD><TD>16629</TD><TD>15</TD>
<TD>FAM198B</TD></TR>
<TR><TD>1.922e-03</TD><TD>-6.25</TD><TD>CCCNNGGGAR_V$OLF1_01</TD><TD>MSigDB lists</TD><TD>CCCNNGGGAR_V$OLF1_01</TD><TD>303</TD><TD>3</TD><TD>17758</TD><TD>15</TD>
<TD>FAM198B,SYTL2,MECOM</TD></TR>
<TR><TD>2.057e-03</TD><TD>-6.19</TD><TD>ALDH1A2 (aldehyde dehydrogenase 1 family, member A2)</TD><TD>protein interactions</TD><TD>8854</TD><TD>3</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>ALDH2</TD></TR>
<TR><TD>2.076e-03</TD><TD>-6.18</TD><TD>TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_6HR_UP</TD><TD>MSigDB lists</TD><TD>TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_6HR_UP</TD><TD>81</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>FAM198B,MECOM</TD></TR>
<TR><TD>2.093e-03</TD><TD>-6.17</TD><TD>Sleep duration(PMID:17903308)</TD><TD>GWAS genes</TD><TD>Sleep duration(PMID:17903308)</TD><TD>1</TD><TD>1</TD><TD>2389</TD><TD>5</TD>
<TD>MYRIP</TD></TR>
<TR><TD>2.178e-03</TD><TD>-6.13</TD><TD>REACTOME_EXTRACELLULAR_MATRIX_ORGANIZATION</TD><TD>MSigDB lists</TD><TD>REACTOME_EXTRACELLULAR_MATRIX_ORGANIZATION</TD><TD>83</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>COL4A5,PLOD2</TD></TR>
<TR><TD>2.205e-03</TD><TD>-6.12</TD><TD>FAF1 (Fas (TNFRSF6) associated factor 1)</TD><TD>protein interactions</TD><TD>11124</TD><TD>104</TD><TD>2</TD><TD>16036</TD><TD>11</TD>
<TD>PLOD2,NR4A1</TD></TR>
<TR><TD>2.290e-03</TD><TD>-6.08</TD><TD>NCOA1 (nuclear receptor coactivator 1)</TD><TD>protein interactions</TD><TD>8648</TD><TD>106</TD><TD>2</TD><TD>16036</TD><TD>11</TD>
<TD>NR4A1,SYTL2</TD></TR>
<TR><TD>2.444e-03</TD><TD>-6.01</TD><TD>typical</TD><TD>COSMIC cancer mutations</TD><TD>typical</TD><TD>330</TD><TD>3</TD><TD>17775</TD><TD>15</TD>
<TD>COL4A5,CNTNAP2,PLOD2</TD></TR>
<TR><TD>2.444e-03</TD><TD>-6.01</TD><TD>lung-carcinoid-endocrine_tumour-typical</TD><TD>COSMIC cancer mutations</TD><TD>lung-carcinoid-endocrine_tumour-typical</TD><TD>330</TD><TD>3</TD><TD>17775</TD><TD>15</TD>
<TD>COL4A5,CNTNAP2,PLOD2</TD></TR>
<TR><TD>2.458e-03</TD><TD>-6.01</TD><TD>Transferrin</TD><TD>interpro domains</TD><TD>IPR016357</TD><TD>3</TD><TD>1</TD><TD>18293</TD><TD>15</TD>
<TD>MFI2</TD></TR>
<TR><TD>2.458e-03</TD><TD>-6.01</TD><TD>Procol_lys_dOase</TD><TD>interpro domains</TD><TD>IPR001006</TD><TD>3</TD><TD>1</TD><TD>18293</TD><TD>15</TD>
<TD>PLOD2</TD></TR>
<TR><TD>2.458e-03</TD><TD>-6.01</TD><TD>Transferrin_Fe_BS</TD><TD>interpro domains</TD><TD>IPR018195</TD><TD>3</TD><TD>1</TD><TD>18293</TD><TD>15</TD>
<TD>MFI2</TD></TR>
<TR><TD>2.458e-03</TD><TD>-6.01</TD><TD>Transferrin-like_dom</TD><TD>interpro domains</TD><TD>IPR001156</TD><TD>3</TD><TD>1</TD><TD>18293</TD><TD>15</TD>
<TD>MFI2</TD></TR>
<TR><TD>2.458e-03</TD><TD>-6.01</TD><TD>Nuc_orph_rcpt</TD><TD>interpro domains</TD><TD>IPR003070</TD><TD>3</TD><TD>1</TD><TD>18293</TD><TD>15</TD>
<TD>NR4A1</TD></TR>
<TR><TD>2.513e-03</TD><TD>-5.99</TD><TD>Rab GTPase binding</TD><TD>molecular function</TD><TD>GO:0017137</TD><TD>89</TD><TD>2</TD><TD>16491</TD><TD>14</TD>
<TD>MYRIP,SYTL2</TD></TR>
<TR><TD>2.545e-03</TD><TD>-5.97</TD><TD>NUYTTEN_NIPP1_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>NUYTTEN_NIPP1_TARGETS_UP</TD><TD>719</TD><TD>4</TD><TD>17758</TD><TD>15</TD>
<TD>PLOD2,NR4A1,MECOM,NETO2</TD></TR>
<TR><TD>2.545e-03</TD><TD>-5.97</TD><TD>procollagen-lysine 5-dioxygenase activity</TD><TD>molecular function</TD><TD>GO:0008475</TD><TD>3</TD><TD>1</TD><TD>16491</TD><TD>14</TD>
<TD>PLOD2</TD></TR>
<TR><TD>2.553e-03</TD><TD>-5.97</TD><TD>clustering of voltage-gated potassium channels</TD><TD>biological process</TD><TD>GO:0045163</TD><TD>3</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>2.704e-03</TD><TD>-5.91</TD><TD>Transferrin</TD><TD>pfam domains</TD><TD>PF00405</TD><TD>3</TD><TD>1</TD><TD>16629</TD><TD>15</TD>
<TD>MFI2</TD></TR>
<TR><TD>2.741e-03</TD><TD>-5.90</TD><TD>ANKIB1 (ankyrin repeat and IBR domain containing 1)</TD><TD>protein interactions</TD><TD>54467</TD><TD>4</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>NR4A1</TD></TR>
<TR><TD>2.741e-03</TD><TD>-5.90</TD><TD>LSS (lanosterol synthase (2,3-oxidosqualene-lanosterol cyclase))</TD><TD>protein interactions</TD><TD>4047</TD><TD>4</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>NR4A1</TD></TR>
<TR><TD>2.741e-03</TD><TD>-5.90</TD><TD>ABCB11 (ATP binding cassette subfamily B member 11)</TD><TD>protein interactions</TD><TD>8647</TD><TD>4</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>NR4A1</TD></TR>
<TR><TD>2.741e-03</TD><TD>-5.90</TD><TD>ARHGEF10L (Rho guanine nucleotide exchange factor 10 like)</TD><TD>protein interactions</TD><TD>55160</TD><TD>4</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>NR4A1</TD></TR>
<TR><TD>2.741e-03</TD><TD>-5.90</TD><TD>ZNF461 (zinc finger protein 461)</TD><TD>protein interactions</TD><TD>92283</TD><TD>4</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>TOX2</TD></TR>
<TR><TD>2.901e-03</TD><TD>-5.84</TD><TD>GRADE_COLON_AND_RECTAL_CANCER_DN</TD><TD>MSigDB lists</TD><TD>GRADE_COLON_AND_RECTAL_CANCER_DN</TD><TD>96</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>COL4A5,TOX2</TD></TR>
<TR><TD>2.920e-03</TD><TD>-5.84</TD><TD>WGGAATGY_V$TEF1_Q6</TD><TD>MSigDB lists</TD><TD>WGGAATGY_V$TEF1_Q6</TD><TD>351</TD><TD>3</TD><TD>17758</TD><TD>15</TD>
<TD>COL4A5,NR4A1,SYTL2</TD></TR>
<TR><TD>3.308e-03</TD><TD>-5.71</TD><TD>putrescine degradation III</TD><TD>BIOCYC pathways</TD><TD>META_PWY-0</TD><TD>3</TD><TD>1</TD><TD>907</TD><TD>1</TD>
<TD>ALDH2</TD></TR>
<TR><TD>3.330e-03</TD><TD>-5.70</TD><TD>IZADPANAH_STEM_CELL_ADIPOSE_VS_BONE_DN</TD><TD>MSigDB lists</TD><TD>IZADPANAH_STEM_CELL_ADIPOSE_VS_BONE_DN</TD><TD>103</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>PLOD2,SYTL2</TD></TR>
<TR><TD>3.392e-03</TD><TD>-5.69</TD><TD>peptidyl-lysine 5-dioxygenase activity</TD><TD>molecular function</TD><TD>GO:0070815</TD><TD>4</TD><TD>1</TD><TD>16491</TD><TD>14</TD>
<TD>PLOD2</TD></TR>
<TR><TD>3.400e-03</TD><TD>-5.68</TD><TD>pigment granule</TD><TD>cellular component</TD><TD>GO:0048770</TD><TD>103</TD><TD>2</TD><TD>17570</TD><TD>15</TD>
<TD>MYRIP,SYTL2</TD></TR>
<TR><TD>3.400e-03</TD><TD>-5.68</TD><TD>melanosome</TD><TD>cellular component</TD><TD>GO:0042470</TD><TD>103</TD><TD>2</TD><TD>17570</TD><TD>15</TD>
<TD>MYRIP,SYTL2</TD></TR>
<TR><TD>3.402e-03</TD><TD>-5.68</TD><TD>protein localization to juxtaparanode region of axon</TD><TD>biological process</TD><TD>GO:0071205</TD><TD>4</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>3.426e-03</TD><TD>-5.68</TD><TD>IGHG3 (immunoglobulin heavy constant gamma 3 (G3m marker))</TD><TD>protein interactions</TD><TD>3502</TD><TD>5</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>ALDH2</TD></TR>
<TR><TD>3.426e-03</TD><TD>-5.68</TD><TD>FXYD3 (FXYD domain containing ion transport regulator 3)</TD><TD>protein interactions</TD><TD>5349</TD><TD>5</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>NR4A1</TD></TR>
<TR><TD>3.426e-03</TD><TD>-5.68</TD><TD>Fam107b (family with sequence similarity 107, member B)</TD><TD>protein interactions</TD><TD>66540</TD><TD>5</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>PLOD2</TD></TR>
<TR><TD>3.426e-03</TD><TD>-5.68</TD><TD>HPGDS (hematopoietic prostaglandin D synthase)</TD><TD>protein interactions</TD><TD>27306</TD><TD>5</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>MFI2</TD></TR>
<TR><TD>3.426e-03</TD><TD>-5.68</TD><TD>ABCC6 (ATP binding cassette subfamily C member 6)</TD><TD>protein interactions</TD><TD>368</TD><TD>5</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>NR4A1</TD></TR>
<TR><TD>3.426e-03</TD><TD>-5.68</TD><TD>DERL3 (derlin 3)</TD><TD>protein interactions</TD><TD>91319</TD><TD>5</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>MFI2</TD></TR>
<TR><TD>3.426e-03</TD><TD>-5.68</TD><TD>ALDH1A1 (aldehyde dehydrogenase 1 family, member A1)</TD><TD>protein interactions</TD><TD>216</TD><TD>5</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>ALDH2</TD></TR>
<TR><TD>3.536e-03</TD><TD>-5.64</TD><TD>TRANSFERRIN_LIKE_4</TD><TD>prosite domains</TD><TD>PS51408</TD><TD>3</TD><TD>1</TD><TD>11866</TD><TD>14</TD>
<TD>MFI2</TD></TR>
<TR><TD>3.536e-03</TD><TD>-5.64</TD><TD>TRANSFERRIN_LIKE_3</TD><TD>prosite domains</TD><TD>PS00207</TD><TD>3</TD><TD>1</TD><TD>11866</TD><TD>14</TD>
<TD>MFI2</TD></TR>
<TR><TD>3.536e-03</TD><TD>-5.64</TD><TD>TRANSFERRIN_LIKE_2</TD><TD>prosite domains</TD><TD>PS00206</TD><TD>3</TD><TD>1</TD><TD>11866</TD><TD>14</TD>
<TD>MFI2</TD></TR>
<TR><TD>3.536e-03</TD><TD>-5.64</TD><TD>TRANSFERRIN_LIKE_1</TD><TD>prosite domains</TD><TD>PS00205</TD><TD>3</TD><TD>1</TD><TD>11866</TD><TD>14</TD>
<TD>MFI2</TD></TR>
<TR><TD>3.536e-03</TD><TD>-5.64</TD><TD>LYS_HYDROXYLASE</TD><TD>prosite domains</TD><TD>PS01325</TD><TD>3</TD><TD>1</TD><TD>11866</TD><TD>14</TD>
<TD>PLOD2</TD></TR>
<TR><TD>3.604e-03</TD><TD>-5.63</TD><TD>2OG-FeII_Oxy</TD><TD>pfam domains</TD><TD>PF03171</TD><TD>4</TD><TD>1</TD><TD>16629</TD><TD>15</TD>
<TD>PLOD2</TD></TR>
<TR><TD>3.610e-03</TD><TD>-5.62</TD><TD>TR_FER</TD><TD>smart domains</TD><TD>SM00094</TD><TD>3</TD><TD>1</TD><TD>9131</TD><TD>11</TD>
<TD>MFI2</TD></TR>
<TR><TD>3.680e-03</TD><TD>-5.60</TD><TD>CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_2</TD><TD>MSigDB lists</TD><TD>CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_2</TD><TD>381</TD><TD>3</TD><TD>17758</TD><TD>15</TD>
<TD>ZNF432,MFI2,NETO2</TD></TR>
<TR><TD>3.992e-03</TD><TD>-5.52</TD><TD>LEE_NEURAL_CREST_STEM_CELL_DN</TD><TD>MSigDB lists</TD><TD>LEE_NEURAL_CREST_STEM_CELL_DN</TD><TD>113</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>COL4A5,CNTNAP2</TD></TR>
<TR><TD>3.992e-03</TD><TD>-5.52</TD><TD>WANG_ESOPHAGUS_CANCER_VS_NORMAL_UP</TD><TD>MSigDB lists</TD><TD>WANG_ESOPHAGUS_CANCER_VS_NORMAL_UP</TD><TD>113</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>NR4A1,MECOM</TD></TR>
<TR><TD>4.094e-03</TD><TD>-5.50</TD><TD>Achaete-scute-rel</TD><TD>interpro domains</TD><TD>IPR015660</TD><TD>5</TD><TD>1</TD><TD>18293</TD><TD>15</TD>
<TD>ASCL5</TD></TR>
<TR><TD>4.169e-03</TD><TD>-5.48</TD><TD>upper_aerodigestive_tract-larynx-carcinoma-squamous_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>upper_aerodigestive_tract-larynx-carcinoma-squamous_cell_carcinoma</TD><TD>2007</TD><TD>6</TD><TD>17775</TD><TD>15</TD>
<TD>COL4A5,SUN3,CNTNAP2,NR4A1,SYTL2,NETO2</TD></TR>
<TR><TD>4.182e-03</TD><TD>-5.48</TD><TD>Esophageal cancer(PMID:19698717)</TD><TD>GWAS genes</TD><TD>Esophageal cancer(PMID:19698717)</TD><TD>2</TD><TD>1</TD><TD>2389</TD><TD>5</TD>
<TD>ALDH2</TD></TR>
<TR><TD>4.182e-03</TD><TD>-5.48</TD><TD>Coronary heart disease(PMID:21971053)</TD><TD>GWAS genes</TD><TD>Coronary heart disease(PMID:21971053)</TD><TD>2</TD><TD>1</TD><TD>2389</TD><TD>5</TD>
<TD>ALDH2</TD></TR>
<TR><TD>4.182e-03</TD><TD>-5.48</TD><TD>Drinking behavior(PMID:21372407)</TD><TD>GWAS genes</TD><TD>Drinking behavior(PMID:21372407)</TD><TD>2</TD><TD>1</TD><TD>2389</TD><TD>5</TD>
<TD>ALDH2</TD></TR>
<TR><TD>4.190e-03</TD><TD>-5.48</TD><TD>larynx</TD><TD>COSMIC cancer mutations</TD><TD>larynx</TD><TD>2009</TD><TD>6</TD><TD>17775</TD><TD>15</TD>
<TD>COL4A5,SUN3,CNTNAP2,NR4A1,SYTL2,NETO2</TD></TR>
<TR><TD>4.217e-03</TD><TD>-5.47</TD><TD>chr16q11</TD><TD>MSigDB lists</TD><TD>chr16q11</TD><TD>5</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>NETO2</TD></TR>
<TR><TD>4.251e-03</TD><TD>-5.46</TD><TD>positive regulation of plasminogen activation</TD><TD>biological process</TD><TD>GO:0010756</TD><TD>5</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>MFI2</TD></TR>
<TR><TD>4.251e-03</TD><TD>-5.46</TD><TD>response to corticotropin-releasing hormone</TD><TD>biological process</TD><TD>GO:0043435</TD><TD>5</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>NR4A1</TD></TR>
<TR><TD>4.251e-03</TD><TD>-5.46</TD><TD>ethanol catabolic process</TD><TD>biological process</TD><TD>GO:0006068</TD><TD>5</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>ALDH2</TD></TR>
<TR><TD>4.251e-03</TD><TD>-5.46</TD><TD>regulation of type B pancreatic cell proliferation</TD><TD>biological process</TD><TD>GO:0061469</TD><TD>5</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>NR4A1</TD></TR>
<TR><TD>4.251e-03</TD><TD>-5.46</TD><TD>vocal learning</TD><TD>biological process</TD><TD>GO:0042297</TD><TD>5</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>4.251e-03</TD><TD>-5.46</TD><TD>learned vocalization behavior or vocal learning</TD><TD>biological process</TD><TD>GO:0098598</TD><TD>5</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>4.251e-03</TD><TD>-5.46</TD><TD>cellular response to corticotropin-releasing hormone stimulus</TD><TD>biological process</TD><TD>GO:0071376</TD><TD>5</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>NR4A1</TD></TR>
<TR><TD>4.251e-03</TD><TD>-5.46</TD><TD>positive regulation of extracellular matrix disassembly</TD><TD>biological process</TD><TD>GO:0090091</TD><TD>5</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>MFI2</TD></TR>
<TR><TD>4.251e-03</TD><TD>-5.46</TD><TD>imitative learning</TD><TD>biological process</TD><TD>GO:0098596</TD><TD>5</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>4.344e-03</TD><TD>-5.44</TD><TD>REACTOME_SIGNALING_BY_PDGF</TD><TD>MSigDB lists</TD><TD>REACTOME_SIGNALING_BY_PDGF</TD><TD>118</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>COL4A5,NR4A1</TD></TR>
<TR><TD>4.410e-03</TD><TD>-5.42</TD><TD>phenylethylamine degradation I</TD><TD>BIOCYC pathways</TD><TD>HUMAN_2PHENDEG-PWY</TD><TD>4</TD><TD>1</TD><TD>907</TD><TD>1</TD>
<TD>ALDH2</TD></TR>
<TR><TD>4.410e-03</TD><TD>-5.42</TD><TD>ethanol degradation II</TD><TD>BIOCYC pathways</TD><TD>META_PWY66-21</TD><TD>4</TD><TD>1</TD><TD>907</TD><TD>1</TD>
<TD>ALDH2</TD></TR>
<TR><TD>4.410e-03</TD><TD>-5.42</TD><TD>oxidative ethanol degradation III</TD><TD>BIOCYC pathways</TD><TD>META_PWY66-161</TD><TD>4</TD><TD>1</TD><TD>907</TD><TD>1</TD>
<TD>ALDH2</TD></TR>
<TR><TD>4.410e-03</TD><TD>-5.42</TD><TD>L-phenylalanine degradation IV (mammalian, via side chain)</TD><TD>BIOCYC pathways</TD><TD>META_PWY-6318</TD><TD>4</TD><TD>1</TD><TD>907</TD><TD>1</TD>
<TD>ALDH2</TD></TR>
<TR><TD>4.410e-03</TD><TD>-5.42</TD><TD>ethanol degradation IV</TD><TD>BIOCYC pathways</TD><TD>META_PWY66-162</TD><TD>4</TD><TD>1</TD><TD>907</TD><TD>1</TD>
<TD>ALDH2</TD></TR>
<TR><TD>4.562e-03</TD><TD>-5.39</TD><TD>MISSIAGLIA_REGULATED_BY_METHYLATION_UP</TD><TD>MSigDB lists</TD><TD>MISSIAGLIA_REGULATED_BY_METHYLATION_UP</TD><TD>121</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>MFI2,MYRIP</TD></TR>
<TR><TD>4.793e-03</TD><TD>-5.34</TD><TD>HABP2 (hyaluronan binding protein 2)</TD><TD>protein interactions</TD><TD>3026</TD><TD>7</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>COL4A5</TD></TR>
<TR><TD>4.793e-03</TD><TD>-5.34</TD><TD>MTERF1 (mitochondrial transcription termination factor 1)</TD><TD>protein interactions</TD><TD>7978</TD><TD>7</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>SYTL2</TD></TR>
<TR><TD>4.911e-03</TD><TD>-5.32</TD><TD>Collagen_VI_NC</TD><TD>interpro domains</TD><TD>IPR001442</TD><TD>6</TD><TD>1</TD><TD>18293</TD><TD>15</TD>
<TD>COL4A5</TD></TR>
<TR><TD>5.058e-03</TD><TD>-5.29</TD><TD>PARK_OSTEOBLAST_DIFFERENTIATION_BY_PHENYLAMIL_DN</TD><TD>MSigDB lists</TD><TD>PARK_OSTEOBLAST_DIFFERENTIATION_BY_PHENYLAMIL_DN</TD><TD>6</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>PLOD2</TD></TR>
<TR><TD>5.090e-03</TD><TD>-5.28</TD><TD>NRL_DN.V1_DN</TD><TD>MSigDB lists</TD><TD>NRL_DN.V1_DN</TD><TD>128</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>ALDH2,NR4A1</TD></TR>
<TR><TD>5.099e-03</TD><TD>-5.28</TD><TD>positive regulation of brown fat cell differentiation</TD><TD>biological process</TD><TD>GO:0090336</TD><TD>6</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>MECOM</TD></TR>
<TR><TD>5.112e-03</TD><TD>-5.28</TD><TD>collagen type IV trimer</TD><TD>cellular component</TD><TD>GO:0005587</TD><TD>6</TD><TD>1</TD><TD>17570</TD><TD>15</TD>
<TD>COL4A5</TD></TR>
<TR><TD>5.132e-03</TD><TD>-5.27</TD><TD>human chr12q24.2</TD><TD>chromosome location</TD><TD>human chr12q24.2</TD><TD>9</TD><TD>1</TD><TD>26250</TD><TD>15</TD>
<TD>ALDH2</TD></TR>
<TR><TD>5.132e-03</TD><TD>-5.27</TD><TD>human chr11q14</TD><TD>chromosome location</TD><TD>human chr11q14</TD><TD>9</TD><TD>1</TD><TD>26250</TD><TD>15</TD>
<TD>SYTL2</TD></TR>
<TR><TD>5.368e-03</TD><TD>-5.23</TD><TD>HELLER_HDAC_TARGETS_SILENCED_BY_METHYLATION_UP</TD><TD>MSigDB lists</TD><TD>HELLER_HDAC_TARGETS_SILENCED_BY_METHYLATION_UP</TD><TD>436</TD><TD>3</TD><TD>17758</TD><TD>15</TD>
<TD>CNTNAP2,ALDH2,NR4A1</TD></TR>
<TR><TD>5.401e-03</TD><TD>-5.22</TD><TD>C4</TD><TD>pfam domains</TD><TD>PF01413</TD><TD>6</TD><TD>1</TD><TD>16629</TD><TD>15</TD>
<TD>COL4A5</TD></TR>
<TR><TD>5.476e-03</TD><TD>-5.21</TD><TD>ABCG8 (ATP binding cassette subfamily G member 8)</TD><TD>protein interactions</TD><TD>64241</TD><TD>8</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>NR4A1</TD></TR>
<TR><TD>5.476e-03</TD><TD>-5.21</TD><TD>SOCS4 (suppressor of cytokine signaling 4)</TD><TD>protein interactions</TD><TD>122809</TD><TD>8</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>NR4A1</TD></TR>
<TR><TD>5.476e-03</TD><TD>-5.21</TD><TD>ZNF331 (zinc finger protein 331)</TD><TD>protein interactions</TD><TD>55422</TD><TD>8</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>NR4A1</TD></TR>
<TR><TD>5.484e-03</TD><TD>-5.21</TD><TD>LINDGREN_BLADDER_CANCER_CLUSTER_2A_DN</TD><TD>MSigDB lists</TD><TD>LINDGREN_BLADDER_CANCER_CLUSTER_2A_DN</TD><TD>133</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>ALDH2,TOX2</TD></TR>
<TR><TD>5.513e-03</TD><TD>-5.20</TD><TD>serotonin degradation</TD><TD>BIOCYC pathways</TD><TD>META_PWY-6313</TD><TD>5</TD><TD>1</TD><TD>907</TD><TD>1</TD>
<TD>ALDH2</TD></TR>
<TR><TD>5.513e-03</TD><TD>-5.20</TD><TD>ethanol degradation IV</TD><TD>BIOCYC pathways</TD><TD>HUMAN_PWY66-162</TD><TD>5</TD><TD>1</TD><TD>907</TD><TD>1</TD>
<TD>ALDH2</TD></TR>
<TR><TD>5.513e-03</TD><TD>-5.20</TD><TD>ethanol degradation II</TD><TD>BIOCYC pathways</TD><TD>HUMAN_PWY66-21</TD><TD>5</TD><TD>1</TD><TD>907</TD><TD>1</TD>
<TD>ALDH2</TD></TR>
<TR><TD>5.645e-03</TD><TD>-5.18</TD><TD>WAMUNYOKOLI_OVARIAN_CANCER_GRADES_1_2_UP</TD><TD>MSigDB lists</TD><TD>WAMUNYOKOLI_OVARIAN_CANCER_GRADES_1_2_UP</TD><TD>135</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>SYTL2,MECOM</TD></TR>
<TR><TD>5.727e-03</TD><TD>-5.16</TD><TD>SUN_dom</TD><TD>interpro domains</TD><TD>IPR012919</TD><TD>7</TD><TD>1</TD><TD>18293</TD><TD>15</TD>
<TD>SUN3</TD></TR>
<TR><TD>5.840e-03</TD><TD>-5.14</TD><TD>Neurotransmitter Clearance In The Synaptic Cleft</TD><TD>REACTOME pathways</TD><TD>R-HSA-112311</TD><TD>8</TD><TD>1</TD><TD>8202</TD><TD>6</TD>
<TD>ALDH2</TD></TR>
<TR><TD>5.899e-03</TD><TD>-5.13</TD><TD>LOPEZ_MESOTELIOMA_SURVIVAL_TIME_DN</TD><TD>MSigDB lists</TD><TD>LOPEZ_MESOTELIOMA_SURVIVAL_TIME_DN</TD><TD>7</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>ALDH2</TD></TR>
<TR><TD>5.899e-03</TD><TD>-5.13</TD><TD>MYLLYKANGAS_AMPLIFICATION_HOT_SPOT_7</TD><TD>MSigDB lists</TD><TD>MYLLYKANGAS_AMPLIFICATION_HOT_SPOT_7</TD><TD>7</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>MECOM</TD></TR>
<TR><TD>5.899e-03</TD><TD>-5.13</TD><TD>BUSA_SAM68_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>BUSA_SAM68_TARGETS_UP</TD><TD>7</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>NR4A1</TD></TR>
<TR><TD>5.899e-03</TD><TD>-5.13</TD><TD>INGRAM_SHH_TARGETS</TD><TD>MSigDB lists</TD><TD>INGRAM_SHH_TARGETS</TD><TD>7</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>NR4A1</TD></TR>
<TR><TD>5.929e-03</TD><TD>-5.13</TD><TD>aldehyde dehydrogenase [NAD(P)+] activity</TD><TD>molecular function</TD><TD>GO:0004030</TD><TD>7</TD><TD>1</TD><TD>16491</TD><TD>14</TD>
<TD>ALDH2</TD></TR>
<TR><TD>5.947e-03</TD><TD>-5.12</TD><TD>regulation of brown fat cell differentiation</TD><TD>biological process</TD><TD>GO:0090335</TD><TD>7</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>MECOM</TD></TR>
<TR><TD>5.947e-03</TD><TD>-5.12</TD><TD>observational learning</TD><TD>biological process</TD><TD>GO:0098597</TD><TD>7</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>5.947e-03</TD><TD>-5.12</TD><TD>positive regulation of mucus secretion</TD><TD>biological process</TD><TD>GO:0070257</TD><TD>7</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>SYTL2</TD></TR>
<TR><TD>5.962e-03</TD><TD>-5.12</TD><TD>collagen network</TD><TD>cellular component</TD><TD>GO:0098645</TD><TD>7</TD><TD>1</TD><TD>17570</TD><TD>15</TD>
<TD>COL4A5</TD></TR>
<TR><TD>5.962e-03</TD><TD>-5.12</TD><TD>network-forming collagen trimer</TD><TD>cellular component</TD><TD>GO:0098642</TD><TD>7</TD><TD>1</TD><TD>17570</TD><TD>15</TD>
<TD>COL4A5</TD></TR>
<TR><TD>5.962e-03</TD><TD>-5.12</TD><TD>kainate selective glutamate receptor complex</TD><TD>cellular component</TD><TD>GO:0032983</TD><TD>7</TD><TD>1</TD><TD>17570</TD><TD>15</TD>
<TD>NETO2</TD></TR>
<TR><TD>5.962e-03</TD><TD>-5.12</TD><TD>microtubule organizing center attachment site</TD><TD>cellular component</TD><TD>GO:0034992</TD><TD>7</TD><TD>1</TD><TD>17570</TD><TD>15</TD>
<TD>SUN3</TD></TR>
<TR><TD>5.962e-03</TD><TD>-5.12</TD><TD>LINC complex</TD><TD>cellular component</TD><TD>GO:0034993</TD><TD>7</TD><TD>1</TD><TD>17570</TD><TD>15</TD>
<TD>SUN3</TD></TR>
<TR><TD>6.081e-03</TD><TD>-5.10</TD><TD>LIU_PROSTATE_CANCER_DN</TD><TD>MSigDB lists</TD><TD>LIU_PROSTATE_CANCER_DN</TD><TD>456</TD><TD>3</TD><TD>17758</TD><TD>15</TD>
<TD>ALDH2,MFI2,MECOM</TD></TR>
<TR><TD>6.158e-03</TD><TD>-5.09</TD><TD>RAB27B (RAB27B, member RAS oncogene family)</TD><TD>protein interactions</TD><TD>5874</TD><TD>9</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>SYTL2</TD></TR>
<TR><TD>6.158e-03</TD><TD>-5.09</TD><TD>BCL2L10 (BCL2-like 10 (apoptosis facilitator))</TD><TD>protein interactions</TD><TD>10017</TD><TD>9</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>NR4A1</TD></TR>
<TR><TD>6.158e-03</TD><TD>-5.09</TD><TD>CNTN2 (contactin 2 (axonal))</TD><TD>protein interactions</TD><TD>6900</TD><TD>9</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>6.158e-03</TD><TD>-5.09</TD><TD>CUTA (cutA divalent cation tolerance homolog (E. coli))</TD><TD>protein interactions</TD><TD>51596</TD><TD>9</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>NR4A1</TD></TR>
<TR><TD>6.158e-03</TD><TD>-5.09</TD><TD>ANTXR2 (anthrax toxin receptor 2)</TD><TD>protein interactions</TD><TD>118429</TD><TD>9</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>COL4A5</TD></TR>
<TR><TD>6.158e-03</TD><TD>-5.09</TD><TD>ZMIZ1 (zinc finger, MIZ-type containing 1)</TD><TD>protein interactions</TD><TD>57178</TD><TD>9</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>6.220e-03</TD><TD>-5.08</TD><TD>oesophagus-carcinoma-squamous_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>oesophagus-carcinoma-squamous_cell_carcinoma</TD><TD>6791</TD><TD>11</TD><TD>17775</TD><TD>15</TD>
<TD>ZNF432,ALDH2,PLOD2,TOX2,SUN3,COL4A5,FAM198B,CNTNAP2,MYRIP,SYTL2,MECOM</TD></TR>
<TR><TD>6.268e-03</TD><TD>-5.07</TD><TD>Nasopharyngeal carcinoma(PMID:20512145)</TD><TD>GWAS genes</TD><TD>Nasopharyngeal carcinoma(PMID:20512145)</TD><TD>3</TD><TD>1</TD><TD>2389</TD><TD>5</TD>
<TD>MECOM</TD></TR>
<TR><TD>6.268e-03</TD><TD>-5.07</TD><TD>Triglycerides(PMID:22171074)</TD><TD>GWAS genes</TD><TD>Triglycerides(PMID:22171074)</TD><TD>3</TD><TD>1</TD><TD>2389</TD><TD>5</TD>
<TD>ALDH2</TD></TR>
<TR><TD>6.268e-03</TD><TD>-5.07</TD><TD>Bone mineral density(PMID:17903296)</TD><TD>GWAS genes</TD><TD>Bone mineral density(PMID:17903296)</TD><TD>3</TD><TD>1</TD><TD>2389</TD><TD>5</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>6.286e-03</TD><TD>-5.07</TD><TD>RXR and RAR heterodimerization with other nuclear receptor</TD><TD>Pathway Interaction DB</TD><TD>rxr_vdr_pathway</TD><TD>14</TD><TD>1</TD><TD>2227</TD><TD>1</TD>
<TD>NR4A1</TD></TR>
<TR><TD>6.298e-03</TD><TD>-5.07</TD><TD>Sad1_UNC</TD><TD>pfam domains</TD><TD>PF07738</TD><TD>7</TD><TD>1</TD><TD>16629</TD><TD>15</TD>
<TD>SUN3</TD></TR>
<TR><TD>6.568e-03</TD><TD>-5.03</TD><TD>AKT phosphorylates targets in the nucleus</TD><TD>REACTOME pathways</TD><TD>R-HSA-198693</TD><TD>9</TD><TD>1</TD><TD>8202</TD><TD>6</TD>
<TD>NR4A1</TD></TR>
<TR><TD>6.587e-03</TD><TD>-5.02</TD><TD>KAT2B (K(lysine) acetyltransferase 2B)</TD><TD>protein interactions</TD><TD>8850</TD><TD>182</TD><TD>2</TD><TD>16036</TD><TD>11</TD>
<TD>NR4A1,MECOM</TD></TR>
<TR><TD>6.615e-03</TD><TD>-5.02</TD><TD>noradrenaline and adrenaline degradation</TD><TD>BIOCYC pathways</TD><TD>META_PWY-6342</TD><TD>6</TD><TD>1</TD><TD>907</TD><TD>1</TD>
<TD>ALDH2</TD></TR>
<TR><TD>6.615e-03</TD><TD>-5.02</TD><TD>oxidative ethanol degradation III</TD><TD>BIOCYC pathways</TD><TD>HUMAN_PWY66-161</TD><TD>6</TD><TD>1</TD><TD>907</TD><TD>1</TD>
<TD>ALDH2</TD></TR>
<TR><TD>6.739e-03</TD><TD>-5.00</TD><TD>RAMJAUN_APOPTOSIS_BY_TGFB1_VIA_MAPK1_DN</TD><TD>MSigDB lists</TD><TD>RAMJAUN_APOPTOSIS_BY_TGFB1_VIA_MAPK1_DN</TD><TD>8</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>NR4A1</TD></TR>
<TR><TD>6.793e-03</TD><TD>-4.99</TD><TD>neutrophil homeostasis</TD><TD>biological process</TD><TD>GO:0001780</TD><TD>8</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>MECOM</TD></TR>
<TR><TD>6.793e-03</TD><TD>-4.99</TD><TD>auditory behavior</TD><TD>biological process</TD><TD>GO:0031223</TD><TD>8</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>6.793e-03</TD><TD>-4.99</TD><TD>cytoskeletal anchoring at nuclear membrane</TD><TD>biological process</TD><TD>GO:0090286</TD><TD>8</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>SUN3</TD></TR>
<TR><TD>6.793e-03</TD><TD>-4.99</TD><TD>primary alcohol catabolic process</TD><TD>biological process</TD><TD>GO:0034310</TD><TD>8</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>ALDH2</TD></TR>
<TR><TD>6.811e-03</TD><TD>-4.99</TD><TD>basement membrane collagen trimer</TD><TD>cellular component</TD><TD>GO:0098651</TD><TD>8</TD><TD>1</TD><TD>17570</TD><TD>15</TD>
<TD>COL4A5</TD></TR>
<TR><TD>6.840e-03</TD><TD>-4.98</TD><TD>NACAD (NAC alpha domain containing)</TD><TD>protein interactions</TD><TD>23148</TD><TD>10</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>NR4A1</TD></TR>
<TR><TD>7.001e-03</TD><TD>-4.96</TD><TD>chronic_myelomonocytic_leukaemia</TD><TD>COSMIC cancer mutations</TD><TD>chronic_myelomonocytic_leukaemia</TD><TD>151</TD><TD>2</TD><TD>17775</TD><TD>15</TD>
<TD>SYTL2,MECOM</TD></TR>
<TR><TD>7.001e-03</TD><TD>-4.96</TD><TD>haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-chronic_myelomonocytic_leukaemia</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-chronic_myelomonocytic_leukaemia</TD><TD>151</TD><TD>2</TD><TD>17775</TD><TD>15</TD>
<TD>SYTL2,MECOM</TD></TR>
<TR><TD>7.060e-03</TD><TD>-4.95</TD><TD>SUN</TD><TD>prosite domains</TD><TD>PS51469</TD><TD>6</TD><TD>1</TD><TD>11866</TD><TD>14</TD>
<TD>SUN3</TD></TR>
<TR><TD>7.060e-03</TD><TD>-4.95</TD><TD>NC1_IV</TD><TD>prosite domains</TD><TD>PS51403</TD><TD>6</TD><TD>1</TD><TD>11866</TD><TD>14</TD>
<TD>COL4A5</TD></TR>
<TR><TD>7.157e-03</TD><TD>-4.94</TD><TD>Ethanol Degradation</TD><TD>SMPDB pathways</TD><TD>SMP00449</TD><TD>7</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>ALDH2</TD></TR>
<TR><TD>7.189e-03</TD><TD>-4.94</TD><TD>-</TD><TD>gene3d domains</TD><TD>2.170.240.10</TD><TD>6</TD><TD>1</TD><TD>9988</TD><TD>12</TD>
<TD>COL4A5</TD></TR>
<TR><TD>7.208e-03</TD><TD>-4.93</TD><TD>C4</TD><TD>smart domains</TD><TD>SM00111</TD><TD>6</TD><TD>1</TD><TD>9131</TD><TD>11</TD>
<TD>COL4A5</TD></TR>
<TR><TD>7.469e-03</TD><TD>-4.90</TD><TD>GSE6269_HEALTHY_VS_E_COLI_INF_PBMC_DN</TD><TD>MSigDB lists</TD><TD>GSE6269_HEALTHY_VS_E_COLI_INF_PBMC_DN</TD><TD>156</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>COL4A5,MFI2</TD></TR>
<TR><TD>7.522e-03</TD><TD>-4.89</TD><TD>ITGB1BP2 (integrin beta 1 binding protein (melusin) 2)</TD><TD>protein interactions</TD><TD>26548</TD><TD>11</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>PLOD2</TD></TR>
<TR><TD>7.522e-03</TD><TD>-4.89</TD><TD>CDKN2D (cyclin-dependent kinase inhibitor 2D (p19, inhibits CDK4))</TD><TD>protein interactions</TD><TD>1032</TD><TD>11</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>NR4A1</TD></TR>
<TR><TD>7.562e-03</TD><TD>-4.88</TD><TD>GSE18791_CTRL_VS_NEWCASTLE_VIRUS_DC_2H_DN</TD><TD>MSigDB lists</TD><TD>GSE18791_CTRL_VS_NEWCASTLE_VIRUS_DC_2H_DN</TD><TD>157</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>SUN3,NR4A1</TD></TR>
<TR><TD>7.578e-03</TD><TD>-4.88</TD><TD>PEDERSEN_METASTASIS_BY_ERBB2_ISOFORM_5</TD><TD>MSigDB lists</TD><TD>PEDERSEN_METASTASIS_BY_ERBB2_ISOFORM_5</TD><TD>9</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>NR4A1</TD></TR>
<TR><TD>7.718e-03</TD><TD>-4.86</TD><TD>serotonin degradation</TD><TD>BIOCYC pathways</TD><TD>HUMAN_PWY-6313</TD><TD>7</TD><TD>1</TD><TD>907</TD><TD>1</TD>
<TD>ALDH2</TD></TR>
<TR><TD>7.800e-03</TD><TD>-4.85</TD><TD>LIAO_METASTASIS</TD><TD>MSigDB lists</TD><TD>LIAO_METASTASIS</TD><TD>499</TD><TD>3</TD><TD>17758</TD><TD>15</TD>
<TD>ZNF432,MECOM,NETO2</TD></TR>
<TR><TD>8.124e-03</TD><TD>-4.81</TD><TD>regulation of neurotransmitter levels</TD><TD>biological process</TD><TD>GO:0001505</TD><TD>162</TD><TD>2</TD><TD>16441</TD><TD>14</TD>
<TD>ALDH2,SYTL2</TD></TR>
<TR><TD>8.173e-03</TD><TD>-4.81</TD><TD>iron ion binding</TD><TD>molecular function</TD><TD>GO:0005506</TD><TD>163</TD><TD>2</TD><TD>16491</TD><TD>14</TD>
<TD>MFI2,PLOD2</TD></TR>
<TR><TD>8.180e-03</TD><TD>-4.81</TD><TD>Oxidation of Branched Chain Fatty Acids</TD><TD>SMPDB pathways</TD><TD>SMP00030</TD><TD>8</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>ALDH2</TD></TR>
<TR><TD>8.203e-03</TD><TD>-4.80</TD><TD>BBS10 (Bardet-Biedl syndrome 10)</TD><TD>protein interactions</TD><TD>79738</TD><TD>12</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>NR4A1</TD></TR>
<TR><TD>8.203e-03</TD><TD>-4.80</TD><TD>SPDEF (SAM pointed domain containing ETS transcription factor)</TD><TD>protein interactions</TD><TD>25803</TD><TD>12</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>MECOM</TD></TR>
<TR><TD>8.322e-03</TD><TD>-4.79</TD><TD>KATSANOU_ELAVL1_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>KATSANOU_ELAVL1_TARGETS_UP</TD><TD>165</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>PLOD2,SYTL2</TD></TR>
<TR><TD>8.351e-03</TD><TD>-4.79</TD><TD>Intracranial aneurysm(PMID:22286173)</TD><TD>GWAS genes</TD><TD>Intracranial aneurysm(PMID:22286173)</TD><TD>4</TD><TD>1</TD><TD>2389</TD><TD>5</TD>
<TD>ALDH2</TD></TR>
<TR><TD>8.417e-03</TD><TD>-4.78</TD><TD>OXIDOREDUCTASE_ACTIVITY_GO_0016706</TD><TD>MSigDB lists</TD><TD>OXIDOREDUCTASE_ACTIVITY_GO_0016706</TD><TD>10</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>PLOD2</TD></TR>
<TR><TD>8.417e-03</TD><TD>-4.78</TD><TD>REACTOME_ETHANOL_OXIDATION</TD><TD>MSigDB lists</TD><TD>REACTOME_ETHANOL_OXIDATION</TD><TD>10</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>ALDH2</TD></TR>
<TR><TD>8.417e-03</TD><TD>-4.78</TD><TD>KEGG_LIMONENE_AND_PINENE_DEGRADATION</TD><TD>MSigDB lists</TD><TD>KEGG_LIMONENE_AND_PINENE_DEGRADATION</TD><TD>10</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>ALDH2</TD></TR>
<TR><TD>8.485e-03</TD><TD>-4.77</TD><TD>regulation of mucus secretion</TD><TD>biological process</TD><TD>GO:0070255</TD><TD>10</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>SYTL2</TD></TR>
<TR><TD>8.485e-03</TD><TD>-4.77</TD><TD>regulation of plasminogen activation</TD><TD>biological process</TD><TD>GO:0010755</TD><TD>10</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>MFI2</TD></TR>
<TR><TD>8.485e-03</TD><TD>-4.77</TD><TD>endothelial cell chemotaxis</TD><TD>biological process</TD><TD>GO:0035767</TD><TD>10</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>NR4A1</TD></TR>
<TR><TD>8.507e-03</TD><TD>-4.77</TD><TD>exocytic vesicle</TD><TD>cellular component</TD><TD>GO:0070382</TD><TD>10</TD><TD>1</TD><TD>17570</TD><TD>15</TD>
<TD>SYTL2</TD></TR>
<TR><TD>8.507e-03</TD><TD>-4.77</TD><TD>juxtaparanode region of axon</TD><TD>cellular component</TD><TD>GO:0044224</TD><TD>10</TD><TD>1</TD><TD>17570</TD><TD>15</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>8.507e-03</TD><TD>-4.77</TD><TD>dense core granule</TD><TD>cellular component</TD><TD>GO:0031045</TD><TD>10</TD><TD>1</TD><TD>17570</TD><TD>15</TD>
<TD>MYRIP</TD></TR>
<TR><TD>8.518e-03</TD><TD>-4.77</TD><TD>GSE11864_UNTREATED_VS_CSF1_IFNG_PAM3CYS_IN_MAC_UP</TD><TD>MSigDB lists</TD><TD>GSE11864_UNTREATED_VS_CSF1_IFNG_PAM3CYS_IN_MAC_UP</TD><TD>167</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>FAM198B,SYTL2</TD></TR>
<TR><TD>8.539e-03</TD><TD>-4.76</TD><TD>human chr7p12.3</TD><TD>chromosome location</TD><TD>human chr7p12.3</TD><TD>15</TD><TD>1</TD><TD>26250</TD><TD>15</TD>
<TD>SUN3</TD></TR>
<TR><TD>8.616e-03</TD><TD>-4.75</TD><TD>GSE29617_DAY3_VS_DAY7_TIV_FLU_VACCINE_PBMC_2008_UP</TD><TD>MSigDB lists</TD><TD>GSE29617_DAY3_VS_DAY7_TIV_FLU_VACCINE_PBMC_2008_UP</TD><TD>168</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>COL4A5,PLOD2</TD></TR>
<TR><TD>8.643e-03</TD><TD>-4.75</TD><TD>BRUINS_UVC_RESPONSE_VIA_TP53_GROUP_B</TD><TD>MSigDB lists</TD><TD>BRUINS_UVC_RESPONSE_VIA_TP53_GROUP_B</TD><TD>518</TD><TD>3</TD><TD>17758</TD><TD>15</TD>
<TD>COL4A5,FAM198B,NR4A1</TD></TR>
<TR><TD>8.715e-03</TD><TD>-4.74</TD><TD>GSE17974_IL4_AND_ANTI_IL12_VS_UNTREATED_12H_ACT_CD4_TCELL_DN</TD><TD>MSigDB lists</TD><TD>GSE17974_IL4_AND_ANTI_IL12_VS_UNTREATED_12H_ACT_CD4_TCELL_DN</TD><TD>169</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>COL4A5,SYTL2</TD></TR>
<TR><TD>8.749e-03</TD><TD>-4.74</TD><TD>Ethanol oxidation</TD><TD>REACTOME pathways</TD><TD>R-HSA-71384</TD><TD>12</TD><TD>1</TD><TD>8202</TD><TD>6</TD>
<TD>ALDH2</TD></TR>
<TR><TD>8.758e-03</TD><TD>-4.74</TD><TD>skin-ear-carcinoma-squamous_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-ear-carcinoma-squamous_cell_carcinoma</TD><TD>521</TD><TD>3</TD><TD>17775</TD><TD>15</TD>
<TD>CNTNAP2,TOX2,NETO2</TD></TR>
<TR><TD>8.884e-03</TD><TD>-4.72</TD><TD>PGBD1 (piggyBac transposable element derived 1)</TD><TD>protein interactions</TD><TD>84547</TD><TD>13</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>NR4A1</TD></TR>
<TR><TD>8.884e-03</TD><TD>-4.72</TD><TD>ALDH6A1 (aldehyde dehydrogenase 6 family, member A1)</TD><TD>protein interactions</TD><TD>4329</TD><TD>13</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>ALDH2</TD></TR>
<TR><TD>9.202e-03</TD><TD>-4.69</TD><TD>Beta-Alanine Metabolism</TD><TD>SMPDB pathways</TD><TD>SMP00007</TD><TD>9</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>ALDH2</TD></TR>
<TR><TD>9.202e-03</TD><TD>-4.69</TD><TD>Carnosinuria- carnosinemia</TD><TD>SMPDB pathways</TD><TD>SMP00493</TD><TD>9</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>ALDH2</TD></TR>
<TR><TD>9.202e-03</TD><TD>-4.69</TD><TD>GABA-Transaminase Deficiency</TD><TD>SMPDB pathways</TD><TD>SMP00351</TD><TD>9</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>ALDH2</TD></TR>
<TR><TD>9.202e-03</TD><TD>-4.69</TD><TD>Ureidopropionase deficiency</TD><TD>SMPDB pathways</TD><TD>SMP00492</TD><TD>9</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>ALDH2</TD></TR>
<TR><TD>9.217e-03</TD><TD>-4.69</TD><TD>DOANE_RESPONSE_TO_ANDROGEN_UP</TD><TD>MSigDB lists</TD><TD>DOANE_RESPONSE_TO_ANDROGEN_UP</TD><TD>174</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>ZNF432,CNTNAP2</TD></TR>
<TR><TD>9.250e-03</TD><TD>-4.68</TD><TD>CHICAS_RB1_TARGETS_CONFLUENT</TD><TD>MSigDB lists</TD><TD>CHICAS_RB1_TARGETS_CONFLUENT</TD><TD>531</TD><TD>3</TD><TD>17758</TD><TD>15</TD>
<TD>FAM198B,SYTL2,MECOM</TD></TR>
<TR><TD>9.255e-03</TD><TD>-4.68</TD><TD>BIOCARTA_VITCB_PATHWAY</TD><TD>MSigDB lists</TD><TD>BIOCARTA_VITCB_PATHWAY</TD><TD>11</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>COL4A5</TD></TR>
<TR><TD>9.320e-03</TD><TD>-4.68</TD><TD>MODULE_126</TD><TD>MSigDB lists</TD><TD>MODULE_126</TD><TD>175</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>MFI2,MECOM</TD></TR>
<TR><TD>9.330e-03</TD><TD>-4.67</TD><TD>mechanosensory behavior</TD><TD>biological process</TD><TD>GO:0007638</TD><TD>11</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>9.330e-03</TD><TD>-4.67</TD><TD>negative regulation of substrate adhesion-dependent cell spreading</TD><TD>biological process</TD><TD>GO:1900025</TD><TD>11</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>MFI2</TD></TR>
<TR><TD>9.525e-03</TD><TD>-4.65</TD><TD>GSE9988_ANTI_TREM1_VS_CTRL_TREATED_MONOCYTES_UP</TD><TD>MSigDB lists</TD><TD>GSE9988_ANTI_TREM1_VS_CTRL_TREATED_MONOCYTES_UP</TD><TD>177</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>MFI2,NR4A1</TD></TR>
<TR><TD>9.565e-03</TD><TD>-4.65</TD><TD>COLGALT1 (collagen beta(1-O)galactosyltransferase 1)</TD><TD>protein interactions</TD><TD>79709</TD><TD>14</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>PLOD2</TD></TR>
<TR><TD>9.565e-03</TD><TD>-4.65</TD><TD>SERPING1 (serpin peptidase inhibitor, clade G (C1 inhibitor), member 1)</TD><TD>protein interactions</TD><TD>710</TD><TD>14</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>NR4A1</TD></TR>
<TR><TD>9.629e-03</TD><TD>-4.64</TD><TD>ATF2_UP.V1_DN</TD><TD>MSigDB lists</TD><TD>ATF2_UP.V1_DN</TD><TD>178</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>ZNF432,FAM198B</TD></TR>
<TR><TD>9.629e-03</TD><TD>-4.64</TD><TD>GSE17974_IL4_AND_ANTI_IL12_VS_UNTREATED_6H_ACT_CD4_TCELL_DN</TD><TD>MSigDB lists</TD><TD>GSE17974_IL4_AND_ANTI_IL12_VS_UNTREATED_6H_ACT_CD4_TCELL_DN</TD><TD>178</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>TOX2,SYTL2</TD></TR>
<TR><TD>9.673e-03</TD><TD>-4.64</TD><TD>human chr4q32.1</TD><TD>chromosome location</TD><TD>human chr4q32.1</TD><TD>17</TD><TD>1</TD><TD>26250</TD><TD>15</TD>
<TD>FAM198B</TD></TR>
<TR><TD>9.673e-03</TD><TD>-4.64</TD><TD>human chr3q26.2</TD><TD>chromosome location</TD><TD>human chr3q26.2</TD><TD>17</TD><TD>1</TD><TD>26250</TD><TD>15</TD>
<TD>MECOM</TD></TR>
<TR><TD>9.733e-03</TD><TD>-4.63</TD><TD>GSE17974_CTRL_VS_ACT_IL4_AND_ANTI_IL12_6H_CD4_TCELL_DN</TD><TD>MSigDB lists</TD><TD>GSE17974_CTRL_VS_ACT_IL4_AND_ANTI_IL12_6H_CD4_TCELL_DN</TD><TD>179</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>MECOM,NETO2</TD></TR>
<TR><TD>9.837e-03</TD><TD>-4.62</TD><TD>LI_WILMS_TUMOR_VS_FETAL_KIDNEY_1_UP</TD><TD>MSigDB lists</TD><TD>LI_WILMS_TUMOR_VS_FETAL_KIDNEY_1_UP</TD><TD>180</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>COL4A5,MECOM</TD></TR>
<TR><TD>9.923e-03</TD><TD>-4.61</TD><TD>putrescine degradation III</TD><TD>BIOCYC pathways</TD><TD>HUMAN_PWY-0</TD><TD>9</TD><TD>1</TD><TD>907</TD><TD>1</TD>
<TD>ALDH2</TD></TR>
<TR><TD>9.942e-03</TD><TD>-4.61</TD><TD>GSE8515_CTRL_VS_IL6_4H_STIM_MAC_DN</TD><TD>MSigDB lists</TD><TD>GSE8515_CTRL_VS_IL6_4H_STIM_MAC_DN</TD><TD>181</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>PLOD2,MECOM</TD></TR>
<TR><TD>9.942e-03</TD><TD>-4.61</TD><TD>GSE25087_TREG_VS_TCONV_FETUS_UP</TD><TD>MSigDB lists</TD><TD>GSE25087_TREG_VS_TCONV_FETUS_UP</TD><TD>181</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>TOX2,NETO2</TD></TR>
<TR><TD>1.009e-02</TD><TD>-4.60</TD><TD>BOYERINAS_ONCOFETAL_TARGETS_OF_LET7A1</TD><TD>MSigDB lists</TD><TD>BOYERINAS_ONCOFETAL_TARGETS_OF_LET7A1</TD><TD>12</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>COL4A5</TD></TR>
<TR><TD>1.015e-02</TD><TD>-4.59</TD><TD>LEF1_UP.V1_DN</TD><TD>MSigDB lists</TD><TD>LEF1_UP.V1_DN</TD><TD>183</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>MYRIP,PLOD2</TD></TR>
<TR><TD>1.017e-02</TD><TD>-4.59</TD><TD>ethanol oxidation</TD><TD>biological process</TD><TD>GO:0006069</TD><TD>12</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>ALDH2</TD></TR>
<TR><TD>1.017e-02</TD><TD>-4.59</TD><TD>regulation of extracellular matrix disassembly</TD><TD>biological process</TD><TD>GO:0010715</TD><TD>12</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>MFI2</TD></TR>
<TR><TD>1.017e-02</TD><TD>-4.59</TD><TD>iron ion import</TD><TD>biological process</TD><TD>GO:0097286</TD><TD>12</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>MFI2</TD></TR>
<TR><TD>1.017e-02</TD><TD>-4.59</TD><TD>neuronal ion channel clustering</TD><TD>biological process</TD><TD>GO:0045161</TD><TD>12</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>1.019e-02</TD><TD>-4.59</TD><TD>soft_tissue</TD><TD>COSMIC cancer mutations</TD><TD>soft_tissue</TD><TD>6065</TD><TD>10</TD><TD>17775</TD><TD>15</TD>
<TD>MFI2,PLOD2,NR4A1,TOX2,NETO2,COL4A5,CNTNAP2,MYRIP,SYTL2,MECOM</TD></TR>
<TR><TD>1.024e-02</TD><TD>-4.58</TD><TD>human chrXq22</TD><TD>chromosome location</TD><TD>human chrXq22</TD><TD>18</TD><TD>1</TD><TD>26250</TD><TD>15</TD>
<TD>COL4A5</TD></TR>
<TR><TD>1.043e-02</TD><TD>-4.56</TD><TD>Alzheimer&#39;s disease(PMID:22159054)</TD><TD>GWAS genes</TD><TD>Alzheimer&#39;s disease(PMID:22159054)</TD><TD>5</TD><TD>1</TD><TD>2389</TD><TD>5</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>1.043e-02</TD><TD>-4.56</TD><TD>Diastolic blood pressure(PMID:19430483)</TD><TD>GWAS genes</TD><TD>Diastolic blood pressure(PMID:19430483)</TD><TD>5</TD><TD>1</TD><TD>2389</TD><TD>5</TD>
<TD>MECOM</TD></TR>
<TR><TD>1.048e-02</TD><TD>-4.56</TD><TD>GSE17721_PAM3CSK4_VS_CPG_16H_BMDM_UP</TD><TD>MSigDB lists</TD><TD>GSE17721_PAM3CSK4_VS_CPG_16H_BMDM_UP</TD><TD>186</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>COL4A5,ALDH2</TD></TR>
<TR><TD>1.069e-02</TD><TD>-4.54</TD><TD>V$FOXD3_01</TD><TD>MSigDB lists</TD><TD>V$FOXD3_01</TD><TD>188</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>NR4A1,SYTL2</TD></TR>
<TR><TD>1.080e-02</TD><TD>-4.53</TD><TD>GSE30083_SP1_VS_SP4_THYMOCYTE_UP</TD><TD>MSigDB lists</TD><TD>GSE30083_SP1_VS_SP4_THYMOCYTE_UP</TD><TD>189</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>PLOD2,SYTL2</TD></TR>
<TR><TD>1.080e-02</TD><TD>-4.53</TD><TD>GSE1460_NAIVE_CD4_TCELL_ADULT_BLOOD_VS_THYMIC_STROMAL_CELL_DN</TD><TD>MSigDB lists</TD><TD>GSE1460_NAIVE_CD4_TCELL_ADULT_BLOOD_VS_THYMIC_STROMAL_CELL_DN</TD><TD>189</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>COL4A5,ALDH2</TD></TR>
<TR><TD>1.081e-02</TD><TD>-4.53</TD><TD>human chr3q24</TD><TD>chromosome location</TD><TD>human chr3q24</TD><TD>19</TD><TD>1</TD><TD>26250</TD><TD>15</TD>
<TD>PLOD2</TD></TR>
<TR><TD>1.091e-02</TD><TD>-4.52</TD><TD>GSE360_T_GONDII_VS_M_TUBERCULOSIS_DC_UP</TD><TD>MSigDB lists</TD><TD>GSE360_T_GONDII_VS_M_TUBERCULOSIS_DC_UP</TD><TD>190</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>COL4A5,ALDH2</TD></TR>
<TR><TD>1.092e-02</TD><TD>-4.52</TD><TD>BCL2A1 (BCL2-related protein A1)</TD><TD>protein interactions</TD><TD>597</TD><TD>16</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>NR4A1</TD></TR>
<TR><TD>1.092e-02</TD><TD>-4.52</TD><TD>MYO7A (myosin VIIA)</TD><TD>protein interactions</TD><TD>4647</TD><TD>16</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>MYRIP</TD></TR>
<TR><TD>1.092e-02</TD><TD>-4.52</TD><TD>OSM (oncostatin M)</TD><TD>protein interactions</TD><TD>5008</TD><TD>16</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>COL4A5</TD></TR>
<TR><TD>1.093e-02</TD><TD>-4.52</TD><TD>WANG_RESPONSE_TO_PACLITAXEL_VIA_MAPK8_UP</TD><TD>MSigDB lists</TD><TD>WANG_RESPONSE_TO_PACLITAXEL_VIA_MAPK8_UP</TD><TD>13</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>PLOD2</TD></TR>
<TR><TD>1.093e-02</TD><TD>-4.52</TD><TD>EXTRINSIC_TO_PLASMA_MEMBRANE</TD><TD>MSigDB lists</TD><TD>EXTRINSIC_TO_PLASMA_MEMBRANE</TD><TD>13</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>SYTL2</TD></TR>
<TR><TD>1.093e-02</TD><TD>-4.52</TD><TD>BIOCARTA_ACE2_PATHWAY</TD><TD>MSigDB lists</TD><TD>BIOCARTA_ACE2_PATHWAY</TD><TD>13</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>COL4A5</TD></TR>
<TR><TD>1.098e-02</TD><TD>-4.51</TD><TD>neurexin family protein binding</TD><TD>molecular function</TD><TD>GO:0042043</TD><TD>13</TD><TD>1</TD><TD>16491</TD><TD>14</TD>
<TD>SYTL2</TD></TR>
<TR><TD>1.102e-02</TD><TD>-4.51</TD><TD>thalamus development</TD><TD>biological process</TD><TD>GO:0021794</TD><TD>13</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>1.103e-02</TD><TD>-4.51</TD><TD>noradrenaline and adrenaline degradation</TD><TD>BIOCYC pathways</TD><TD>HUMAN_PWY-6342</TD><TD>10</TD><TD>1</TD><TD>907</TD><TD>1</TD>
<TD>ALDH2</TD></TR>
<TR><TD>1.113e-02</TD><TD>-4.50</TD><TD>GSE17721_CTRL_VS_GARDIQUIMOD_12H_BMDM_UP</TD><TD>MSigDB lists</TD><TD>GSE17721_CTRL_VS_GARDIQUIMOD_12H_BMDM_UP</TD><TD>192</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>COL4A5,FAM198B</TD></TR>
<TR><TD>1.113e-02</TD><TD>-4.50</TD><TD>GSE36476_CTRL_VS_TSST_ACT_16H_MEMORY_CD4_TCELL_YOUNG_DN</TD><TD>MSigDB lists</TD><TD>GSE36476_CTRL_VS_TSST_ACT_16H_MEMORY_CD4_TCELL_YOUNG_DN</TD><TD>192</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>ALDH2,NETO2</TD></TR>
<TR><TD>1.113e-02</TD><TD>-4.50</TD><TD>GSE31082_DP_VS_CD8_SP_THYMOCYTE_UP</TD><TD>MSigDB lists</TD><TD>GSE31082_DP_VS_CD8_SP_THYMOCYTE_UP</TD><TD>192</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>ALDH2,NETO2</TD></TR>
<TR><TD>1.124e-02</TD><TD>-4.49</TD><TD>GSE30962_ACUTE_VS_CHRONIC_LCMV_PRIMARY_INF_CD8_TCELL_DN</TD><TD>MSigDB lists</TD><TD>GSE30962_ACUTE_VS_CHRONIC_LCMV_PRIMARY_INF_CD8_TCELL_DN</TD><TD>193</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>PLOD2,TOX2</TD></TR>
<TR><TD>1.124e-02</TD><TD>-4.49</TD><TD>GSE17721_LPS_VS_CPG_24H_BMDM_DN</TD><TD>MSigDB lists</TD><TD>GSE17721_LPS_VS_CPG_24H_BMDM_DN</TD><TD>193</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>CNTNAP2,ALDH2</TD></TR>
<TR><TD>1.124e-02</TD><TD>-4.49</TD><TD>TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_8D_DN</TD><TD>MSigDB lists</TD><TD>TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_8D_DN</TD><TD>193</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>FAM198B,ALDH2</TD></TR>
<TR><TD>1.130e-02</TD><TD>-4.48</TD><TD>upper_aerodigestive_tract-mouth-carcinoma-squamous_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>upper_aerodigestive_tract-mouth-carcinoma-squamous_cell_carcinoma</TD><TD>7269</TD><TD>11</TD><TD>17775</TD><TD>15</TD>
<TD>ZNF432,ALDH2,MFI2,PLOD2,NR4A1,NETO2,COL4A5,FAM198B,CNTNAP2,MYRIP,MECOM</TD></TR>
<TR><TD>1.135e-02</TD><TD>-4.48</TD><TD>GSE39820_CTRL_VS_TGFBETA1_IL6_CD4_TCELL_DN</TD><TD>MSigDB lists</TD><TD>GSE39820_CTRL_VS_TGFBETA1_IL6_CD4_TCELL_DN</TD><TD>194</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>PLOD2,TOX2</TD></TR>
<TR><TD>1.135e-02</TD><TD>-4.48</TD><TD>GSE3982_BASOPHIL_VS_TH1_DN</TD><TD>MSigDB lists</TD><TD>GSE3982_BASOPHIL_VS_TH1_DN</TD><TD>194</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>SYTL2,NETO2</TD></TR>
<TR><TD>1.135e-02</TD><TD>-4.48</TD><TD>GSE7764_NKCELL_VS_SPLENOCYTE_UP</TD><TD>MSigDB lists</TD><TD>GSE7764_NKCELL_VS_SPLENOCYTE_UP</TD><TD>194</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>PLOD2,SYTL2</TD></TR>
<TR><TD>1.135e-02</TD><TD>-4.48</TD><TD>GSE29618_BCELL_VS_MONOCYTE_DAY7_FLU_VACCINE_DN</TD><TD>MSigDB lists</TD><TD>GSE29618_BCELL_VS_MONOCYTE_DAY7_FLU_VACCINE_DN</TD><TD>194</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>FAM198B,ALDH2</TD></TR>
<TR><TD>1.135e-02</TD><TD>-4.48</TD><TD>GSE20366_TREG_VS_NAIVE_CD4_TCELL_DEC205_CONVERSION_UP</TD><TD>MSigDB lists</TD><TD>GSE20366_TREG_VS_NAIVE_CD4_TCELL_DEC205_CONVERSION_UP</TD><TD>194</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>SYTL2,NETO2</TD></TR>
<TR><TD>1.142e-02</TD><TD>-4.47</TD><TD>Neurexin-like</TD><TD>interpro domains</TD><TD>IPR003585</TD><TD>14</TD><TD>1</TD><TD>18293</TD><TD>15</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>1.147e-02</TD><TD>-4.47</TD><TD>GSE7852_LN_VS_FAT_TCONV_DN</TD><TD>MSigDB lists</TD><TD>GSE7852_LN_VS_FAT_TCONV_DN</TD><TD>195</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>NR4A1,MECOM</TD></TR>
<TR><TD>1.147e-02</TD><TD>-4.47</TD><TD>transport vesicle</TD><TD>cellular component</TD><TD>GO:0030133</TD><TD>193</TD><TD>2</TD><TD>17570</TD><TD>15</TD>
<TD>MYRIP,SYTL2</TD></TR>
<TR><TD>1.156e-02</TD><TD>-4.46</TD><TD>bone-femur-other-chondroblastoma</TD><TD>COSMIC cancer mutations</TD><TD>bone-femur-other-chondroblastoma</TD><TD>196</TD><TD>2</TD><TD>17775</TD><TD>15</TD>
<TD>CNTNAP2,PLOD2</TD></TR>
<TR><TD>1.160e-02</TD><TD>-4.46</TD><TD>SERPINA4 (serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 4)</TD><TD>protein interactions</TD><TD>5267</TD><TD>17</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>NR4A1</TD></TR>
<TR><TD>1.160e-02</TD><TD>-4.46</TD><TD>SLC35F6 (solute carrier family 35, member F6)</TD><TD>protein interactions</TD><TD>54978</TD><TD>17</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>ALDH2</TD></TR>
<TR><TD>1.164e-02</TD><TD>-4.45</TD><TD>carboxylic acid binding</TD><TD>molecular function</TD><TD>GO:0031406</TD><TD>196</TD><TD>2</TD><TD>16491</TD><TD>14</TD>
<TD>PLOD2,SYTL2</TD></TR>
<TR><TD>1.176e-02</TD><TD>-4.44</TD><TD>organic acid binding</TD><TD>molecular function</TD><TD>GO:0043177</TD><TD>197</TD><TD>2</TD><TD>16491</TD><TD>14</TD>
<TD>PLOD2,SYTL2</TD></TR>
<TR><TD>1.177e-02</TD><TD>-4.44</TD><TD>BIOCARTA_PLATELETAPP_PATHWAY</TD><TD>MSigDB lists</TD><TD>BIOCARTA_PLATELETAPP_PATHWAY</TD><TD>14</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>COL4A5</TD></TR>
<TR><TD>1.181e-02</TD><TD>-4.44</TD><TD>HALLMARK_MTORC1_SIGNALING</TD><TD>MSigDB lists</TD><TD>HALLMARK_MTORC1_SIGNALING</TD><TD>198</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>PLOD2,SYTL2</TD></TR>
<TR><TD>1.181e-02</TD><TD>-4.44</TD><TD>GSE360_DC_VS_MAC_M_TUBERCULOSIS_DN</TD><TD>MSigDB lists</TD><TD>GSE360_DC_VS_MAC_M_TUBERCULOSIS_DN</TD><TD>198</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>ALDH2,PLOD2</TD></TR>
<TR><TD>1.186e-02</TD><TD>-4.43</TD><TD>vocalization behavior</TD><TD>biological process</TD><TD>GO:0071625</TD><TD>14</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>1.186e-02</TD><TD>-4.43</TD><TD>ethanol metabolic process</TD><TD>biological process</TD><TD>GO:0006067</TD><TD>14</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>ALDH2</TD></TR>
<TR><TD>1.186e-02</TD><TD>-4.43</TD><TD>hematopoietic stem cell proliferation</TD><TD>biological process</TD><TD>GO:0071425</TD><TD>14</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>MECOM</TD></TR>
<TR><TD>1.215e-02</TD><TD>-4.41</TD><TD>MANALO_HYPOXIA_UP</TD><TD>MSigDB lists</TD><TD>MANALO_HYPOXIA_UP</TD><TD>201</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>ALDH2,PLOD2</TD></TR>
<TR><TD>1.226e-02</TD><TD>-4.40</TD><TD>MIYAGAWA_TARGETS_OF_EWSR1_ETS_FUSIONS_DN</TD><TD>MSigDB lists</TD><TD>MIYAGAWA_TARGETS_OF_EWSR1_ETS_FUSIONS_DN</TD><TD>202</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>FAM198B,PLOD2</TD></TR>
<TR><TD>1.228e-02</TD><TD>-4.40</TD><TD>ARHGEF5 (Rho guanine nucleotide exchange factor 5)</TD><TD>protein interactions</TD><TD>7984</TD><TD>18</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>NR4A1</TD></TR>
<TR><TD>1.228e-02</TD><TD>-4.40</TD><TD>ROBO2 (roundabout guidance receptor 2)</TD><TD>protein interactions</TD><TD>6092</TD><TD>18</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>NR4A1</TD></TR>
<TR><TD>1.238e-02</TD><TD>-4.39</TD><TD>LEE_RECENT_THYMIC_EMIGRANT</TD><TD>MSigDB lists</TD><TD>LEE_RECENT_THYMIC_EMIGRANT</TD><TD>203</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>SYTL2,TOX2</TD></TR>
<TR><TD>1.250e-02</TD><TD>-4.38</TD><TD>CAIRO_HEPATOBLASTOMA_CLASSES_DN</TD><TD>MSigDB lists</TD><TD>CAIRO_HEPATOBLASTOMA_CLASSES_DN</TD><TD>204</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>ALDH2,MYRIP</TD></TR>
<TR><TD>1.251e-02</TD><TD>-4.38</TD><TD>Magnesium levels(PMID:20700443)</TD><TD>GWAS genes</TD><TD>Magnesium levels(PMID:20700443)</TD><TD>6</TD><TD>1</TD><TD>2389</TD><TD>5</TD>
<TD>MECOM</TD></TR>
<TR><TD>1.251e-02</TD><TD>-4.38</TD><TD>Conduct disorder (symptom count)(PMID:20585324)</TD><TD>GWAS genes</TD><TD>Conduct disorder (symptom count)(PMID:20585324)</TD><TD>6</TD><TD>1</TD><TD>2389</TD><TD>5</TD>
<TD>TOX2</TD></TR>
<TR><TD>1.260e-02</TD><TD>-4.37</TD><TD>DEMAGALHAES_AGING_DN</TD><TD>MSigDB lists</TD><TD>DEMAGALHAES_AGING_DN</TD><TD>15</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>COL4A5</TD></TR>
<TR><TD>1.260e-02</TD><TD>-4.37</TD><TD>OXIDOREDUCTASE_ACTIVITY_ACTING_ON_THE_ALDEHYDE_OR_OXO_GROUP_OF_DONORSNAD_OR_NADP_AS_ACCEPTOR</TD><TD>MSigDB lists</TD><TD>OXIDOREDUCTASE_ACTIVITY_ACTING_ON_THE_ALDEHYDE_OR_OXO_GROUP_OF_DONORSNAD_OR_NADP_AS_ACCEPTOR</TD><TD>15</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>ALDH2</TD></TR>
<TR><TD>1.260e-02</TD><TD>-4.37</TD><TD>alveolar</TD><TD>COSMIC cancer mutations</TD><TD>alveolar</TD><TD>2511</TD><TD>6</TD><TD>17775</TD><TD>15</TD>
<TD>COL4A5,CNTNAP2,MFI2,PLOD2,NR4A1,TOX2</TD></TR>
<TR><TD>1.260e-02</TD><TD>-4.37</TD><TD>soft_tissue-striated_muscle-rhabdomyosarcoma-alveolar</TD><TD>COSMIC cancer mutations</TD><TD>soft_tissue-striated_muscle-rhabdomyosarcoma-alveolar</TD><TD>2511</TD><TD>6</TD><TD>17775</TD><TD>15</TD>
<TD>COL4A5,CNTNAP2,MFI2,PLOD2,NR4A1,TOX2</TD></TR>
<TR><TD>1.266e-02</TD><TD>-4.37</TD><TD>protein anchor</TD><TD>molecular function</TD><TD>GO:0043495</TD><TD>15</TD><TD>1</TD><TD>16491</TD><TD>14</TD>
<TD>SUN3</TD></TR>
<TR><TD>1.270e-02</TD><TD>-4.37</TD><TD>cell migration involved in sprouting angiogenesis</TD><TD>biological process</TD><TD>GO:0002042</TD><TD>15</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>NR4A1</TD></TR>
<TR><TD>1.270e-02</TD><TD>-4.37</TD><TD>positive regulation of extracellular matrix organization</TD><TD>biological process</TD><TD>GO:1903055</TD><TD>15</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>MFI2</TD></TR>
<TR><TD>1.296e-02</TD><TD>-4.35</TD><TD>ZNF579 (zinc finger protein 579)</TD><TD>protein interactions</TD><TD>163033</TD><TD>19</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>NR4A1</TD></TR>
<TR><TD>1.304e-02</TD><TD>-4.34</TD><TD>Ald_DH_CS_CYS</TD><TD>interpro domains</TD><TD>IPR016160</TD><TD>16</TD><TD>1</TD><TD>18293</TD><TD>15</TD>
<TD>ALDH2</TD></TR>
<TR><TD>1.304e-02</TD><TD>-4.34</TD><TD>Ald_DH_CS_GLU</TD><TD>interpro domains</TD><TD>IPR029510</TD><TD>16</TD><TD>1</TD><TD>18293</TD><TD>15</TD>
<TD>ALDH2</TD></TR>
<TR><TD>1.304e-02</TD><TD>-4.34</TD><TD>Pro_4_hyd_alph</TD><TD>interpro domains</TD><TD>IPR006620</TD><TD>16</TD><TD>1</TD><TD>18293</TD><TD>15</TD>
<TD>PLOD2</TD></TR>
<TR><TD>1.321e-02</TD><TD>-4.33</TD><TD>BOQUEST_STEM_CELL_DN</TD><TD>MSigDB lists</TD><TD>BOQUEST_STEM_CELL_DN</TD><TD>210</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>MYRIP,MECOM</TD></TR>
<TR><TD>1.324e-02</TD><TD>-4.32</TD><TD>cellular protein localization</TD><TD>biological process</TD><TD>GO:0034613</TD><TD>1143</TD><TD>4</TD><TD>16441</TD><TD>14</TD>
<TD>SUN3,CNTNAP2,MYRIP,SYTL2</TD></TR>
<TR><TD>1.340e-02</TD><TD>-4.31</TD><TD>Fatty Acid Omega Oxidation</TD><TD>WikiPathways</TD><TD>WP206</TD><TD>15</TD><TD>1</TD><TD>4455</TD><TD>4</TD>
<TD>ALDH2</TD></TR>
<TR><TD>1.344e-02</TD><TD>-4.31</TD><TD>LEE_LIVER_CANCER_HEPATOBLAST</TD><TD>MSigDB lists</TD><TD>LEE_LIVER_CANCER_HEPATOBLAST</TD><TD>16</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>NR4A1</TD></TR>
<TR><TD>1.344e-02</TD><TD>-4.31</TD><TD>CAIRO_HEPATOBLASTOMA_POOR_SURVIVAL</TD><TD>MSigDB lists</TD><TD>CAIRO_HEPATOBLASTOMA_POOR_SURVIVAL</TD><TD>16</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>ALDH2</TD></TR>
<TR><TD>1.354e-02</TD><TD>-4.30</TD><TD>striatum development</TD><TD>biological process</TD><TD>GO:0021756</TD><TD>16</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>1.356e-02</TD><TD>-4.30</TD><TD>cellular macromolecule localization</TD><TD>biological process</TD><TD>GO:0070727</TD><TD>1151</TD><TD>4</TD><TD>16441</TD><TD>14</TD>
<TD>SUN3,CNTNAP2,MYRIP,SYTL2</TD></TR>
<TR><TD>1.364e-02</TD><TD>-4.29</TD><TD>KCNA2 (potassium channel, voltage gated shaker related subfamily A, member 2)</TD><TD>protein interactions</TD><TD>3737</TD><TD>20</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>1.364e-02</TD><TD>-4.29</TD><TD>MATN2 (matrilin 2)</TD><TD>protein interactions</TD><TD>4147</TD><TD>20</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>COL4A5</TD></TR>
<TR><TD>1.364e-02</TD><TD>-4.29</TD><TD>RNF123 (ring finger protein 123)</TD><TD>protein interactions</TD><TD>63891</TD><TD>20</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>PLOD2</TD></TR>
<TR><TD>1.364e-02</TD><TD>-4.29</TD><TD>SERPINE2 (serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 2)</TD><TD>protein interactions</TD><TD>5270</TD><TD>20</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>COL4A5</TD></TR>
<TR><TD>1.426e-02</TD><TD>-4.25</TD><TD>central_nervous_system-diencephalon-glioma-astrocytoma_Grade_I</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-diencephalon-glioma-astrocytoma_Grade_I</TD><TD>17</TD><TD>1</TD><TD>17775</TD><TD>15</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>1.427e-02</TD><TD>-4.25</TD><TD>TOMIDA_METASTASIS_DN</TD><TD>MSigDB lists</TD><TD>TOMIDA_METASTASIS_DN</TD><TD>17</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>NR4A1</TD></TR>
<TR><TD>1.427e-02</TD><TD>-4.25</TD><TD>SILIGAN_TARGETS_OF_EWS_FLI1_FUSION_DN</TD><TD>MSigDB lists</TD><TD>SILIGAN_TARGETS_OF_EWS_FLI1_FUSION_DN</TD><TD>17</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>1.427e-02</TD><TD>-4.25</TD><TD>NIELSEN_MALIGNAT_FIBROUS_HISTIOCYTOMA_DN</TD><TD>MSigDB lists</TD><TD>NIELSEN_MALIGNAT_FIBROUS_HISTIOCYTOMA_DN</TD><TD>17</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>COL4A5</TD></TR>
<TR><TD>1.431e-02</TD><TD>-4.25</TD><TD>Histidinemia</TD><TD>SMPDB pathways</TD><TD>SMP00191</TD><TD>14</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>ALDH2</TD></TR>
<TR><TD>1.431e-02</TD><TD>-4.25</TD><TD>Histidine Metabolism</TD><TD>SMPDB pathways</TD><TD>SMP00044</TD><TD>14</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>ALDH2</TD></TR>
<TR><TD>1.432e-02</TD><TD>-4.25</TD><TD>TPP2 (tripeptidyl peptidase II)</TD><TD>protein interactions</TD><TD>7174</TD><TD>21</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>PLOD2</TD></TR>
<TR><TD>1.432e-02</TD><TD>-4.25</TD><TD>IGKC (immunoglobulin kappa constant)</TD><TD>protein interactions</TD><TD>3514</TD><TD>21</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>ALDH2</TD></TR>
<TR><TD>1.432e-02</TD><TD>-4.25</TD><TD>rhabdomyosarcoma</TD><TD>COSMIC cancer mutations</TD><TD>rhabdomyosarcoma</TD><TD>4310</TD><TD>8</TD><TD>17775</TD><TD>15</TD>
<TD>MFI2,PLOD2,NR4A1,TOX2,NETO2,COL4A5,CNTNAP2,SYTL2</TD></TR>
<TR><TD>1.438e-02</TD><TD>-4.24</TD><TD>neurotransmitter biosynthetic process</TD><TD>biological process</TD><TD>GO:0042136</TD><TD>17</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>ALDH2</TD></TR>
<TR><TD>1.452e-02</TD><TD>-4.23</TD><TD>Extracellular matrix organization</TD><TD>REACTOME pathways</TD><TD>R-HSA-1474244</TD><TD>267</TD><TD>2</TD><TD>8202</TD><TD>6</TD>
<TD>COL4A5,PLOD2</TD></TR>
<TR><TD>1.458e-02</TD><TD>-4.23</TD><TD>Renal function-related traits (sCR)(PMID:22797727)</TD><TD>GWAS genes</TD><TD>Renal function-related traits (sCR)(PMID:22797727)</TD><TD>7</TD><TD>1</TD><TD>2389</TD><TD>5</TD>
<TD>ALDH2</TD></TR>
<TR><TD>1.458e-02</TD><TD>-4.23</TD><TD>Systolic blood pressure(PMID:19430479)</TD><TD>GWAS genes</TD><TD>Systolic blood pressure(PMID:19430479)</TD><TD>7</TD><TD>1</TD><TD>2389</TD><TD>5</TD>
<TD>MECOM</TD></TR>
<TR><TD>1.468e-02</TD><TD>-4.22</TD><TD>BENPORATH_MYC_TARGETS_WITH_EBOX</TD><TD>MSigDB lists</TD><TD>BENPORATH_MYC_TARGETS_WITH_EBOX</TD><TD>222</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>ALDH2,MFI2</TD></TR>
<TR><TD>1.493e-02</TD><TD>-4.20</TD><TD>RICKMAN_TUMOR_DIFFERENTIATED_WELL_VS_POORLY_UP</TD><TD>MSigDB lists</TD><TD>RICKMAN_TUMOR_DIFFERENTIATED_WELL_VS_POORLY_UP</TD><TD>224</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>ALDH2,MECOM</TD></TR>
<TR><TD>1.493e-02</TD><TD>-4.20</TD><TD>V$SOX9_B1</TD><TD>MSigDB lists</TD><TD>V$SOX9_B1</TD><TD>224</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>NR4A1,SYTL2</TD></TR>
<TR><TD>1.499e-02</TD><TD>-4.20</TD><TD>MECOM (MDS1 and EVI1 complex locus)</TD><TD>protein interactions</TD><TD>2122</TD><TD>22</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>MECOM</TD></TR>
<TR><TD>1.499e-02</TD><TD>-4.20</TD><TD>FGG (fibrinogen gamma chain)</TD><TD>protein interactions</TD><TD>2266</TD><TD>22</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>ALDH2</TD></TR>
<TR><TD>1.501e-02</TD><TD>-4.20</TD><TD>Ras GTPase binding</TD><TD>molecular function</TD><TD>GO:0017016</TD><TD>224</TD><TD>2</TD><TD>16491</TD><TD>14</TD>
<TD>MYRIP,SYTL2</TD></TR>
<TR><TD>1.509e-02</TD><TD>-4.19</TD><TD>diencephalon</TD><TD>COSMIC cancer mutations</TD><TD>diencephalon</TD><TD>18</TD><TD>1</TD><TD>17775</TD><TD>15</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>1.510e-02</TD><TD>-4.19</TD><TD>MODULE_478</TD><TD>MSigDB lists</TD><TD>MODULE_478</TD><TD>18</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>PLOD2</TD></TR>
<TR><TD>1.518e-02</TD><TD>-4.19</TD><TD>aldehyde dehydrogenase (NAD) activity</TD><TD>molecular function</TD><TD>GO:0004029</TD><TD>18</TD><TD>1</TD><TD>16491</TD><TD>14</TD>
<TD>ALDH2</TD></TR>
<TR><TD>1.522e-02</TD><TD>-4.18</TD><TD>pericardium development</TD><TD>biological process</TD><TD>GO:0060039</TD><TD>18</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>MECOM</TD></TR>
<TR><TD>1.522e-02</TD><TD>-4.18</TD><TD>positive regulation of protein processing</TD><TD>biological process</TD><TD>GO:0010954</TD><TD>18</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>MFI2</TD></TR>
<TR><TD>1.526e-02</TD><TD>-4.18</TD><TD>axolemma</TD><TD>cellular component</TD><TD>GO:0030673</TD><TD>18</TD><TD>1</TD><TD>17570</TD><TD>15</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>1.526e-02</TD><TD>-4.18</TD><TD>exocyst</TD><TD>cellular component</TD><TD>GO:0000145</TD><TD>18</TD><TD>1</TD><TD>17570</TD><TD>15</TD>
<TD>MYRIP</TD></TR>
<TR><TD>1.542e-02</TD><TD>-4.17</TD><TD>ear</TD><TD>COSMIC cancer mutations</TD><TD>ear</TD><TD>642</TD><TD>3</TD><TD>17775</TD><TD>15</TD>
<TD>CNTNAP2,TOX2,NETO2</TD></TR>
<TR><TD>1.547e-02</TD><TD>-4.17</TD><TD>Ald_DH_N</TD><TD>interpro domains</TD><TD>IPR016162</TD><TD>19</TD><TD>1</TD><TD>18293</TD><TD>15</TD>
<TD>ALDH2</TD></TR>
<TR><TD>1.547e-02</TD><TD>-4.17</TD><TD>Aldehyde_DH_dom</TD><TD>interpro domains</TD><TD>IPR015590</TD><TD>19</TD><TD>1</TD><TD>18293</TD><TD>15</TD>
<TD>ALDH2</TD></TR>
<TR><TD>1.547e-02</TD><TD>-4.17</TD><TD>Ald_DH/histidinol_DH</TD><TD>interpro domains</TD><TD>IPR016161</TD><TD>19</TD><TD>1</TD><TD>18293</TD><TD>15</TD>
<TD>ALDH2</TD></TR>
<TR><TD>1.547e-02</TD><TD>-4.17</TD><TD>Ald_DH_C</TD><TD>interpro domains</TD><TD>IPR016163</TD><TD>19</TD><TD>1</TD><TD>18293</TD><TD>15</TD>
<TD>ALDH2</TD></TR>
<TR><TD>1.567e-02</TD><TD>-4.16</TD><TD>FBLN2 (fibulin 2)</TD><TD>protein interactions</TD><TD>2199</TD><TD>23</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>COL4A5</TD></TR>
<TR><TD>1.567e-02</TD><TD>-4.16</TD><TD>IL9R (interleukin 9 receptor)</TD><TD>protein interactions</TD><TD>3581</TD><TD>23</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>NETO2</TD></TR>
<TR><TD>1.567e-02</TD><TD>-4.16</TD><TD>CALML5 (calmodulin-like 5)</TD><TD>protein interactions</TD><TD>51806</TD><TD>23</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>ALDH2</TD></TR>
<TR><TD>1.567e-02</TD><TD>-4.16</TD><TD>PPBP (pro-platelet basic protein)</TD><TD>protein interactions</TD><TD>5473</TD><TD>23</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>NR4A1</TD></TR>
<TR><TD>1.582e-02</TD><TD>-4.15</TD><TD>DOANE_RESPONSE_TO_ANDROGEN_DN</TD><TD>MSigDB lists</TD><TD>DOANE_RESPONSE_TO_ANDROGEN_DN</TD><TD>231</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>FAM198B,PLOD2</TD></TR>
<TR><TD>1.582e-02</TD><TD>-4.15</TD><TD>V$CEBPDELTA_Q6</TD><TD>MSigDB lists</TD><TD>V$CEBPDELTA_Q6</TD><TD>231</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>CNTNAP2,NR4A1</TD></TR>
<TR><TD>1.592e-02</TD><TD>-4.14</TD><TD>BLALOCK_ALZHEIMERS_DISEASE_DN</TD><TD>MSigDB lists</TD><TD>BLALOCK_ALZHEIMERS_DISEASE_DN</TD><TD>1209</TD><TD>4</TD><TD>17758</TD><TD>15</TD>
<TD>FAM198B,CNTNAP2,ALDH2,NETO2</TD></TR>
<TR><TD>1.594e-02</TD><TD>-4.14</TD><TD>MODULE_305</TD><TD>MSigDB lists</TD><TD>MODULE_305</TD><TD>19</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>ALDH2</TD></TR>
<TR><TD>1.594e-02</TD><TD>-4.14</TD><TD>chr3q24</TD><TD>MSigDB lists</TD><TD>chr3q24</TD><TD>19</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>PLOD2</TD></TR>
<TR><TD>1.594e-02</TD><TD>-4.14</TD><TD>DELLA_RESPONSE_TO_TSA_AND_BUTYRATE</TD><TD>MSigDB lists</TD><TD>DELLA_RESPONSE_TO_TSA_AND_BUTYRATE</TD><TD>19</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>NR4A1</TD></TR>
<TR><TD>1.594e-02</TD><TD>-4.14</TD><TD>NIELSEN_GIST_AND_SYNOVIAL_SARCOMA_UP</TD><TD>MSigDB lists</TD><TD>NIELSEN_GIST_AND_SYNOVIAL_SARCOMA_UP</TD><TD>19</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>COL4A5</TD></TR>
<TR><TD>1.594e-02</TD><TD>-4.14</TD><TD>chr7p12</TD><TD>MSigDB lists</TD><TD>chr7p12</TD><TD>19</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>SUN3</TD></TR>
<TR><TD>1.595e-02</TD><TD>-4.14</TD><TD>V$COUP_DR1_Q6</TD><TD>MSigDB lists</TD><TD>V$COUP_DR1_Q6</TD><TD>232</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>NR4A1,SYTL2</TD></TR>
<TR><TD>1.595e-02</TD><TD>-4.14</TD><TD>V$TBP_01</TD><TD>MSigDB lists</TD><TD>V$TBP_01</TD><TD>232</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>NR4A1,SYTL2</TD></TR>
<TR><TD>1.602e-02</TD><TD>-4.13</TD><TD>ionotropic glutamate receptor binding</TD><TD>molecular function</TD><TD>GO:0035255</TD><TD>19</TD><TD>1</TD><TD>16491</TD><TD>14</TD>
<TD>NETO2</TD></TR>
<TR><TD>1.606e-02</TD><TD>-4.13</TD><TD>positive regulation of protein maturation</TD><TD>biological process</TD><TD>GO:1903319</TD><TD>19</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>MFI2</TD></TR>
<TR><TD>1.606e-02</TD><TD>-4.13</TD><TD>response to auditory stimulus</TD><TD>biological process</TD><TD>GO:0010996</TD><TD>19</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>1.607e-02</TD><TD>-4.13</TD><TD>striated_muscle</TD><TD>COSMIC cancer mutations</TD><TD>striated_muscle</TD><TD>4392</TD><TD>8</TD><TD>17775</TD><TD>15</TD>
<TD>MFI2,PLOD2,NR4A1,TOX2,NETO2,COL4A5,CNTNAP2,SYTL2</TD></TR>
<TR><TD>1.610e-02</TD><TD>-4.13</TD><TD>rough endoplasmic reticulum membrane</TD><TD>cellular component</TD><TD>GO:0030867</TD><TD>19</TD><TD>1</TD><TD>17570</TD><TD>15</TD>
<TD>PLOD2</TD></TR>
<TR><TD>1.635e-02</TD><TD>-4.11</TD><TD>GK (glycerol kinase)</TD><TD>protein interactions</TD><TD>2710</TD><TD>24</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>NR4A1</TD></TR>
<TR><TD>1.635e-02</TD><TD>-4.11</TD><TD>V$GATA1_03</TD><TD>MSigDB lists</TD><TD>V$GATA1_03</TD><TD>235</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>SYTL2,MECOM</TD></TR>
<TR><TD>1.665e-02</TD><TD>-4.10</TD><TD>Immune reponse to smallpox (secreted IL-1beta)(PMID:22610502)</TD><TD>GWAS genes</TD><TD>Immune reponse to smallpox (secreted IL-1beta)(PMID:22610502)</TD><TD>8</TD><TD>1</TD><TD>2389</TD><TD>5</TD>
<TD>MECOM</TD></TR>
<TR><TD>1.675e-02</TD><TD>-4.09</TD><TD>4.1m</TD><TD>smart domains</TD><TD>SM00294</TD><TD>14</TD><TD>1</TD><TD>9131</TD><TD>11</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>1.677e-02</TD><TD>-4.09</TD><TD>chr3q28</TD><TD>MSigDB lists</TD><TD>chr3q28</TD><TD>20</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>MFI2</TD></TR>
<TR><TD>1.677e-02</TD><TD>-4.09</TD><TD>TIAN_TNF_SIGNALING_NOT_VIA_NFKB</TD><TD>MSigDB lists</TD><TD>TIAN_TNF_SIGNALING_NOT_VIA_NFKB</TD><TD>20</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>NR4A1</TD></TR>
<TR><TD>1.677e-02</TD><TD>-4.09</TD><TD>GESERICK_TERT_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>GESERICK_TERT_TARGETS_DN</TD><TD>20</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>NR4A1</TD></TR>
<TR><TD>1.677e-02</TD><TD>-4.09</TD><TD>BIOCARTA_AMI_PATHWAY</TD><TD>MSigDB lists</TD><TD>BIOCARTA_AMI_PATHWAY</TD><TD>20</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>COL4A5</TD></TR>
<TR><TD>1.688e-02</TD><TD>-4.08</TD><TD>VERHAAK_AML_WITH_NPM1_MUTATED_DN</TD><TD>MSigDB lists</TD><TD>VERHAAK_AML_WITH_NPM1_MUTATED_DN</TD><TD>239</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>ALDH2,MECOM</TD></TR>
<TR><TD>1.688e-02</TD><TD>-4.08</TD><TD>HSIAO_LIVER_SPECIFIC_GENES</TD><TD>MSigDB lists</TD><TD>HSIAO_LIVER_SPECIFIC_GENES</TD><TD>239</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>ALDH2,PLOD2</TD></TR>
<TR><TD>1.701e-02</TD><TD>-4.07</TD><TD>Aldedh</TD><TD>pfam domains</TD><TD>PF00171</TD><TD>19</TD><TD>1</TD><TD>16629</TD><TD>15</TD>
<TD>ALDH2</TD></TR>
<TR><TD>1.702e-02</TD><TD>-4.07</TD><TD>FGB (fibrinogen beta chain)</TD><TD>protein interactions</TD><TD>2244</TD><TD>25</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>ALDH2</TD></TR>
<TR><TD>1.702e-02</TD><TD>-4.07</TD><TD>FGA (fibrinogen alpha chain)</TD><TD>protein interactions</TD><TD>2243</TD><TD>25</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>ALDH2</TD></TR>
<TR><TD>1.702e-02</TD><TD>-4.07</TD><TD>CD93 (CD93 molecule)</TD><TD>protein interactions</TD><TD>22918</TD><TD>25</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>COL4A5</TD></TR>
<TR><TD>1.709e-02</TD><TD>-4.07</TD><TD>Oxoglu/Fe-dep_dioxygenase</TD><TD>interpro domains</TD><TD>IPR005123</TD><TD>21</TD><TD>1</TD><TD>18293</TD><TD>15</TD>
<TD>PLOD2</TD></TR>
<TR><TD>1.743e-02</TD><TD>-4.05</TD><TD>Constitutive Signaling by AKT1 E17K in Cancer</TD><TD>REACTOME pathways</TD><TD>R-HSA-5674400</TD><TD>24</TD><TD>1</TD><TD>8202</TD><TD>6</TD>
<TD>NR4A1</TD></TR>
<TR><TD>1.760e-02</TD><TD>-4.04</TD><TD>OXIDOREDUCTASE_ACTIVITY_ACTING_ON_THE_ALDEHYDE_OR_OXO_GROUP_OF_DONORS</TD><TD>MSigDB lists</TD><TD>OXIDOREDUCTASE_ACTIVITY_ACTING_ON_THE_ALDEHYDE_OR_OXO_GROUP_OF_DONORS</TD><TD>21</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>ALDH2</TD></TR>
<TR><TD>1.760e-02</TD><TD>-4.04</TD><TD>HUI_MAPK14_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>HUI_MAPK14_TARGETS_UP</TD><TD>21</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>1.760e-02</TD><TD>-4.04</TD><TD>GAVIN_PDE3B_TARGETS</TD><TD>MSigDB lists</TD><TD>GAVIN_PDE3B_TARGETS</TD><TD>21</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>SYTL2</TD></TR>
<TR><TD>1.760e-02</TD><TD>-4.04</TD><TD>NUMATA_CSF3_SIGNALING_VIA_STAT3</TD><TD>MSigDB lists</TD><TD>NUMATA_CSF3_SIGNALING_VIA_STAT3</TD><TD>21</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>MECOM</TD></TR>
<TR><TD>1.765e-02</TD><TD>-4.04</TD><TD>small GTPase binding</TD><TD>molecular function</TD><TD>GO:0031267</TD><TD>244</TD><TD>2</TD><TD>16491</TD><TD>14</TD>
<TD>MYRIP,SYTL2</TD></TR>
<TR><TD>1.769e-02</TD><TD>-4.03</TD><TD>L-ascorbic acid binding</TD><TD>molecular function</TD><TD>GO:0031418</TD><TD>21</TD><TD>1</TD><TD>16491</TD><TD>14</TD>
<TD>PLOD2</TD></TR>
<TR><TD>1.770e-02</TD><TD>-4.03</TD><TD>LDHAL6A (lactate dehydrogenase A-like 6A)</TD><TD>protein interactions</TD><TD>160287</TD><TD>26</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>ALDH2</TD></TR>
<TR><TD>1.770e-02</TD><TD>-4.03</TD><TD>NUSAP1 (nucleolar and spindle associated protein 1)</TD><TD>protein interactions</TD><TD>51203</TD><TD>26</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>PLOD2</TD></TR>
<TR><TD>1.777e-02</TD><TD>-4.03</TD><TD>bone-tibia-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour</TD><TD>COSMIC cancer mutations</TD><TD>bone-tibia-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour</TD><TD>677</TD><TD>3</TD><TD>17775</TD><TD>15</TD>
<TD>MFI2,NR4A1,SYTL2</TD></TR>
<TR><TD>1.837e-02</TD><TD>-4.00</TD><TD>WAMUNYOKOLI_OVARIAN_CANCER_LMP_UP</TD><TD>MSigDB lists</TD><TD>WAMUNYOKOLI_OVARIAN_CANCER_LMP_UP</TD><TD>250</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>SYTL2,MECOM</TD></TR>
<TR><TD>1.837e-02</TD><TD>-4.00</TD><TD>GLUD1 (glutamate dehydrogenase 1)</TD><TD>protein interactions</TD><TD>2746</TD><TD>27</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>NR4A1</TD></TR>
<TR><TD>1.837e-02</TD><TD>-4.00</TD><TD>DNPEP (aspartyl aminopeptidase)</TD><TD>protein interactions</TD><TD>23549</TD><TD>27</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>PLOD2</TD></TR>
<TR><TD>1.843e-02</TD><TD>-3.99</TD><TD>KEGG_BETA_ALANINE_METABOLISM</TD><TD>MSigDB lists</TD><TD>KEGG_BETA_ALANINE_METABOLISM</TD><TD>22</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>ALDH2</TD></TR>
<TR><TD>1.845e-02</TD><TD>-3.99</TD><TD>MAPK signaling pathway</TD><TD>KEGG pathways</TD><TD>ko04010</TD><TD>255</TD><TD>2</TD><TD>6908</TD><TD>6</TD>
<TD>NR4A1,MECOM</TD></TR>
<TR><TD>1.845e-02</TD><TD>-3.99</TD><TD>MAPK signaling pathway</TD><TD>KEGG pathways</TD><TD>hsa04010</TD><TD>255</TD><TD>2</TD><TD>6908</TD><TD>6</TD>
<TD>NR4A1,MECOM</TD></TR>
<TR><TD>1.847e-02</TD><TD>-3.99</TD><TD>synapse</TD><TD>cellular component</TD><TD>GO:0045202</TD><TD>679</TD><TD>3</TD><TD>17570</TD><TD>15</TD>
<TD>COL4A5,MYRIP,NETO2</TD></TR>
<TR><TD>1.851e-02</TD><TD>-3.99</TD><TD>V$SOX5_01</TD><TD>MSigDB lists</TD><TD>V$SOX5_01</TD><TD>251</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>COL4A5,NR4A1</TD></TR>
<TR><TD>1.851e-02</TD><TD>-3.99</TD><TD>V$STAT4_01</TD><TD>MSigDB lists</TD><TD>V$STAT4_01</TD><TD>251</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>NR4A1,MECOM</TD></TR>
<TR><TD>1.858e-02</TD><TD>-3.99</TD><TD>subpallium development</TD><TD>biological process</TD><TD>GO:0021544</TD><TD>22</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>1.870e-02</TD><TD>-3.98</TD><TD>human chr3p22.1</TD><TD>chromosome location</TD><TD>human chr3p22.1</TD><TD>33</TD><TD>1</TD><TD>26250</TD><TD>15</TD>
<TD>MYRIP</TD></TR>
<TR><TD>1.870e-02</TD><TD>-3.98</TD><TD>FA58C</TD><TD>interpro domains</TD><TD>IPR000421</TD><TD>23</TD><TD>1</TD><TD>18293</TD><TD>15</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>1.871e-02</TD><TD>-3.98</TD><TD>Information processing speed(PMID:21130836)</TD><TD>GWAS genes</TD><TD>Information processing speed(PMID:21130836)</TD><TD>9</TD><TD>1</TD><TD>2389</TD><TD>5</TD>
<TD>MYRIP</TD></TR>
<TR><TD>1.872e-02</TD><TD>-3.98</TD><TD>ALDEHYDE_DEHYDR_GLU</TD><TD>prosite domains</TD><TD>PS00687</TD><TD>16</TD><TD>1</TD><TD>11866</TD><TD>14</TD>
<TD>ALDH2</TD></TR>
<TR><TD>1.872e-02</TD><TD>-3.98</TD><TD>FA58C_2</TD><TD>prosite domains</TD><TD>PS01286</TD><TD>16</TD><TD>1</TD><TD>11866</TD><TD>14</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>1.872e-02</TD><TD>-3.98</TD><TD>ALDEHYDE_DEHYDR_CYS</TD><TD>prosite domains</TD><TD>PS00070</TD><TD>16</TD><TD>1</TD><TD>11866</TD><TD>14</TD>
<TD>ALDH2</TD></TR>
<TR><TD>1.881e-02</TD><TD>-3.97</TD><TD>GOZGIT_ESR1_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>GOZGIT_ESR1_TARGETS_DN</TD><TD>691</TD><TD>3</TD><TD>17758</TD><TD>15</TD>
<TD>COL4A5,FAM198B,SYTL2</TD></TR>
<TR><TD>1.905e-02</TD><TD>-3.96</TD><TD>C1orf216 (chromosome 1 open reading frame 216)</TD><TD>protein interactions</TD><TD>127703</TD><TD>28</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>MYRIP</TD></TR>
<TR><TD>1.907e-02</TD><TD>-3.96</TD><TD>LU_AGING_BRAIN_UP</TD><TD>MSigDB lists</TD><TD>LU_AGING_BRAIN_UP</TD><TD>255</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>COL4A5,PLOD2</TD></TR>
<TR><TD>1.912e-02</TD><TD>-3.96</TD><TD>P4Hc</TD><TD>smart domains</TD><TD>SM00702</TD><TD>16</TD><TD>1</TD><TD>9131</TD><TD>11</TD>
<TD>PLOD2</TD></TR>
<TR><TD>1.924e-02</TD><TD>-3.95</TD><TD>STROIDFINGER</TD><TD>prints domains</TD><TD>PR00047</TD><TD>46</TD><TD>1</TD><TD>4759</TD><TD>2</TD>
<TD>NR4A1</TD></TR>
<TR><TD>1.926e-02</TD><TD>-3.95</TD><TD>BIOCARTA_INTRINSIC_PATHWAY</TD><TD>MSigDB lists</TD><TD>BIOCARTA_INTRINSIC_PATHWAY</TD><TD>23</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>COL4A5</TD></TR>
<TR><TD>1.926e-02</TD><TD>-3.95</TD><TD>COLLAGEN</TD><TD>MSigDB lists</TD><TD>COLLAGEN</TD><TD>23</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>COL4A5</TD></TR>
<TR><TD>1.943e-02</TD><TD>-3.94</TD><TD>Tryptophan Metabolism</TD><TD>SMPDB pathways</TD><TD>SMP00063</TD><TD>19</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>ALDH2</TD></TR>
<TR><TD>1.946e-02</TD><TD>-3.94</TD><TD>basal lamina</TD><TD>cellular component</TD><TD>GO:0005605</TD><TD>23</TD><TD>1</TD><TD>17570</TD><TD>15</TD>
<TD>COL4A5</TD></TR>
<TR><TD>1.966e-02</TD><TD>-3.93</TD><TD>STRDHORMONER</TD><TD>prints domains</TD><TD>PR00398</TD><TD>47</TD><TD>1</TD><TD>4759</TD><TD>2</TD>
<TD>NR4A1</TD></TR>
<TR><TD>1.972e-02</TD><TD>-3.93</TD><TD>membrane-bounded organelle</TD><TD>cellular component</TD><TD>GO:0043227</TD><TD>11730</TD><TD>14</TD><TD>17570</TD><TD>15</TD>
<TD>ZNF432,ALDH2,MFI2,PLOD2,ASCL5,NR4A1,TOX2,SUN3,COL4A5,CNTNAP2,FAM198B,MYRIP,SYTL2,MECOM</TD></TR>
<TR><TD>1.972e-02</TD><TD>-3.93</TD><TD>SWAP70 (SWAP switching B-cell complex 70kDa subunit)</TD><TD>protein interactions</TD><TD>23075</TD><TD>29</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>PLOD2</TD></TR>
<TR><TD>1.972e-02</TD><TD>-3.93</TD><TD>NRXN1 (neurexin 1)</TD><TD>protein interactions</TD><TD>9378</TD><TD>29</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>SYTL2</TD></TR>
<TR><TD>1.972e-02</TD><TD>-3.93</TD><TD>ESD (esterase D)</TD><TD>protein interactions</TD><TD>2098</TD><TD>29</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>ALDH2</TD></TR>
<TR><TD>1.982e-02</TD><TD>-3.92</TD><TD>Histidine metabolism</TD><TD>KEGG pathways</TD><TD>hsa00340</TD><TD>23</TD><TD>1</TD><TD>6908</TD><TD>6</TD>
<TD>ALDH2</TD></TR>
<TR><TD>1.982e-02</TD><TD>-3.92</TD><TD>Histidine metabolism</TD><TD>KEGG pathways</TD><TD>ko00340</TD><TD>23</TD><TD>1</TD><TD>6908</TD><TD>6</TD>
<TD>ALDH2</TD></TR>
<TR><TD>2.009e-02</TD><TD>-3.91</TD><TD>ROYLANCE_BREAST_CANCER_16Q_COPY_NUMBER_DN</TD><TD>MSigDB lists</TD><TD>ROYLANCE_BREAST_CANCER_16Q_COPY_NUMBER_DN</TD><TD>24</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>NETO2</TD></TR>
<TR><TD>2.009e-02</TD><TD>-3.91</TD><TD>CHIANG_LIVER_CANCER_SUBCLASS_POLYSOMY7_DN</TD><TD>MSigDB lists</TD><TD>CHIANG_LIVER_CANCER_SUBCLASS_POLYSOMY7_DN</TD><TD>24</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>PLOD2</TD></TR>
<TR><TD>2.022e-02</TD><TD>-3.90</TD><TD>diffuse_adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>diffuse_adenocarcinoma</TD><TD>4562</TD><TD>8</TD><TD>17775</TD><TD>15</TD>
<TD>MFI2,PLOD2,TOX2,COL4A5,CNTNAP2,MYRIP,SYTL2,MECOM</TD></TR>
<TR><TD>2.022e-02</TD><TD>-3.90</TD><TD>stomach-carcinoma-diffuse_adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>stomach-carcinoma-diffuse_adenocarcinoma</TD><TD>4562</TD><TD>8</TD><TD>17775</TD><TD>15</TD>
<TD>MFI2,PLOD2,TOX2,COL4A5,CNTNAP2,MYRIP,SYTL2,MECOM</TD></TR>
<TR><TD>2.030e-02</TD><TD>-3.90</TD><TD>complex of collagen trimers</TD><TD>cellular component</TD><TD>GO:0098644</TD><TD>24</TD><TD>1</TD><TD>17570</TD><TD>15</TD>
<TD>COL4A5</TD></TR>
<TR><TD>2.039e-02</TD><TD>-3.89</TD><TD>VASN (vasorin)</TD><TD>protein interactions</TD><TD>114990</TD><TD>30</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>PLOD2</TD></TR>
<TR><TD>2.056e-02</TD><TD>-3.88</TD><TD>F5_F8_type_C</TD><TD>pfam domains</TD><TD>PF00754</TD><TD>23</TD><TD>1</TD><TD>16629</TD><TD>15</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>2.061e-02</TD><TD>-3.88</TD><TD>GTPase binding</TD><TD>molecular function</TD><TD>GO:0051020</TD><TD>265</TD><TD>2</TD><TD>16491</TD><TD>14</TD>
<TD>MYRIP,SYTL2</TD></TR>
<TR><TD>2.064e-02</TD><TD>-3.88</TD><TD>KEGG_MAPK_SIGNALING_PATHWAY</TD><TD>MSigDB lists</TD><TD>KEGG_MAPK_SIGNALING_PATHWAY</TD><TD>266</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>NR4A1,MECOM</TD></TR>
<TR><TD>2.077e-02</TD><TD>-3.87</TD><TD>Renal function-related traits (BUN)(PMID:22797727)</TD><TD>GWAS genes</TD><TD>Renal function-related traits (BUN)(PMID:22797727)</TD><TD>10</TD><TD>1</TD><TD>2389</TD><TD>5</TD>
<TD>MECOM</TD></TR>
<TR><TD>2.090e-02</TD><TD>-3.87</TD><TD>bone-humerus-chondrosarcoma-central</TD><TD>COSMIC cancer mutations</TD><TD>bone-humerus-chondrosarcoma-central</TD><TD>25</TD><TD>1</TD><TD>17775</TD><TD>15</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>2.092e-02</TD><TD>-3.87</TD><TD>EXTRINSIC_TO_MEMBRANE</TD><TD>MSigDB lists</TD><TD>EXTRINSIC_TO_MEMBRANE</TD><TD>25</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>SYTL2</TD></TR>
<TR><TD>2.092e-02</TD><TD>-3.87</TD><TD>KEGG_ASCORBATE_AND_ALDARATE_METABOLISM</TD><TD>MSigDB lists</TD><TD>KEGG_ASCORBATE_AND_ALDARATE_METABOLISM</TD><TD>25</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>ALDH2</TD></TR>
<TR><TD>2.093e-02</TD><TD>-3.87</TD><TD>CACTGCC,MIR-34A,MIR-34C,MIR-449</TD><TD>MSigDB lists</TD><TD>CACTGCC,MIR-34A,MIR-34C,MIR-449</TD><TD>268</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>CNTNAP2,MYRIP</TD></TR>
<TR><TD>2.104e-02</TD><TD>-3.86</TD><TD>FA58C_1</TD><TD>prosite domains</TD><TD>PS01285</TD><TD>18</TD><TD>1</TD><TD>11866</TD><TD>14</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>2.107e-02</TD><TD>-3.86</TD><TD>CPT1A (carnitine palmitoyltransferase 1A (liver))</TD><TD>protein interactions</TD><TD>1374</TD><TD>31</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>NR4A1</TD></TR>
<TR><TD>2.109e-02</TD><TD>-3.86</TD><TD>response to gonadotropin</TD><TD>biological process</TD><TD>GO:0034698</TD><TD>25</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>TOX2</TD></TR>
<TR><TD>2.109e-02</TD><TD>-3.86</TD><TD>blood vessel endothelial cell migration</TD><TD>biological process</TD><TD>GO:0043534</TD><TD>25</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>NR4A1</TD></TR>
<TR><TD>2.150e-02</TD><TD>-3.84</TD><TD>human chr7q35</TD><TD>chromosome location</TD><TD>human chr7q35</TD><TD>38</TD><TD>1</TD><TD>26250</TD><TD>15</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>2.174e-02</TD><TD>-3.83</TD><TD>IGHG1 (immunoglobulin heavy constant gamma 1 (G1m marker))</TD><TD>protein interactions</TD><TD>3500</TD><TD>32</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>ALDH2</TD></TR>
<TR><TD>2.174e-02</TD><TD>-3.83</TD><TD>IGSF21 (immunoglobin superfamily, member 21)</TD><TD>protein interactions</TD><TD>84966</TD><TD>32</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>ALDH2</TD></TR>
<TR><TD>2.174e-02</TD><TD>-3.83</TD><TD>RXRG (retinoid X receptor gamma)</TD><TD>protein interactions</TD><TD>6258</TD><TD>32</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>NR4A1</TD></TR>
<TR><TD>2.174e-02</TD><TD>-3.83</TD><TD>MMP9 (matrix metallopeptidase 9)</TD><TD>protein interactions</TD><TD>4318</TD><TD>32</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>COL4A5</TD></TR>
<TR><TD>2.175e-02</TD><TD>-3.83</TD><TD>VALK_AML_CLUSTER_1</TD><TD>MSigDB lists</TD><TD>VALK_AML_CLUSTER_1</TD><TD>26</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>MECOM</TD></TR>
<TR><TD>2.175e-02</TD><TD>-3.83</TD><TD>PID_RXR_VDR_PATHWAY</TD><TD>MSigDB lists</TD><TD>PID_RXR_VDR_PATHWAY</TD><TD>26</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>NR4A1</TD></TR>
<TR><TD>2.197e-02</TD><TD>-3.82</TD><TD>HELLER_SILENCED_BY_METHYLATION_UP</TD><TD>MSigDB lists</TD><TD>HELLER_SILENCED_BY_METHYLATION_UP</TD><TD>275</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>CNTNAP2,ALDH2</TD></TR>
<TR><TD>2.241e-02</TD><TD>-3.80</TD><TD>GLOD4 (glyoxalase domain containing 4)</TD><TD>protein interactions</TD><TD>51031</TD><TD>33</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>NR4A1</TD></TR>
<TR><TD>2.249e-02</TD><TD>-3.79</TD><TD>Pyruvate Dehydrogenase Complex Deficiency</TD><TD>SMPDB pathways</TD><TD>SMP00212</TD><TD>22</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>ALDH2</TD></TR>
<TR><TD>2.249e-02</TD><TD>-3.79</TD><TD>Pyruvate Decarboxylase E1 Component Deficiency (PDHE1 Deficiency)</TD><TD>SMPDB pathways</TD><TD>SMP00334</TD><TD>22</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>ALDH2</TD></TR>
<TR><TD>2.249e-02</TD><TD>-3.79</TD><TD>Primary hyperoxaluria II- PH2</TD><TD>SMPDB pathways</TD><TD>SMP00558</TD><TD>22</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>ALDH2</TD></TR>
<TR><TD>2.249e-02</TD><TD>-3.79</TD><TD>Pyruvate Metabolism</TD><TD>SMPDB pathways</TD><TD>SMP00060</TD><TD>22</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>ALDH2</TD></TR>
<TR><TD>2.249e-02</TD><TD>-3.79</TD><TD>Pyruvate kinase deficiency</TD><TD>SMPDB pathways</TD><TD>SMP00559</TD><TD>22</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>ALDH2</TD></TR>
<TR><TD>2.249e-02</TD><TD>-3.79</TD><TD>Leigh Syndrome</TD><TD>SMPDB pathways</TD><TD>SMP00196</TD><TD>22</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>ALDH2</TD></TR>
<TR><TD>2.257e-02</TD><TD>-3.79</TD><TD>RESPONSE_TO_HYPOXIA</TD><TD>MSigDB lists</TD><TD>RESPONSE_TO_HYPOXIA</TD><TD>27</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>PLOD2</TD></TR>
<TR><TD>2.257e-02</TD><TD>-3.79</TD><TD>ZHANG_ANTIVIRAL_RESPONSE_TO_RIBAVIRIN_UP</TD><TD>MSigDB lists</TD><TD>ZHANG_ANTIVIRAL_RESPONSE_TO_RIBAVIRIN_UP</TD><TD>27</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>ALDH2</TD></TR>
<TR><TD>2.257e-02</TD><TD>-3.79</TD><TD>KEGG_HISTIDINE_METABOLISM</TD><TD>MSigDB lists</TD><TD>KEGG_HISTIDINE_METABOLISM</TD><TD>27</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>ALDH2</TD></TR>
<TR><TD>2.257e-02</TD><TD>-3.79</TD><TD>REACTOME_PIP3_ACTIVATES_AKT_SIGNALING</TD><TD>MSigDB lists</TD><TD>REACTOME_PIP3_ACTIVATES_AKT_SIGNALING</TD><TD>27</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>NR4A1</TD></TR>
<TR><TD>2.257e-02</TD><TD>-3.79</TD><TD>KAMIKUBO_MYELOID_CEBPA_NETWORK</TD><TD>MSigDB lists</TD><TD>KAMIKUBO_MYELOID_CEBPA_NETWORK</TD><TD>27</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>ALDH2</TD></TR>
<TR><TD>2.257e-02</TD><TD>-3.79</TD><TD>WOTTON_RUNX_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>WOTTON_RUNX_TARGETS_DN</TD><TD>27</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>PLOD2</TD></TR>
<TR><TD>2.260e-02</TD><TD>-3.79</TD><TD>-</TD><TD>gene3d domains</TD><TD>3.40.309.10</TD><TD>19</TD><TD>1</TD><TD>9988</TD><TD>12</TD>
<TD>ALDH2</TD></TR>
<TR><TD>2.260e-02</TD><TD>-3.79</TD><TD>-</TD><TD>gene3d domains</TD><TD>3.40.605.10</TD><TD>19</TD><TD>1</TD><TD>9988</TD><TD>12</TD>
<TD>ALDH2</TD></TR>
<TR><TD>2.268e-02</TD><TD>-3.79</TD><TD>skin-arm-malignant_melanoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-arm-malignant_melanoma</TD><TD>1345</TD><TD>4</TD><TD>17775</TD><TD>15</TD>
<TD>COL4A5,PLOD2,NETO2,MECOM</TD></TR>
<TR><TD>2.269e-02</TD><TD>-3.79</TD><TD>phosphatidylserine binding</TD><TD>molecular function</TD><TD>GO:0001786</TD><TD>27</TD><TD>1</TD><TD>16491</TD><TD>14</TD>
<TD>SYTL2</TD></TR>
<TR><TD>2.274e-02</TD><TD>-3.78</TD><TD>large_intestine-colon</TD><TD>COSMIC cancer mutations</TD><TD>large_intestine-colon</TD><TD>1346</TD><TD>4</TD><TD>17775</TD><TD>15</TD>
<TD>CNTNAP2,MYRIP,SYTL2,NETO2</TD></TR>
<TR><TD>2.283e-02</TD><TD>-3.78</TD><TD>Diastolic blood pressure(PMID:21909115)</TD><TD>GWAS genes</TD><TD>Diastolic blood pressure(PMID:21909115)</TD><TD>11</TD><TD>1</TD><TD>2389</TD><TD>5</TD>
<TD>MECOM</TD></TR>
<TR><TD>2.287e-02</TD><TD>-3.78</TD><TD>OXIDOREDUCTASE_ACTIVITY</TD><TD>MSigDB lists</TD><TD>OXIDOREDUCTASE_ACTIVITY</TD><TD>281</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>ALDH2,PLOD2</TD></TR>
<TR><TD>2.290e-02</TD><TD>-3.78</TD><TD>Role of Calcineurin-dependent NFAT signaling in lymphocytes</TD><TD>Pathway Interaction DB</TD><TD>nfat_3pathway</TD><TD>51</TD><TD>1</TD><TD>2227</TD><TD>1</TD>
<TD>NR4A1</TD></TR>
<TR><TD>2.308e-02</TD><TD>-3.77</TD><TD>DERL2 (derlin 2)</TD><TD>protein interactions</TD><TD>51009</TD><TD>34</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>MFI2</TD></TR>
<TR><TD>2.308e-02</TD><TD>-3.77</TD><TD>CSDE1 (cold shock domain containing E1, RNA binding)</TD><TD>protein interactions</TD><TD>7812</TD><TD>34</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>PLOD2</TD></TR>
<TR><TD>2.308e-02</TD><TD>-3.77</TD><TD>LONRF1 (LON peptidase N-terminal domain and ring finger 1)</TD><TD>protein interactions</TD><TD>91694</TD><TD>34</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>NR4A1</TD></TR>
<TR><TD>2.323e-02</TD><TD>-3.76</TD><TD>Ascorbate and aldarate metabolism</TD><TD>KEGG pathways</TD><TD>hsa00053</TD><TD>27</TD><TD>1</TD><TD>6908</TD><TD>6</TD>
<TD>ALDH2</TD></TR>
<TR><TD>2.323e-02</TD><TD>-3.76</TD><TD>Ascorbate and aldarate metabolism</TD><TD>KEGG pathways</TD><TD>ko00053</TD><TD>27</TD><TD>1</TD><TD>6908</TD><TD>6</TD>
<TD>ALDH2</TD></TR>
<TR><TD>2.340e-02</TD><TD>-3.75</TD><TD>BERENJENO_ROCK_SIGNALING_NOT_VIA_RHOA_UP</TD><TD>MSigDB lists</TD><TD>BERENJENO_ROCK_SIGNALING_NOT_VIA_RHOA_UP</TD><TD>28</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>ALDH2</TD></TR>
<TR><TD>2.340e-02</TD><TD>-3.75</TD><TD>ABE_VEGFA_TARGETS_30MIN</TD><TD>MSigDB lists</TD><TD>ABE_VEGFA_TARGETS_30MIN</TD><TD>28</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>NR4A1</TD></TR>
<TR><TD>2.353e-02</TD><TD>-3.75</TD><TD>mucosal</TD><TD>COSMIC cancer mutations</TD><TD>mucosal</TD><TD>2071</TD><TD>5</TD><TD>17775</TD><TD>15</TD>
<TD>COL4A5,CNTNAP2,MYRIP,TOX2,SYTL2</TD></TR>
<TR><TD>2.353e-02</TD><TD>-3.75</TD><TD>skin-mucosal-malignant_melanoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-mucosal-malignant_melanoma</TD><TD>2071</TD><TD>5</TD><TD>17775</TD><TD>15</TD>
<TD>COL4A5,CNTNAP2,MYRIP,TOX2,SYTL2</TD></TR>
<TR><TD>2.359e-02</TD><TD>-3.75</TD><TD>cellular response to vascular endothelial growth factor stimulus</TD><TD>biological process</TD><TD>GO:0035924</TD><TD>28</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>NR4A1</TD></TR>
<TR><TD>2.365e-02</TD><TD>-3.74</TD><TD>Signaling by PDGF</TD><TD>REACTOME pathways</TD><TD>R-HSA-186797</TD><TD>345</TD><TD>2</TD><TD>8202</TD><TD>6</TD>
<TD>COL4A5,NR4A1</TD></TR>
<TR><TD>2.376e-02</TD><TD>-3.74</TD><TD>RNF10 (ring finger protein 10)</TD><TD>protein interactions</TD><TD>9921</TD><TD>35</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>COL4A5</TD></TR>
<TR><TD>2.376e-02</TD><TD>-3.74</TD><TD>DCN (decorin)</TD><TD>protein interactions</TD><TD>1634</TD><TD>35</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>COL4A5</TD></TR>
<TR><TD>2.376e-02</TD><TD>-3.74</TD><TD>FARSB (phenylalanyl-tRNA synthetase beta subunit)</TD><TD>protein interactions</TD><TD>10056</TD><TD>35</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>PLOD2</TD></TR>
<TR><TD>2.376e-02</TD><TD>-3.74</TD><TD>GADD45GIP1 (growth arrest and DNA-damage-inducible, gamma interacting protein 1)</TD><TD>protein interactions</TD><TD>90480</TD><TD>35</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>NR4A1</TD></TR>
<TR><TD>2.379e-02</TD><TD>-3.74</TD><TD>GTGCCAA,MIR-96</TD><TD>MSigDB lists</TD><TD>GTGCCAA,MIR-96</TD><TD>287</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>PLOD2,MYRIP</TD></TR>
<TR><TD>2.399e-02</TD><TD>-3.73</TD><TD>arm</TD><TD>COSMIC cancer mutations</TD><TD>arm</TD><TD>1368</TD><TD>4</TD><TD>17775</TD><TD>15</TD>
<TD>COL4A5,PLOD2,NETO2,MECOM</TD></TR>
<TR><TD>2.405e-02</TD><TD>-3.73</TD><TD>SMAD3 (SMAD family member 3)</TD><TD>protein interactions</TD><TD>4088</TD><TD>359</TD><TD>2</TD><TD>16036</TD><TD>11</TD>
<TD>NR4A1,MECOM</TD></TR>
<TR><TD>2.423e-02</TD><TD>-3.72</TD><TD>DORN_ADENOVIRUS_INFECTION_12HR_UP</TD><TD>MSigDB lists</TD><TD>DORN_ADENOVIRUS_INFECTION_12HR_UP</TD><TD>29</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>NR4A1</TD></TR>
<TR><TD>2.423e-02</TD><TD>-3.72</TD><TD>MODULE_184</TD><TD>MSigDB lists</TD><TD>MODULE_184</TD><TD>29</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>ALDH2</TD></TR>
<TR><TD>2.423e-02</TD><TD>-3.72</TD><TD>chr7q35</TD><TD>MSigDB lists</TD><TD>chr7q35</TD><TD>29</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>2.427e-02</TD><TD>-3.72</TD><TD>ion channel complex</TD><TD>cellular component</TD><TD>GO:0034702</TD><TD>287</TD><TD>2</TD><TD>17570</TD><TD>15</TD>
<TD>CNTNAP2,NETO2</TD></TR>
<TR><TD>2.442e-02</TD><TD>-3.71</TD><TD>embryonic hindlimb morphogenesis</TD><TD>biological process</TD><TD>GO:0035116</TD><TD>29</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>MECOM</TD></TR>
<TR><TD>2.442e-02</TD><TD>-3.71</TD><TD>regulation of extracellular matrix organization</TD><TD>biological process</TD><TD>GO:1903053</TD><TD>29</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>MFI2</TD></TR>
<TR><TD>2.443e-02</TD><TD>-3.71</TD><TD>PRMT3 (protein arginine methyltransferase 3)</TD><TD>protein interactions</TD><TD>10196</TD><TD>36</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>PLOD2</TD></TR>
<TR><TD>2.443e-02</TD><TD>-3.71</TD><TD>RPS6KA6 (ribosomal protein S6 kinase, 90kDa, polypeptide 6)</TD><TD>protein interactions</TD><TD>27330</TD><TD>36</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>NR4A1</TD></TR>
<TR><TD>2.451e-02</TD><TD>-3.71</TD><TD>FA58C_3</TD><TD>prosite domains</TD><TD>PS50022</TD><TD>21</TD><TD>1</TD><TD>11866</TD><TD>14</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>2.451e-02</TD><TD>-3.71</TD><TD>FE2OG_OXY</TD><TD>prosite domains</TD><TD>PS51471</TD><TD>21</TD><TD>1</TD><TD>11866</TD><TD>14</TD>
<TD>PLOD2</TD></TR>
<TR><TD>2.454e-02</TD><TD>-3.71</TD><TD>Disulfiram Action Pathway</TD><TD>SMPDB pathways</TD><TD>SMP00429</TD><TD>24</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>ALDH2</TD></TR>
<TR><TD>2.473e-02</TD><TD>-3.70</TD><TD>IVANOVA_HEMATOPOIESIS_STEM_CELL_LONG_TERM</TD><TD>MSigDB lists</TD><TD>IVANOVA_HEMATOPOIESIS_STEM_CELL_LONG_TERM</TD><TD>293</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>ALDH2,MECOM</TD></TR>
<TR><TD>2.488e-02</TD><TD>-3.69</TD><TD>Systolic blood pressure(PMID:21909115)</TD><TD>GWAS genes</TD><TD>Systolic blood pressure(PMID:21909115)</TD><TD>12</TD><TD>1</TD><TD>2389</TD><TD>5</TD>
<TD>MECOM</TD></TR>
<TR><TD>2.502e-02</TD><TD>-3.69</TD><TD>FA58C</TD><TD>smart domains</TD><TD>SM00231</TD><TD>21</TD><TD>1</TD><TD>9131</TD><TD>11</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>2.505e-02</TD><TD>-3.69</TD><TD>MODULE_221</TD><TD>MSigDB lists</TD><TD>MODULE_221</TD><TD>30</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>ALDH2</TD></TR>
<TR><TD>2.505e-02</TD><TD>-3.69</TD><TD>SIMBULAN_PARP1_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>SIMBULAN_PARP1_TARGETS_UP</TD><TD>30</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>COL4A5</TD></TR>
<TR><TD>2.510e-02</TD><TD>-3.68</TD><TD>ALDH2 (aldehyde dehydrogenase 2 family (mitochondrial))</TD><TD>protein interactions</TD><TD>217</TD><TD>37</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>ALDH2</TD></TR>
<TR><TD>2.525e-02</TD><TD>-3.68</TD><TD>regulation of glutamate receptor signaling pathway</TD><TD>biological process</TD><TD>GO:1900449</TD><TD>30</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>NETO2</TD></TR>
<TR><TD>2.564e-02</TD><TD>-3.66</TD><TD>transition metal ion binding</TD><TD>molecular function</TD><TD>GO:0046914</TD><TD>1395</TD><TD>4</TD><TD>16491</TD><TD>14</TD>
<TD>MFI2,PLOD2,MYRIP,NR4A1</TD></TR>
<TR><TD>2.577e-02</TD><TD>-3.66</TD><TD>CTR9 (CTR9 homolog, Paf1/RNA polymerase II complex component)</TD><TD>protein interactions</TD><TD>9646</TD><TD>38</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>2.588e-02</TD><TD>-3.65</TD><TD>TAVOR_CEBPA_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>TAVOR_CEBPA_TARGETS_DN</TD><TD>31</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>PLOD2</TD></TR>
<TR><TD>2.588e-02</TD><TD>-3.65</TD><TD>GNF2_MMP1</TD><TD>MSigDB lists</TD><TD>GNF2_MMP1</TD><TD>31</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>PLOD2</TD></TR>
<TR><TD>2.588e-02</TD><TD>-3.65</TD><TD>ROZANOV_MMP14_TARGETS_SUBSET</TD><TD>MSigDB lists</TD><TD>ROZANOV_MMP14_TARGETS_SUBSET</TD><TD>31</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>PLOD2</TD></TR>
<TR><TD>2.588e-02</TD><TD>-3.65</TD><TD>AMIT_SERUM_RESPONSE_40_MCF10A</TD><TD>MSigDB lists</TD><TD>AMIT_SERUM_RESPONSE_40_MCF10A</TD><TD>31</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>NR4A1</TD></TR>
<TR><TD>2.588e-02</TD><TD>-3.65</TD><TD>VALK_AML_CLUSTER_3</TD><TD>MSigDB lists</TD><TD>VALK_AML_CLUSTER_3</TD><TD>31</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>COL4A5</TD></TR>
<TR><TD>2.588e-02</TD><TD>-3.65</TD><TD>JOSEPH_RESPONSE_TO_SODIUM_BUTYRATE_UP</TD><TD>MSigDB lists</TD><TD>JOSEPH_RESPONSE_TO_SODIUM_BUTYRATE_UP</TD><TD>31</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>NR4A1</TD></TR>
<TR><TD>2.593e-02</TD><TD>-3.65</TD><TD>Fibrinogen_a/b/g_C_dom</TD><TD>interpro domains</TD><TD>IPR002181</TD><TD>32</TD><TD>1</TD><TD>18293</TD><TD>15</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>2.609e-02</TD><TD>-3.65</TD><TD>neuron maturation</TD><TD>biological process</TD><TD>GO:0042551</TD><TD>31</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>2.644e-02</TD><TD>-3.63</TD><TD>CHD1L (chromodomain helicase DNA binding protein 1-like)</TD><TD>protein interactions</TD><TD>9557</TD><TD>39</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>NR4A1</TD></TR>
<TR><TD>2.658e-02</TD><TD>-3.63</TD><TD>Glycine and Serine Metabolism</TD><TD>SMPDB pathways</TD><TD>SMP00004</TD><TD>26</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>ALDH2</TD></TR>
<TR><TD>2.658e-02</TD><TD>-3.63</TD><TD>Dihydropyrimidine Dehydrogenase Deficiency (DHPD)</TD><TD>SMPDB pathways</TD><TD>SMP00179</TD><TD>26</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>ALDH2</TD></TR>
<TR><TD>2.658e-02</TD><TD>-3.63</TD><TD>Non Ketotic Hyperglycinemia</TD><TD>SMPDB pathways</TD><TD>SMP00223</TD><TD>26</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>ALDH2</TD></TR>
<TR><TD>2.658e-02</TD><TD>-3.63</TD><TD>Dimethylglycine Dehydrogenase Deficiency</TD><TD>SMPDB pathways</TD><TD>SMP00484</TD><TD>26</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>ALDH2</TD></TR>
<TR><TD>2.658e-02</TD><TD>-3.63</TD><TD>Sarcosinemia</TD><TD>SMPDB pathways</TD><TD>SMP00244</TD><TD>26</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>ALDH2</TD></TR>
<TR><TD>2.658e-02</TD><TD>-3.63</TD><TD>3-Phosphoglycerate dehydrogenase deficiency</TD><TD>SMPDB pathways</TD><TD>SMP00721</TD><TD>26</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>ALDH2</TD></TR>
<TR><TD>2.658e-02</TD><TD>-3.63</TD><TD>Hyperglycinemia- non-ketotic</TD><TD>SMPDB pathways</TD><TD>SMP00485</TD><TD>26</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>ALDH2</TD></TR>
<TR><TD>2.658e-02</TD><TD>-3.63</TD><TD>Dimethylglycine Dehydrogenase Deficiency</TD><TD>SMPDB pathways</TD><TD>SMP00242</TD><TD>26</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>ALDH2</TD></TR>
<TR><TD>2.663e-02</TD><TD>-3.63</TD><TD>beta-Alanine metabolism</TD><TD>KEGG pathways</TD><TD>ko00410</TD><TD>31</TD><TD>1</TD><TD>6908</TD><TD>6</TD>
<TD>ALDH2</TD></TR>
<TR><TD>2.663e-02</TD><TD>-3.63</TD><TD>beta-Alanine metabolism</TD><TD>KEGG pathways</TD><TD>hsa00410</TD><TD>31</TD><TD>1</TD><TD>6908</TD><TD>6</TD>
<TD>ALDH2</TD></TR>
<TR><TD>2.669e-02</TD><TD>-3.62</TD><TD>single-organism membrane organization</TD><TD>biological process</TD><TD>GO:0044802</TD><TD>786</TD><TD>3</TD><TD>16441</TD><TD>14</TD>
<TD>SUN3,CNTNAP2,SYTL2</TD></TR>
<TR><TD>2.670e-02</TD><TD>-3.62</TD><TD>GRADE_COLON_CANCER_DN</TD><TD>MSigDB lists</TD><TD>GRADE_COLON_CANCER_DN</TD><TD>32</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>PLOD2</TD></TR>
<TR><TD>2.670e-02</TD><TD>-3.62</TD><TD>ABE_VEGFA_TARGETS_2HR</TD><TD>MSigDB lists</TD><TD>ABE_VEGFA_TARGETS_2HR</TD><TD>32</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>NR4A1</TD></TR>
<TR><TD>2.670e-02</TD><TD>-3.62</TD><TD>KEGG_PROPANOATE_METABOLISM</TD><TD>MSigDB lists</TD><TD>KEGG_PROPANOATE_METABOLISM</TD><TD>32</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>ALDH2</TD></TR>
<TR><TD>2.677e-02</TD><TD>-3.62</TD><TD>NCAM1 interactions</TD><TD>REACTOME pathways</TD><TD>R-HSA-419037</TD><TD>37</TD><TD>1</TD><TD>8202</TD><TD>6</TD>
<TD>COL4A5</TD></TR>
<TR><TD>2.692e-02</TD><TD>-3.61</TD><TD>neurotransmitter metabolic process</TD><TD>biological process</TD><TD>GO:0042133</TD><TD>32</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>ALDH2</TD></TR>
<TR><TD>2.692e-02</TD><TD>-3.61</TD><TD>neuron recognition</TD><TD>biological process</TD><TD>GO:0008038</TD><TD>32</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>2.692e-02</TD><TD>-3.61</TD><TD>negative regulation of JNK cascade</TD><TD>biological process</TD><TD>GO:0046329</TD><TD>32</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>MECOM</TD></TR>
<TR><TD>2.694e-02</TD><TD>-3.61</TD><TD>haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma</TD><TD>793</TD><TD>3</TD><TD>17775</TD><TD>15</TD>
<TD>ZNF432,CNTNAP2,MYRIP</TD></TR>
<TR><TD>2.711e-02</TD><TD>-3.61</TD><TD>TF (transferrin)</TD><TD>protein interactions</TD><TD>7018</TD><TD>40</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>ALDH2</TD></TR>
<TR><TD>2.713e-02</TD><TD>-3.61</TD><TD>PASINI_SUZ12_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>PASINI_SUZ12_TARGETS_DN</TD><TD>308</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>COL4A5,PLOD2</TD></TR>
<TR><TD>2.753e-02</TD><TD>-3.59</TD><TD>YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_15</TD><TD>MSigDB lists</TD><TD>YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_15</TD><TD>33</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>COL4A5</TD></TR>
<TR><TD>2.753e-02</TD><TD>-3.59</TD><TD>DOANE_BREAST_CANCER_CLASSES_DN</TD><TD>MSigDB lists</TD><TD>DOANE_BREAST_CANCER_CLASSES_DN</TD><TD>33</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>PLOD2</TD></TR>
<TR><TD>2.753e-02</TD><TD>-3.59</TD><TD>VALK_AML_CLUSTER_5</TD><TD>MSigDB lists</TD><TD>VALK_AML_CLUSTER_5</TD><TD>33</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>FAM198B</TD></TR>
<TR><TD>2.778e-02</TD><TD>-3.58</TD><TD>DIABLO (diablo, IAP-binding mitochondrial protein)</TD><TD>protein interactions</TD><TD>56616</TD><TD>41</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>NR4A1</TD></TR>
<TR><TD>2.778e-02</TD><TD>-3.58</TD><TD>SOD2 (superoxide dismutase 2, mitochondrial)</TD><TD>protein interactions</TD><TD>6648</TD><TD>41</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>ALDH2</TD></TR>
<TR><TD>2.778e-02</TD><TD>-3.58</TD><TD>PLOD2 (procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2)</TD><TD>protein interactions</TD><TD>5352</TD><TD>41</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>PLOD2</TD></TR>
<TR><TD>2.782e-02</TD><TD>-3.58</TD><TD>aggresome</TD><TD>cellular component</TD><TD>GO:0016235</TD><TD>33</TD><TD>1</TD><TD>17570</TD><TD>15</TD>
<TD>MECOM</TD></TR>
<TR><TD>2.835e-02</TD><TD>-3.56</TD><TD>KEGG_BUTANOATE_METABOLISM</TD><TD>MSigDB lists</TD><TD>KEGG_BUTANOATE_METABOLISM</TD><TD>34</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>ALDH2</TD></TR>
<TR><TD>2.835e-02</TD><TD>-3.56</TD><TD>PLASARI_TGFB1_TARGETS_1HR_UP</TD><TD>MSigDB lists</TD><TD>PLASARI_TGFB1_TARGETS_1HR_UP</TD><TD>34</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>NR4A1</TD></TR>
<TR><TD>2.844e-02</TD><TD>-3.56</TD><TD>BTNL8 (butyrophilin-like 8)</TD><TD>protein interactions</TD><TD>79908</TD><TD>42</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>NETO2</TD></TR>
<TR><TD>2.849e-02</TD><TD>-3.56</TD><TD>glutamate receptor binding</TD><TD>molecular function</TD><TD>GO:0035254</TD><TD>34</TD><TD>1</TD><TD>16491</TD><TD>14</TD>
<TD>NETO2</TD></TR>
<TR><TD>2.849e-02</TD><TD>-3.56</TD><TD>oxidoreductase activity, acting on the aldehyde or oxo group of donors, NAD or NADP as acceptor</TD><TD>molecular function</TD><TD>GO:0016620</TD><TD>34</TD><TD>1</TD><TD>16491</TD><TD>14</TD>
<TD>ALDH2</TD></TR>
<TR><TD>2.858e-02</TD><TD>-3.56</TD><TD>calcium ion-dependent exocytosis of neurotransmitter</TD><TD>biological process</TD><TD>GO:0048791</TD><TD>34</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>SYTL2</TD></TR>
<TR><TD>2.858e-02</TD><TD>-3.56</TD><TD>embryonic forelimb morphogenesis</TD><TD>biological process</TD><TD>GO:0035115</TD><TD>34</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>MECOM</TD></TR>
<TR><TD>2.859e-02</TD><TD>-3.55</TD><TD>intracellular membrane-bounded organelle</TD><TD>cellular component</TD><TD>GO:0043231</TD><TD>10597</TD><TD>13</TD><TD>17570</TD><TD>15</TD>
<TD>ZNF432,ALDH2,PLOD2,ASCL5,NR4A1,TOX2,SUN3,COL4A5,CNTNAP2,FAM198B,MYRIP,SYTL2,MECOM</TD></TR>
<TR><TD>2.898e-02</TD><TD>-3.54</TD><TD>Visceral adipose tissue/subcutaneous adipose tissue ratio(PMID:22589738)</TD><TD>GWAS genes</TD><TD>Visceral adipose tissue/subcutaneous adipose tissue ratio(PMID:22589738)</TD><TD>14</TD><TD>1</TD><TD>2389</TD><TD>5</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>2.911e-02</TD><TD>-3.54</TD><TD>SERPINB5 (serpin peptidase inhibitor, clade B (ovalbumin), member 5)</TD><TD>protein interactions</TD><TD>5268</TD><TD>43</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>ALDH2</TD></TR>
<TR><TD>2.911e-02</TD><TD>-3.54</TD><TD>POLA2 (polymerase (DNA directed), alpha 2, accessory subunit)</TD><TD>protein interactions</TD><TD>23649</TD><TD>43</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>NR4A1</TD></TR>
<TR><TD>2.911e-02</TD><TD>-3.54</TD><TD>RANBP3 (RAN binding protein 3)</TD><TD>protein interactions</TD><TD>8498</TD><TD>43</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>PLOD2</TD></TR>
<TR><TD>2.911e-02</TD><TD>-3.54</TD><TD>HLA-DRA (major histocompatibility complex, class II, DR alpha)</TD><TD>protein interactions</TD><TD>3122</TD><TD>43</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>NETO2</TD></TR>
<TR><TD>2.911e-02</TD><TD>-3.54</TD><TD>SERPINA1 (serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1)</TD><TD>protein interactions</TD><TD>5265</TD><TD>43</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>ALDH2</TD></TR>
<TR><TD>2.917e-02</TD><TD>-3.53</TD><TD>VALK_AML_CLUSTER_11</TD><TD>MSigDB lists</TD><TD>VALK_AML_CLUSTER_11</TD><TD>35</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>ALDH2</TD></TR>
<TR><TD>2.917e-02</TD><TD>-3.53</TD><TD>OXIDOREDUCTASE_ACTIVITY_GO_0016705</TD><TD>MSigDB lists</TD><TD>OXIDOREDUCTASE_ACTIVITY_GO_0016705</TD><TD>35</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>PLOD2</TD></TR>
<TR><TD>2.978e-02</TD><TD>-3.51</TD><TD>PACSIN2 (protein kinase C and casein kinase substrate in neurons 2)</TD><TD>protein interactions</TD><TD>11252</TD><TD>44</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>PLOD2</TD></TR>
<TR><TD>2.978e-02</TD><TD>-3.51</TD><TD>PGM1 (phosphoglucomutase 1)</TD><TD>protein interactions</TD><TD>5236</TD><TD>44</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>ALDH2</TD></TR>
<TR><TD>2.978e-02</TD><TD>-3.51</TD><TD>TMOD3 (tropomodulin 3 (ubiquitous))</TD><TD>protein interactions</TD><TD>29766</TD><TD>44</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>NR4A1</TD></TR>
<TR><TD>2.987e-02</TD><TD>-3.51</TD><TD>transmembrane transporter complex</TD><TD>cellular component</TD><TD>GO:1902495</TD><TD>321</TD><TD>2</TD><TD>17570</TD><TD>15</TD>
<TD>CNTNAP2,NETO2</TD></TR>
<TR><TD>2.999e-02</TD><TD>-3.51</TD><TD>REACTOME_PI3K_EVENTS_IN_ERBB4_SIGNALING</TD><TD>MSigDB lists</TD><TD>REACTOME_PI3K_EVENTS_IN_ERBB4_SIGNALING</TD><TD>36</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>NR4A1</TD></TR>
<TR><TD>2.999e-02</TD><TD>-3.51</TD><TD>UZONYI_RESPONSE_TO_LEUKOTRIENE_AND_THROMBIN</TD><TD>MSigDB lists</TD><TD>UZONYI_RESPONSE_TO_LEUKOTRIENE_AND_THROMBIN</TD><TD>36</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>NR4A1</TD></TR>
<TR><TD>2.999e-02</TD><TD>-3.51</TD><TD>REACTOME_PI3K_AKT_ACTIVATION</TD><TD>MSigDB lists</TD><TD>REACTOME_PI3K_AKT_ACTIVATION</TD><TD>36</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>NR4A1</TD></TR>
<TR><TD>2.999e-02</TD><TD>-3.51</TD><TD>QI_HYPOXIA_TARGETS_OF_HIF1A_AND_FOXA2</TD><TD>MSigDB lists</TD><TD>QI_HYPOXIA_TARGETS_OF_HIF1A_AND_FOXA2</TD><TD>36</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>PLOD2</TD></TR>
<TR><TD>2.999e-02</TD><TD>-3.51</TD><TD>REACTOME_GAB1_SIGNALOSOME</TD><TD>MSigDB lists</TD><TD>REACTOME_GAB1_SIGNALOSOME</TD><TD>36</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>NR4A1</TD></TR>
<TR><TD>2.999e-02</TD><TD>-3.51</TD><TD>GNF2_PTX3</TD><TD>MSigDB lists</TD><TD>GNF2_PTX3</TD><TD>36</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>PLOD2</TD></TR>
<TR><TD>2.999e-02</TD><TD>-3.51</TD><TD>ZHAN_MULTIPLE_MYELOMA_MF_DN</TD><TD>MSigDB lists</TD><TD>ZHAN_MULTIPLE_MYELOMA_MF_DN</TD><TD>36</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>ALDH2</TD></TR>
<TR><TD>3.042e-02</TD><TD>-3.49</TD><TD>human chr12q13</TD><TD>chromosome location</TD><TD>human chr12q13</TD><TD>54</TD><TD>1</TD><TD>26250</TD><TD>15</TD>
<TD>NR4A1</TD></TR>
<TR><TD>3.045e-02</TD><TD>-3.49</TD><TD>RPAP1 (RNA polymerase II associated protein 1)</TD><TD>protein interactions</TD><TD>26015</TD><TD>45</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>SYTL2</TD></TR>
<TR><TD>3.045e-02</TD><TD>-3.49</TD><TD>HES1 (hes family bHLH transcription factor 1)</TD><TD>protein interactions</TD><TD>3280</TD><TD>45</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>NR4A1</TD></TR>
<TR><TD>3.045e-02</TD><TD>-3.49</TD><TD>PPM1A (protein phosphatase, Mg2+/Mn2+ dependent, 1A)</TD><TD>protein interactions</TD><TD>5494</TD><TD>45</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>NR4A1</TD></TR>
<TR><TD>3.065e-02</TD><TD>-3.49</TD><TD>PHONG_TNF_RESPONSE_NOT_VIA_P38</TD><TD>MSigDB lists</TD><TD>PHONG_TNF_RESPONSE_NOT_VIA_P38</TD><TD>329</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>ZNF432,NETO2</TD></TR>
<TR><TD>3.067e-02</TD><TD>-3.48</TD><TD>Isovaleric acidemia</TD><TD>SMPDB pathways</TD><TD>SMP00524</TD><TD>30</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>ALDH2</TD></TR>
<TR><TD>3.067e-02</TD><TD>-3.48</TD><TD>Maple Syrup Urine Disease</TD><TD>SMPDB pathways</TD><TD>SMP00199</TD><TD>30</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>ALDH2</TD></TR>
<TR><TD>3.067e-02</TD><TD>-3.48</TD><TD>Isobutyryl-coa dehydrogenase deficiency</TD><TD>SMPDB pathways</TD><TD>SMP00523</TD><TD>30</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>ALDH2</TD></TR>
<TR><TD>3.067e-02</TD><TD>-3.48</TD><TD>3-hydroxyisobutyric aciduria</TD><TD>SMPDB pathways</TD><TD>SMP00522</TD><TD>30</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>ALDH2</TD></TR>
<TR><TD>3.067e-02</TD><TD>-3.48</TD><TD>Beta-Ketothiolase Deficiency</TD><TD>SMPDB pathways</TD><TD>SMP00173</TD><TD>30</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>ALDH2</TD></TR>
<TR><TD>3.067e-02</TD><TD>-3.48</TD><TD>3-hydroxyisobutyric acid dehydrogenase deficiency</TD><TD>SMPDB pathways</TD><TD>SMP00521</TD><TD>30</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>ALDH2</TD></TR>
<TR><TD>3.067e-02</TD><TD>-3.48</TD><TD>2-Methyl-3-Hydroxybutryl CoA Dehydrogenase Deficiency</TD><TD>SMPDB pathways</TD><TD>SMP00137</TD><TD>30</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>ALDH2</TD></TR>
<TR><TD>3.067e-02</TD><TD>-3.48</TD><TD>3-Methylcrotonyl Coa Carboxylase Deficiency Type I</TD><TD>SMPDB pathways</TD><TD>SMP00237</TD><TD>30</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>ALDH2</TD></TR>
<TR><TD>3.067e-02</TD><TD>-3.48</TD><TD>Methylmalonate Semialdehyde Dehydrogenase Deficiency</TD><TD>SMPDB pathways</TD><TD>SMP00384</TD><TD>30</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>ALDH2</TD></TR>
<TR><TD>3.067e-02</TD><TD>-3.48</TD><TD>Propionic Acidemia</TD><TD>SMPDB pathways</TD><TD>SMP00236</TD><TD>30</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>ALDH2</TD></TR>
<TR><TD>3.067e-02</TD><TD>-3.48</TD><TD>Isovaleric Aciduria</TD><TD>SMPDB pathways</TD><TD>SMP00238</TD><TD>30</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>ALDH2</TD></TR>
<TR><TD>3.067e-02</TD><TD>-3.48</TD><TD>3-Methylglutaconic Aciduria Type IV</TD><TD>SMPDB pathways</TD><TD>SMP00141</TD><TD>30</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>ALDH2</TD></TR>
<TR><TD>3.067e-02</TD><TD>-3.48</TD><TD>3-Methylglutaconic Aciduria Type III</TD><TD>SMPDB pathways</TD><TD>SMP00140</TD><TD>30</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>ALDH2</TD></TR>
<TR><TD>3.067e-02</TD><TD>-3.48</TD><TD>Valine- Leucine and Isoleucine Degradation</TD><TD>SMPDB pathways</TD><TD>SMP00032</TD><TD>30</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>ALDH2</TD></TR>
<TR><TD>3.067e-02</TD><TD>-3.48</TD><TD>Methylmalonic Aciduria</TD><TD>SMPDB pathways</TD><TD>SMP00200</TD><TD>30</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>ALDH2</TD></TR>
<TR><TD>3.067e-02</TD><TD>-3.48</TD><TD>3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency</TD><TD>SMPDB pathways</TD><TD>SMP00138</TD><TD>30</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>ALDH2</TD></TR>
<TR><TD>3.067e-02</TD><TD>-3.48</TD><TD>3-Methylglutaconic Aciduria Type I</TD><TD>SMPDB pathways</TD><TD>SMP00139</TD><TD>30</TD><TD>1</TD><TD>978</TD><TD>1</TD>
<TD>ALDH2</TD></TR>
<TR><TD>3.081e-02</TD><TD>-3.48</TD><TD>BASEMENT_MEMBRANE</TD><TD>MSigDB lists</TD><TD>BASEMENT_MEMBRANE</TD><TD>37</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>COL4A5</TD></TR>
<TR><TD>3.081e-02</TD><TD>-3.48</TD><TD>HERNANDEZ_MITOTIC_ARREST_BY_DOCETAXEL_1_DN</TD><TD>MSigDB lists</TD><TD>HERNANDEZ_MITOTIC_ARREST_BY_DOCETAXEL_1_DN</TD><TD>37</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>PLOD2</TD></TR>
<TR><TD>3.081e-02</TD><TD>-3.48</TD><TD>BROWNE_HCMV_INFECTION_2HR_UP</TD><TD>MSigDB lists</TD><TD>BROWNE_HCMV_INFECTION_2HR_UP</TD><TD>37</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>NR4A1</TD></TR>
<TR><TD>3.087e-02</TD><TD>-3.48</TD><TD>Pentose and glucuronate interconversions</TD><TD>KEGG pathways</TD><TD>hsa00040</TD><TD>36</TD><TD>1</TD><TD>6908</TD><TD>6</TD>
<TD>ALDH2</TD></TR>
<TR><TD>3.087e-02</TD><TD>-3.48</TD><TD>Pentose and glucuronate interconversions</TD><TD>KEGG pathways</TD><TD>ko00040</TD><TD>36</TD><TD>1</TD><TD>6908</TD><TD>6</TD>
<TD>ALDH2</TD></TR>
<TR><TD>3.090e-02</TD><TD>-3.48</TD><TD>transporter complex</TD><TD>cellular component</TD><TD>GO:1990351</TD><TD>327</TD><TD>2</TD><TD>17570</TD><TD>15</TD>
<TD>CNTNAP2,NETO2</TD></TR>
<TR><TD>3.099e-02</TD><TD>-3.47</TD><TD>REACTOME_GENERIC_TRANSCRIPTION_PATHWAY</TD><TD>MSigDB lists</TD><TD>REACTOME_GENERIC_TRANSCRIPTION_PATHWAY</TD><TD>331</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>ZNF432,NR4A1</TD></TR>
<TR><TD>3.111e-02</TD><TD>-3.47</TD><TD>PRDX4 (peroxiredoxin 4)</TD><TD>protein interactions</TD><TD>10549</TD><TD>46</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>NR4A1</TD></TR>
<TR><TD>3.112e-02</TD><TD>-3.47</TD><TD>Laminin_G_2</TD><TD>pfam domains</TD><TD>PF02210</TD><TD>35</TD><TD>1</TD><TD>16629</TD><TD>15</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>3.153e-02</TD><TD>-3.46</TD><TD>human chr19q13.41</TD><TD>chromosome location</TD><TD>human chr19q13.41</TD><TD>56</TD><TD>1</TD><TD>26250</TD><TD>15</TD>
<TD>ZNF432</TD></TR>
<TR><TD>3.163e-02</TD><TD>-3.45</TD><TD>skin-ankle-malignant_melanoma-acral_lentiginous</TD><TD>COSMIC cancer mutations</TD><TD>skin-ankle-malignant_melanoma-acral_lentiginous</TD><TD>335</TD><TD>2</TD><TD>17775</TD><TD>15</TD>
<TD>ALDH2,CNTNAP2</TD></TR>
<TR><TD>3.163e-02</TD><TD>-3.45</TD><TD>VALK_AML_WITH_FLT3_ITD</TD><TD>MSigDB lists</TD><TD>VALK_AML_WITH_FLT3_ITD</TD><TD>38</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>COL4A5</TD></TR>
<TR><TD>3.163e-02</TD><TD>-3.45</TD><TD>ELLWOOD_MYC_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>ELLWOOD_MYC_TARGETS_DN</TD><TD>38</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>ALDH2</TD></TR>
<TR><TD>3.189e-02</TD><TD>-3.45</TD><TD>hindlimb morphogenesis</TD><TD>biological process</TD><TD>GO:0035137</TD><TD>38</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>MECOM</TD></TR>
<TR><TD>3.189e-02</TD><TD>-3.45</TD><TD>neuromuscular junction development</TD><TD>biological process</TD><TD>GO:0007528</TD><TD>38</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>COL4A5</TD></TR>
<TR><TD>3.231e-02</TD><TD>-3.43</TD><TD>LDLR_class-A_CS</TD><TD>interpro domains</TD><TD>IPR023415</TD><TD>40</TD><TD>1</TD><TD>18293</TD><TD>15</TD>
<TD>NETO2</TD></TR>
<TR><TD>3.240e-02</TD><TD>-3.43</TD><TD>positive regulation of secretion</TD><TD>biological process</TD><TD>GO:0051047</TD><TD>337</TD><TD>2</TD><TD>16441</TD><TD>14</TD>
<TD>MYRIP,SYTL2</TD></TR>
<TR><TD>3.245e-02</TD><TD>-3.43</TD><TD>MACF1 (microtubule-actin crosslinking factor 1)</TD><TD>protein interactions</TD><TD>23499</TD><TD>48</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>3.245e-02</TD><TD>-3.43</TD><TD>TUBB4A (tubulin, beta 4A class IVa)</TD><TD>protein interactions</TD><TD>10382</TD><TD>48</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>NR4A1</TD></TR>
<TR><TD>3.245e-02</TD><TD>-3.43</TD><TD>RPE (ribulose-5-phosphate-3-epimerase)</TD><TD>protein interactions</TD><TD>6120</TD><TD>48</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>ALDH2</TD></TR>
<TR><TD>3.245e-02</TD><TD>-3.43</TD><TD>SAMHD1 (SAM domain and HD domain 1)</TD><TD>protein interactions</TD><TD>25939</TD><TD>48</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>PLOD2</TD></TR>
<TR><TD>3.245e-02</TD><TD>-3.43</TD><TD>KEGG_PYRUVATE_METABOLISM</TD><TD>MSigDB lists</TD><TD>KEGG_PYRUVATE_METABOLISM</TD><TD>39</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>ALDH2</TD></TR>
<TR><TD>3.245e-02</TD><TD>-3.43</TD><TD>chr11q14</TD><TD>MSigDB lists</TD><TD>chr11q14</TD><TD>39</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>SYTL2</TD></TR>
<TR><TD>3.245e-02</TD><TD>-3.43</TD><TD>REACTOME_NCAM1_INTERACTIONS</TD><TD>MSigDB lists</TD><TD>REACTOME_NCAM1_INTERACTIONS</TD><TD>39</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>COL4A5</TD></TR>
<TR><TD>3.245e-02</TD><TD>-3.43</TD><TD>DORN_ADENOVIRUS_INFECTION_32HR_DN</TD><TD>MSigDB lists</TD><TD>DORN_ADENOVIRUS_INFECTION_32HR_DN</TD><TD>39</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>NR4A1</TD></TR>
<TR><TD>3.245e-02</TD><TD>-3.43</TD><TD>KEGG_TRYPTOPHAN_METABOLISM</TD><TD>MSigDB lists</TD><TD>KEGG_TRYPTOPHAN_METABOLISM</TD><TD>39</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>ALDH2</TD></TR>
<TR><TD>3.272e-02</TD><TD>-3.42</TD><TD>negative regulation of stress-activated protein kinase signaling cascade</TD><TD>biological process</TD><TD>GO:0070303</TD><TD>39</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>MECOM</TD></TR>
<TR><TD>3.272e-02</TD><TD>-3.42</TD><TD>negative regulation of stress-activated MAPK cascade</TD><TD>biological process</TD><TD>GO:0032873</TD><TD>39</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>MECOM</TD></TR>
<TR><TD>3.280e-02</TD><TD>-3.42</TD><TD>neuron projection membrane</TD><TD>cellular component</TD><TD>GO:0032589</TD><TD>39</TD><TD>1</TD><TD>17570</TD><TD>15</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>3.280e-02</TD><TD>-3.42</TD><TD>anchored component of plasma membrane</TD><TD>cellular component</TD><TD>GO:0046658</TD><TD>39</TD><TD>1</TD><TD>17570</TD><TD>15</TD>
<TD>MFI2</TD></TR>
<TR><TD>3.281e-02</TD><TD>-3.42</TD><TD>PI3K-Akt signaling pathway</TD><TD>KEGG pathways</TD><TD>hsa04151</TD><TD>346</TD><TD>2</TD><TD>6908</TD><TD>6</TD>
<TD>COL4A5,NR4A1</TD></TR>
<TR><TD>3.281e-02</TD><TD>-3.42</TD><TD>PI3K-Akt signaling pathway</TD><TD>KEGG pathways</TD><TD>ko04151</TD><TD>346</TD><TD>2</TD><TD>6908</TD><TD>6</TD>
<TD>COL4A5,NR4A1</TD></TR>
<TR><TD>3.309e-02</TD><TD>-3.41</TD><TD>CTAWWWATA_V$RSRFC4_Q2</TD><TD>MSigDB lists</TD><TD>CTAWWWATA_V$RSRFC4_Q2</TD><TD>343</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>NR4A1,SYTL2</TD></TR>
<TR><TD>3.311e-02</TD><TD>-3.41</TD><TD>CD1B (CD1b molecule)</TD><TD>protein interactions</TD><TD>910</TD><TD>49</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>NETO2</TD></TR>
<TR><TD>3.325e-02</TD><TD>-3.40</TD><TD>metal ion binding</TD><TD>molecular function</TD><TD>GO:0046872</TD><TD>4013</TD><TD>7</TD><TD>16491</TD><TD>14</TD>
<TD>ZNF432,MFI2,PLOD2,MYRIP,NR4A1,SYTL2,MECOM</TD></TR>
<TR><TD>3.327e-02</TD><TD>-3.40</TD><TD>TRAYNOR_RETT_SYNDROM_UP</TD><TD>MSigDB lists</TD><TD>TRAYNOR_RETT_SYNDROM_UP</TD><TD>40</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>SYTL2</TD></TR>
<TR><TD>3.327e-02</TD><TD>-3.40</TD><TD>DORN_ADENOVIRUS_INFECTION_48HR_DN</TD><TD>MSigDB lists</TD><TD>DORN_ADENOVIRUS_INFECTION_48HR_DN</TD><TD>40</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>NR4A1</TD></TR>
<TR><TD>3.327e-02</TD><TD>-3.40</TD><TD>NABA_BASEMENT_MEMBRANES</TD><TD>MSigDB lists</TD><TD>NABA_BASEMENT_MEMBRANES</TD><TD>40</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>COL4A5</TD></TR>
<TR><TD>3.354e-02</TD><TD>-3.39</TD><TD>regulation of substrate adhesion-dependent cell spreading</TD><TD>biological process</TD><TD>GO:1900024</TD><TD>40</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>MFI2</TD></TR>
<TR><TD>3.370e-02</TD><TD>-3.39</TD><TD>Nuclear Receptors</TD><TD>WikiPathways</TD><TD>WP170</TD><TD>38</TD><TD>1</TD><TD>4455</TD><TD>4</TD>
<TD>NR4A1</TD></TR>
<TR><TD>3.375e-02</TD><TD>-3.39</TD><TD>human chr20q13.12</TD><TD>chromosome location</TD><TD>human chr20q13.12</TD><TD>60</TD><TD>1</TD><TD>26250</TD><TD>15</TD>
<TD>TOX2</TD></TR>
<TR><TD>3.378e-02</TD><TD>-3.39</TD><TD>NARS (asparaginyl-tRNA synthetase)</TD><TD>protein interactions</TD><TD>4677</TD><TD>50</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>PLOD2</TD></TR>
<TR><TD>3.398e-02</TD><TD>-3.38</TD><TD>COLINA_TARGETS_OF_4EBP1_AND_4EBP2</TD><TD>MSigDB lists</TD><TD>COLINA_TARGETS_OF_4EBP1_AND_4EBP2</TD><TD>348</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>ALDH2,PLOD2</TD></TR>
<TR><TD>3.426e-02</TD><TD>-3.37</TD><TD>Tryptophan metabolism</TD><TD>KEGG pathways</TD><TD>hsa00380</TD><TD>40</TD><TD>1</TD><TD>6908</TD><TD>6</TD>
<TD>ALDH2</TD></TR>
<TR><TD>3.426e-02</TD><TD>-3.37</TD><TD>Tryptophan metabolism</TD><TD>KEGG pathways</TD><TD>ko00380</TD><TD>40</TD><TD>1</TD><TD>6908</TD><TD>6</TD>
<TD>ALDH2</TD></TR>
<TR><TD>3.426e-02</TD><TD>-3.37</TD><TD>Pyruvate metabolism</TD><TD>KEGG pathways</TD><TD>ko00620</TD><TD>40</TD><TD>1</TD><TD>6908</TD><TD>6</TD>
<TD>ALDH2</TD></TR>
<TR><TD>3.426e-02</TD><TD>-3.37</TD><TD>Pyruvate metabolism</TD><TD>KEGG pathways</TD><TD>hsa00620</TD><TD>40</TD><TD>1</TD><TD>6908</TD><TD>6</TD>
<TD>ALDH2</TD></TR>
<TR><TD>3.426e-02</TD><TD>-3.37</TD><TD>protein kinase A binding</TD><TD>molecular function</TD><TD>GO:0051018</TD><TD>41</TD><TD>1</TD><TD>16491</TD><TD>14</TD>
<TD>MYRIP</TD></TR>
<TR><TD>3.432e-02</TD><TD>-3.37</TD><TD>tibia</TD><TD>COSMIC cancer mutations</TD><TD>tibia</TD><TD>871</TD><TD>3</TD><TD>17775</TD><TD>15</TD>
<TD>MFI2,NR4A1,SYTL2</TD></TR>
<TR><TD>3.444e-02</TD><TD>-3.37</TD><TD>UGP2 (UDP-glucose pyrophosphorylase 2)</TD><TD>protein interactions</TD><TD>7360</TD><TD>51</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>PLOD2</TD></TR>
<TR><TD>3.470e-02</TD><TD>-3.36</TD><TD>YNGTTNNNATT_UNKNOWN</TD><TD>MSigDB lists</TD><TD>YNGTTNNNATT_UNKNOWN</TD><TD>352</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>CNTNAP2,SYTL2</TD></TR>
<TR><TD>3.491e-02</TD><TD>-3.36</TD><TD>JAEGER_METASTASIS_UP</TD><TD>MSigDB lists</TD><TD>JAEGER_METASTASIS_UP</TD><TD>42</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>PLOD2</TD></TR>
<TR><TD>3.491e-02</TD><TD>-3.36</TD><TD>KEGG_FATTY_ACID_METABOLISM</TD><TD>MSigDB lists</TD><TD>KEGG_FATTY_ACID_METABOLISM</TD><TD>42</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>ALDH2</TD></TR>
<TR><TD>3.491e-02</TD><TD>-3.36</TD><TD>REACTOME_PI3K_EVENTS_IN_ERBB2_SIGNALING</TD><TD>MSigDB lists</TD><TD>REACTOME_PI3K_EVENTS_IN_ERBB2_SIGNALING</TD><TD>42</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>NR4A1</TD></TR>
<TR><TD>3.491e-02</TD><TD>-3.36</TD><TD>AMIT_EGF_RESPONSE_40_HELA</TD><TD>MSigDB lists</TD><TD>AMIT_EGF_RESPONSE_40_HELA</TD><TD>42</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>NR4A1</TD></TR>
<TR><TD>3.491e-02</TD><TD>-3.36</TD><TD>MODULE_332</TD><TD>MSigDB lists</TD><TD>MODULE_332</TD><TD>42</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>NR4A1</TD></TR>
<TR><TD>3.511e-02</TD><TD>-3.35</TD><TD>TMEM30A (transmembrane protein 30A)</TD><TD>protein interactions</TD><TD>55754</TD><TD>52</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>NETO2</TD></TR>
<TR><TD>3.511e-02</TD><TD>-3.35</TD><TD>GART (phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase)</TD><TD>protein interactions</TD><TD>2618</TD><TD>52</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>PLOD2</TD></TR>
<TR><TD>3.511e-02</TD><TD>-3.35</TD><TD>PTPN12 (protein tyrosine phosphatase, non-receptor type 12)</TD><TD>protein interactions</TD><TD>5782</TD><TD>52</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>PLOD2</TD></TR>
<TR><TD>3.518e-02</TD><TD>-3.35</TD><TD>lower_third</TD><TD>COSMIC cancer mutations</TD><TD>lower_third</TD><TD>8323</TD><TD>11</TD><TD>17775</TD><TD>15</TD>
<TD>ZNF432,MFI2,NR4A1,TOX2,NETO2,SUN3,COL4A5,CNTNAP2,MYRIP,SYTL2,MECOM</TD></TR>
<TR><TD>3.519e-02</TD><TD>-3.35</TD><TD>primary alcohol metabolic process</TD><TD>biological process</TD><TD>GO:0034308</TD><TD>42</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>ALDH2</TD></TR>
<TR><TD>3.519e-02</TD><TD>-3.35</TD><TD>sprouting angiogenesis</TD><TD>biological process</TD><TD>GO:0002040</TD><TD>42</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>NR4A1</TD></TR>
<TR><TD>3.519e-02</TD><TD>-3.35</TD><TD>forelimb morphogenesis</TD><TD>biological process</TD><TD>GO:0035136</TD><TD>42</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>MECOM</TD></TR>
<TR><TD>3.536e-02</TD><TD>-3.34</TD><TD>central_nervous_system-brainstem-glioma</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-brainstem-glioma</TD><TD>356</TD><TD>2</TD><TD>17775</TD><TD>15</TD>
<TD>CNTNAP2,MYRIP</TD></TR>
<TR><TD>3.573e-02</TD><TD>-3.33</TD><TD>KEGG_GLYCEROLIPID_METABOLISM</TD><TD>MSigDB lists</TD><TD>KEGG_GLYCEROLIPID_METABOLISM</TD><TD>43</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>ALDH2</TD></TR>
<TR><TD>3.573e-02</TD><TD>-3.33</TD><TD>DORN_ADENOVIRUS_INFECTION_24HR_DN</TD><TD>MSigDB lists</TD><TD>DORN_ADENOVIRUS_INFECTION_24HR_DN</TD><TD>43</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>NR4A1</TD></TR>
<TR><TD>3.573e-02</TD><TD>-3.33</TD><TD>GALLUZZI_PERMEABILIZE_MITOCHONDRIA</TD><TD>MSigDB lists</TD><TD>GALLUZZI_PERMEABILIZE_MITOCHONDRIA</TD><TD>43</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>NR4A1</TD></TR>
<TR><TD>3.573e-02</TD><TD>-3.33</TD><TD>PID_INTEGRIN3_PATHWAY</TD><TD>MSigDB lists</TD><TD>PID_INTEGRIN3_PATHWAY</TD><TD>43</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>COL4A5</TD></TR>
<TR><TD>3.583e-02</TD><TD>-3.33</TD><TD>forebrain development</TD><TD>biological process</TD><TD>GO:0030900</TD><TD>356</TD><TD>2</TD><TD>16441</TD><TD>14</TD>
<TD>CNTNAP2,MECOM</TD></TR>
<TR><TD>3.597e-02</TD><TD>-3.32</TD><TD>BASAKI_YBX1_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>BASAKI_YBX1_TARGETS_DN</TD><TD>359</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>PLOD2,SYTL2</TD></TR>
<TR><TD>3.654e-02</TD><TD>-3.31</TD><TD>KEGG_VALINE_LEUCINE_AND_ISOLEUCINE_DEGRADATION</TD><TD>MSigDB lists</TD><TD>KEGG_VALINE_LEUCINE_AND_ISOLEUCINE_DEGRADATION</TD><TD>44</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>ALDH2</TD></TR>
<TR><TD>3.654e-02</TD><TD>-3.31</TD><TD>RICKMAN_HEAD_AND_NECK_CANCER_B</TD><TD>MSigDB lists</TD><TD>RICKMAN_HEAD_AND_NECK_CANCER_B</TD><TD>44</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>3.654e-02</TD><TD>-3.31</TD><TD>PARK_HSC_MARKERS</TD><TD>MSigDB lists</TD><TD>PARK_HSC_MARKERS</TD><TD>44</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>MECOM</TD></TR>
<TR><TD>3.654e-02</TD><TD>-3.31</TD><TD>ZHAN_MULTIPLE_MYELOMA_CD1_UP</TD><TD>MSigDB lists</TD><TD>ZHAN_MULTIPLE_MYELOMA_CD1_UP</TD><TD>44</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>TOX2</TD></TR>
<TR><TD>3.654e-02</TD><TD>-3.31</TD><TD>CHANDRAN_METASTASIS_TOP50_DN</TD><TD>MSigDB lists</TD><TD>CHANDRAN_METASTASIS_TOP50_DN</TD><TD>44</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>NR4A1</TD></TR>
<TR><TD>3.654e-02</TD><TD>-3.31</TD><TD>NABA_COLLAGENS</TD><TD>MSigDB lists</TD><TD>NABA_COLLAGENS</TD><TD>44</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>COL4A5</TD></TR>
<TR><TD>3.654e-02</TD><TD>-3.31</TD><TD>MCDOWELL_ACUTE_LUNG_INJURY_UP</TD><TD>MSigDB lists</TD><TD>MCDOWELL_ACUTE_LUNG_INJURY_UP</TD><TD>44</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>NR4A1</TD></TR>
<TR><TD>3.674e-02</TD><TD>-3.30</TD><TD>Nuclear Receptor transcription pathway</TD><TD>REACTOME pathways</TD><TD>R-HSA-383280</TD><TD>51</TD><TD>1</TD><TD>8202</TD><TD>6</TD>
<TD>NR4A1</TD></TR>
<TR><TD>3.682e-02</TD><TD>-3.30</TD><TD>Glucocorticoid receptor regulatory network</TD><TD>Pathway Interaction DB</TD><TD>reg_gr_pathway</TD><TD>82</TD><TD>1</TD><TD>2227</TD><TD>1</TD>
<TD>NR4A1</TD></TR>
<TR><TD>3.687e-02</TD><TD>-3.30</TD><TD>nodular</TD><TD>COSMIC cancer mutations</TD><TD>nodular</TD><TD>1561</TD><TD>4</TD><TD>17775</TD><TD>15</TD>
<TD>COL4A5,MYRIP,NETO2,MECOM</TD></TR>
<TR><TD>3.708e-02</TD><TD>-3.29</TD><TD>Znf_hrmn_rcpt</TD><TD>interpro domains</TD><TD>IPR001628</TD><TD>46</TD><TD>1</TD><TD>18293</TD><TD>15</TD>
<TD>NR4A1</TD></TR>
<TR><TD>3.710e-02</TD><TD>-3.29</TD><TD>UBA5 (ubiquitin-like modifier activating enzyme 5)</TD><TD>protein interactions</TD><TD>79876</TD><TD>55</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>ALDH2</TD></TR>
<TR><TD>3.710e-02</TD><TD>-3.29</TD><TD>RPS6KA3 (ribosomal protein S6 kinase, 90kDa, polypeptide 3)</TD><TD>protein interactions</TD><TD>6197</TD><TD>55</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>NR4A1</TD></TR>
<TR><TD>3.712e-02</TD><TD>-3.29</TD><TD>FIBRINOGEN_C_2</TD><TD>prosite domains</TD><TD>PS51406</TD><TD>32</TD><TD>1</TD><TD>11866</TD><TD>14</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>3.714e-02</TD><TD>-3.29</TD><TD>Pulmonary function(PMID:21946350)</TD><TD>GWAS genes</TD><TD>Pulmonary function(PMID:21946350)</TD><TD>18</TD><TD>1</TD><TD>2389</TD><TD>5</TD>
<TD>MECOM</TD></TR>
<TR><TD>3.736e-02</TD><TD>-3.29</TD><TD>WARTERS_IR_RESPONSE_5GY</TD><TD>MSigDB lists</TD><TD>WARTERS_IR_RESPONSE_5GY</TD><TD>45</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>FAM198B</TD></TR>
<TR><TD>3.736e-02</TD><TD>-3.29</TD><TD>OSADA_ASCL1_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>OSADA_ASCL1_TARGETS_UP</TD><TD>45</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>SYTL2</TD></TR>
<TR><TD>3.742e-02</TD><TD>-3.29</TD><TD>cation binding</TD><TD>molecular function</TD><TD>GO:0043169</TD><TD>4106</TD><TD>7</TD><TD>16491</TD><TD>14</TD>
<TD>ZNF432,MFI2,PLOD2,MYRIP,NR4A1,SYTL2,MECOM</TD></TR>
<TR><TD>3.749e-02</TD><TD>-3.28</TD><TD>superpathway of tryptophan utilization</TD><TD>BIOCYC pathways</TD><TD>HUMAN_PWY66-401</TD><TD>34</TD><TD>1</TD><TD>907</TD><TD>1</TD>
<TD>ALDH2</TD></TR>
<TR><TD>3.755e-02</TD><TD>-3.28</TD><TD>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors</TD><TD>molecular function</TD><TD>GO:0016706</TD><TD>45</TD><TD>1</TD><TD>16491</TD><TD>14</TD>
<TD>PLOD2</TD></TR>
<TR><TD>3.763e-02</TD><TD>-3.28</TD><TD>Fatty acid degradation</TD><TD>KEGG pathways</TD><TD>ko00071</TD><TD>44</TD><TD>1</TD><TD>6908</TD><TD>6</TD>
<TD>ALDH2</TD></TR>
<TR><TD>3.763e-02</TD><TD>-3.28</TD><TD>Fatty acid degradation</TD><TD>KEGG pathways</TD><TD>hsa00071</TD><TD>44</TD><TD>1</TD><TD>6908</TD><TD>6</TD>
<TD>ALDH2</TD></TR>
<TR><TD>3.776e-02</TD><TD>-3.28</TD><TD>NR1H2 (nuclear receptor subfamily 1, group H, member 2)</TD><TD>protein interactions</TD><TD>7376</TD><TD>56</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>COL4A5</TD></TR>
<TR><TD>3.787e-02</TD><TD>-3.27</TD><TD>Nuclear_hrmn_rcpt</TD><TD>interpro domains</TD><TD>IPR001723</TD><TD>47</TD><TD>1</TD><TD>18293</TD><TD>15</TD>
<TD>NR4A1</TD></TR>
<TR><TD>3.801e-02</TD><TD>-3.27</TD><TD>TARTE_PLASMA_CELL_VS_PLASMABLAST_UP</TD><TD>MSigDB lists</TD><TD>TARTE_PLASMA_CELL_VS_PLASMABLAST_UP</TD><TD>370</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>ALDH2,NR4A1</TD></TR>
<TR><TD>3.811e-02</TD><TD>-3.27</TD><TD>Ldl_recept_a</TD><TD>pfam domains</TD><TD>PF00057</TD><TD>43</TD><TD>1</TD><TD>16629</TD><TD>15</TD>
<TD>NETO2</TD></TR>
<TR><TD>3.813e-02</TD><TD>-3.27</TD><TD>pleura-mesothelioma-epithelial</TD><TD>COSMIC cancer mutations</TD><TD>pleura-mesothelioma-epithelial</TD><TD>371</TD><TD>2</TD><TD>17775</TD><TD>15</TD>
<TD>CNTNAP2,TOX2</TD></TR>
<TR><TD>3.817e-02</TD><TD>-3.27</TD><TD>MELLMAN_TUT1_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>MELLMAN_TUT1_TARGETS_DN</TD><TD>46</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>ALDH2</TD></TR>
<TR><TD>3.817e-02</TD><TD>-3.27</TD><TD>ZHAN_MULTIPLE_MYELOMA_MS_UP</TD><TD>MSigDB lists</TD><TD>ZHAN_MULTIPLE_MYELOMA_MS_UP</TD><TD>46</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>MYRIP</TD></TR>
<TR><TD>3.817e-02</TD><TD>-3.27</TD><TD>PID_SYNDECAN_1_PATHWAY</TD><TD>MSigDB lists</TD><TD>PID_SYNDECAN_1_PATHWAY</TD><TD>46</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>COL4A5</TD></TR>
<TR><TD>3.826e-02</TD><TD>-3.26</TD><TD>extracellular matrix organization</TD><TD>biological process</TD><TD>GO:0030198</TD><TD>369</TD><TD>2</TD><TD>16441</TD><TD>14</TD>
<TD>COL4A5,PLOD2</TD></TR>
<TR><TD>3.837e-02</TD><TD>-3.26</TD><TD>oxidoreductase activity, acting on the aldehyde or oxo group of donors</TD><TD>molecular function</TD><TD>GO:0016903</TD><TD>46</TD><TD>1</TD><TD>16491</TD><TD>14</TD>
<TD>ALDH2</TD></TR>
<TR><TD>3.842e-02</TD><TD>-3.26</TD><TD>HADHA (hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase (trifunctional protein), alpha subunit)</TD><TD>protein interactions</TD><TD>3030</TD><TD>57</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>NR4A1</TD></TR>
<TR><TD>3.842e-02</TD><TD>-3.26</TD><TD>DERL1 (derlin 1)</TD><TD>protein interactions</TD><TD>79139</TD><TD>57</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>MFI2</TD></TR>
<TR><TD>3.845e-02</TD><TD>-3.26</TD><TD>extracellular structure organization</TD><TD>biological process</TD><TD>GO:0043062</TD><TD>370</TD><TD>2</TD><TD>16441</TD><TD>14</TD>
<TD>COL4A5,PLOD2</TD></TR>
<TR><TD>3.848e-02</TD><TD>-3.26</TD><TD>intraspecies interaction between organisms</TD><TD>biological process</TD><TD>GO:0051703</TD><TD>46</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>3.848e-02</TD><TD>-3.26</TD><TD>social behavior</TD><TD>biological process</TD><TD>GO:0035176</TD><TD>46</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>3.851e-02</TD><TD>-3.26</TD><TD>epithelial</TD><TD>COSMIC cancer mutations</TD><TD>epithelial</TD><TD>373</TD><TD>2</TD><TD>17775</TD><TD>15</TD>
<TD>CNTNAP2,TOX2</TD></TR>
<TR><TD>3.866e-02</TD><TD>-3.25</TD><TD>Nucl_hrmn_rcpt_lig-bd</TD><TD>interpro domains</TD><TD>IPR000536</TD><TD>48</TD><TD>1</TD><TD>18293</TD><TD>15</TD>
<TD>NR4A1</TD></TR>
<TR><TD>3.866e-02</TD><TD>-3.25</TD><TD>LDrepeatLR_classA_rpt</TD><TD>interpro domains</TD><TD>IPR002172</TD><TD>48</TD><TD>1</TD><TD>18293</TD><TD>15</TD>
<TD>NETO2</TD></TR>
<TR><TD>3.887e-02</TD><TD>-3.25</TD><TD>Assembly of collagen fibrils and other multimeric structures</TD><TD>REACTOME pathways</TD><TD>R-HSA-2022090</TD><TD>54</TD><TD>1</TD><TD>8202</TD><TD>6</TD>
<TD>COL4A5</TD></TR>
<TR><TD>3.889e-02</TD><TD>-3.25</TD><TD>haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-polycythaemia_vera</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-polycythaemia_vera</TD><TD>375</TD><TD>2</TD><TD>17775</TD><TD>15</TD>
<TD>MYRIP,MECOM</TD></TR>
<TR><TD>3.889e-02</TD><TD>-3.25</TD><TD>polycythaemia_vera</TD><TD>COSMIC cancer mutations</TD><TD>polycythaemia_vera</TD><TD>375</TD><TD>2</TD><TD>17775</TD><TD>15</TD>
<TD>MYRIP,MECOM</TD></TR>
<TR><TD>3.899e-02</TD><TD>-3.24</TD><TD>ZWANG_TRANSIENTLY_UP_BY_1ST_EGF_PULSE_ONLY</TD><TD>MSigDB lists</TD><TD>ZWANG_TRANSIENTLY_UP_BY_1ST_EGF_PULSE_ONLY</TD><TD>1587</TD><TD>4</TD><TD>17758</TD><TD>15</TD>
<TD>ZNF432,COL4A5,CNTNAP2,SYTL2</TD></TR>
<TR><TD>3.899e-02</TD><TD>-3.24</TD><TD>REACTOME_NUCLEAR_RECEPTOR_TRANSCRIPTION_PATHWAY</TD><TD>MSigDB lists</TD><TD>REACTOME_NUCLEAR_RECEPTOR_TRANSCRIPTION_PATHWAY</TD><TD>47</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>NR4A1</TD></TR>
<TR><TD>3.909e-02</TD><TD>-3.24</TD><TD>PELP1 (proline, glutamate and leucine rich protein 1)</TD><TD>protein interactions</TD><TD>27043</TD><TD>58</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>NR4A1</TD></TR>
<TR><TD>3.914e-02</TD><TD>-3.24</TD><TD>LINDGREN_BLADDER_CANCER_CLUSTER_2B</TD><TD>MSigDB lists</TD><TD>LINDGREN_BLADDER_CANCER_CLUSTER_2B</TD><TD>376</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>ALDH2,NR4A1</TD></TR>
<TR><TD>3.971e-02</TD><TD>-3.23</TD><TD>HAN_SATB1_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>HAN_SATB1_TARGETS_UP</TD><TD>379</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>TOX2,MECOM</TD></TR>
<TR><TD>3.976e-02</TD><TD>-3.22</TD><TD>haematopoietic_and_lymphoid_tissue-breast-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-breast-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma</TD><TD>48</TD><TD>1</TD><TD>17775</TD><TD>15</TD>
<TD>PLOD2</TD></TR>
<TR><TD>3.980e-02</TD><TD>-3.22</TD><TD>ZHU_CMV_8_HR_UP</TD><TD>MSigDB lists</TD><TD>ZHU_CMV_8_HR_UP</TD><TD>48</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>NR4A1</TD></TR>
<TR><TD>3.980e-02</TD><TD>-3.22</TD><TD>BILBAN_B_CLL_LPL_DN</TD><TD>MSigDB lists</TD><TD>BILBAN_B_CLL_LPL_DN</TD><TD>48</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>3.980e-02</TD><TD>-3.22</TD><TD>NADLER_OBESITY_DN</TD><TD>MSigDB lists</TD><TD>NADLER_OBESITY_DN</TD><TD>48</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>ALDH2</TD></TR>
<TR><TD>3.980e-02</TD><TD>-3.22</TD><TD>GYORFFY_DOXORUBICIN_RESISTANCE</TD><TD>MSigDB lists</TD><TD>GYORFFY_DOXORUBICIN_RESISTANCE</TD><TD>48</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>NETO2</TD></TR>
<TR><TD>3.980e-02</TD><TD>-3.22</TD><TD>LINDGREN_BLADDER_CANCER_HIGH_RECURRENCE</TD><TD>MSigDB lists</TD><TD>LINDGREN_BLADDER_CANCER_HIGH_RECURRENCE</TD><TD>48</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>NR4A1</TD></TR>
<TR><TD>4.012e-02</TD><TD>-3.22</TD><TD>positive regulation of fat cell differentiation</TD><TD>biological process</TD><TD>GO:0045600</TD><TD>48</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>MECOM</TD></TR>
<TR><TD>4.015e-02</TD><TD>-3.22</TD><TD>Valine, leucine and isoleucine degradation</TD><TD>KEGG pathways</TD><TD>hsa00280</TD><TD>47</TD><TD>1</TD><TD>6908</TD><TD>6</TD>
<TD>ALDH2</TD></TR>
<TR><TD>4.015e-02</TD><TD>-3.22</TD><TD>Valine, leucine and isoleucine degradation</TD><TD>KEGG pathways</TD><TD>ko00280</TD><TD>47</TD><TD>1</TD><TD>6908</TD><TD>6</TD>
<TD>ALDH2</TD></TR>
<TR><TD>4.041e-02</TD><TD>-3.21</TD><TD>Hoxa1 (homeobox A1)</TD><TD>protein interactions</TD><TD>15394</TD><TD>60</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>NR4A1</TD></TR>
<TR><TD>4.053e-02</TD><TD>-3.21</TD><TD>LAM_G_DOMAIN</TD><TD>prosite domains</TD><TD>PS50025</TD><TD>35</TD><TD>1</TD><TD>11866</TD><TD>14</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>4.062e-02</TD><TD>-3.20</TD><TD>FRASOR_TAMOXIFEN_RESPONSE_UP</TD><TD>MSigDB lists</TD><TD>FRASOR_TAMOXIFEN_RESPONSE_UP</TD><TD>49</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>MECOM</TD></TR>
<TR><TD>4.062e-02</TD><TD>-3.20</TD><TD>MODULE_61</TD><TD>MSigDB lists</TD><TD>MODULE_61</TD><TD>49</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>MECOM</TD></TR>
<TR><TD>4.062e-02</TD><TD>-3.20</TD><TD>SASAI_RESISTANCE_TO_NEOPLASTIC_TRANSFROMATION</TD><TD>MSigDB lists</TD><TD>SASAI_RESISTANCE_TO_NEOPLASTIC_TRANSFROMATION</TD><TD>49</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>PLOD2</TD></TR>
<TR><TD>4.062e-02</TD><TD>-3.20</TD><TD>SU_PANCREAS</TD><TD>MSigDB lists</TD><TD>SU_PANCREAS</TD><TD>49</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>MECOM</TD></TR>
<TR><TD>4.062e-02</TD><TD>-3.20</TD><TD>ATCMNTCCGY_UNKNOWN</TD><TD>MSigDB lists</TD><TD>ATCMNTCCGY_UNKNOWN</TD><TD>49</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>COL4A5</TD></TR>
<TR><TD>4.062e-02</TD><TD>-3.20</TD><TD>GERHOLD_ADIPOGENESIS_UP</TD><TD>MSigDB lists</TD><TD>GERHOLD_ADIPOGENESIS_UP</TD><TD>49</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>ALDH2</TD></TR>
<TR><TD>4.068e-02</TD><TD>-3.20</TD><TD>Tryptophan metabolism</TD><TD>WikiPathways</TD><TD>WP465</TD><TD>46</TD><TD>1</TD><TD>4455</TD><TD>4</TD>
<TD>ALDH2</TD></TR>
<TR><TD>4.072e-02</TD><TD>-3.20</TD><TD>zf-C4</TD><TD>pfam domains</TD><TD>PF00105</TD><TD>46</TD><TD>1</TD><TD>16629</TD><TD>15</TD>
<TD>NR4A1</TD></TR>
<TR><TD>4.082e-02</TD><TD>-3.20</TD><TD>transcription factor activity, direct ligand regulated sequence-specific DNA binding</TD><TD>molecular function</TD><TD>GO:0098531</TD><TD>49</TD><TD>1</TD><TD>16491</TD><TD>14</TD>
<TD>NR4A1</TD></TR>
<TR><TD>4.082e-02</TD><TD>-3.20</TD><TD>phosphatidylinositol-4,5-bisphosphate binding</TD><TD>molecular function</TD><TD>GO:0005546</TD><TD>49</TD><TD>1</TD><TD>16491</TD><TD>14</TD>
<TD>SYTL2</TD></TR>
<TR><TD>4.082e-02</TD><TD>-3.20</TD><TD>RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding</TD><TD>molecular function</TD><TD>GO:0004879</TD><TD>49</TD><TD>1</TD><TD>16491</TD><TD>14</TD>
<TD>NR4A1</TD></TR>
<TR><TD>4.094e-02</TD><TD>-3.20</TD><TD>negative regulation of cell-substrate adhesion</TD><TD>biological process</TD><TD>GO:0010812</TD><TD>49</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>MFI2</TD></TR>
<TR><TD>4.103e-02</TD><TD>-3.19</TD><TD>SET_dom</TD><TD>interpro domains</TD><TD>IPR001214</TD><TD>51</TD><TD>1</TD><TD>18293</TD><TD>15</TD>
<TD>MECOM</TD></TR>
<TR><TD>4.107e-02</TD><TD>-3.19</TD><TD>STRN3 (striatin, calmodulin binding protein 3)</TD><TD>protein interactions</TD><TD>29966</TD><TD>61</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>COL4A5</TD></TR>
<TR><TD>4.107e-02</TD><TD>-3.19</TD><TD>OS9 (osteosarcoma amplified 9, endoplasmic reticulum lectin)</TD><TD>protein interactions</TD><TD>10956</TD><TD>61</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>PLOD2</TD></TR>
<TR><TD>4.120e-02</TD><TD>-3.19</TD><TD>Blood pressure(PMID:21909110)</TD><TD>GWAS genes</TD><TD>Blood pressure(PMID:21909110)</TD><TD>20</TD><TD>1</TD><TD>2389</TD><TD>5</TD>
<TD>MECOM</TD></TR>
<TR><TD>4.143e-02</TD><TD>-3.18</TD><TD>BURTON_ADIPOGENESIS_PEAK_AT_2HR</TD><TD>MSigDB lists</TD><TD>BURTON_ADIPOGENESIS_PEAK_AT_2HR</TD><TD>50</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>NR4A1</TD></TR>
<TR><TD>4.143e-02</TD><TD>-3.18</TD><TD>LUI_THYROID_CANCER_CLUSTER_1</TD><TD>MSigDB lists</TD><TD>LUI_THYROID_CANCER_CLUSTER_1</TD><TD>50</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>NR4A1</TD></TR>
<TR><TD>4.158e-02</TD><TD>-3.18</TD><TD>HMG_box</TD><TD>pfam domains</TD><TD>PF00505</TD><TD>47</TD><TD>1</TD><TD>16629</TD><TD>15</TD>
<TD>TOX2</TD></TR>
<TR><TD>4.176e-02</TD><TD>-3.18</TD><TD>vesicle docking involved in exocytosis</TD><TD>biological process</TD><TD>GO:0006904</TD><TD>50</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>SYTL2</TD></TR>
<TR><TD>4.183e-02</TD><TD>-3.17</TD><TD>Arginine and proline metabolism</TD><TD>KEGG pathways</TD><TD>hsa00330</TD><TD>49</TD><TD>1</TD><TD>6908</TD><TD>6</TD>
<TD>ALDH2</TD></TR>
<TR><TD>4.183e-02</TD><TD>-3.17</TD><TD>Arginine and proline metabolism</TD><TD>KEGG pathways</TD><TD>ko00330</TD><TD>49</TD><TD>1</TD><TD>6908</TD><TD>6</TD>
<TD>ALDH2</TD></TR>
<TR><TD>4.186e-02</TD><TD>-3.17</TD><TD>neuromuscular junction</TD><TD>cellular component</TD><TD>GO:0031594</TD><TD>50</TD><TD>1</TD><TD>17570</TD><TD>15</TD>
<TD>COL4A5</TD></TR>
<TR><TD>4.224e-02</TD><TD>-3.16</TD><TD>GTAAGAT,MIR-200A</TD><TD>MSigDB lists</TD><TD>GTAAGAT,MIR-200A</TD><TD>51</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>NR4A1</TD></TR>
<TR><TD>4.224e-02</TD><TD>-3.16</TD><TD>GYORFFY_MITOXANTRONE_RESISTANCE</TD><TD>MSigDB lists</TD><TD>GYORFFY_MITOXANTRONE_RESISTANCE</TD><TD>51</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>SYTL2</TD></TR>
<TR><TD>4.235e-02</TD><TD>-3.16</TD><TD>Pathways in cancer</TD><TD>KEGG pathways</TD><TD>hsa05200</TD><TD>397</TD><TD>2</TD><TD>6908</TD><TD>6</TD>
<TD>COL4A5,MECOM</TD></TR>
<TR><TD>4.245e-02</TD><TD>-3.16</TD><TD>CUB</TD><TD>pfam domains</TD><TD>PF00431</TD><TD>48</TD><TD>1</TD><TD>16629</TD><TD>15</TD>
<TD>NETO2</TD></TR>
<TR><TD>4.245e-02</TD><TD>-3.16</TD><TD>Hormone_recep</TD><TD>pfam domains</TD><TD>PF00104</TD><TD>48</TD><TD>1</TD><TD>16629</TD><TD>15</TD>
<TD>NR4A1</TD></TR>
<TR><TD>4.268e-02</TD><TD>-3.15</TD><TD>ionotropic glutamate receptor complex</TD><TD>cellular component</TD><TD>GO:0008328</TD><TD>51</TD><TD>1</TD><TD>17570</TD><TD>15</TD>
<TD>NETO2</TD></TR>
<TR><TD>4.305e-02</TD><TD>-3.15</TD><TD>C14orf1 (chromosome 14 open reading frame 1)</TD><TD>protein interactions</TD><TD>11161</TD><TD>64</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>ALDH2</TD></TR>
<TR><TD>4.305e-02</TD><TD>-3.15</TD><TD>HLA-C (major histocompatibility complex, class I, C)</TD><TD>protein interactions</TD><TD>3107</TD><TD>64</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>NETO2</TD></TR>
<TR><TD>4.305e-02</TD><TD>-3.15</TD><TD>MIKKELSEN_IPS_ICP_WITH_H3K27ME3</TD><TD>MSigDB lists</TD><TD>MIKKELSEN_IPS_ICP_WITH_H3K27ME3</TD><TD>52</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>4.305e-02</TD><TD>-3.15</TD><TD>KEGG_ARGININE_AND_PROLINE_METABOLISM</TD><TD>MSigDB lists</TD><TD>KEGG_ARGININE_AND_PROLINE_METABOLISM</TD><TD>52</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>ALDH2</TD></TR>
<TR><TD>4.321e-02</TD><TD>-3.14</TD><TD>bone</TD><TD>COSMIC cancer mutations</TD><TD>bone</TD><TD>8539</TD><TD>11</TD><TD>17775</TD><TD>15</TD>
<TD>ZNF432,ALDH2,MFI2,PLOD2,NR4A1,SUN3,COL4A5,FAM198B,CNTNAP2,SYTL2,MECOM</TD></TR>
<TR><TD>4.339e-02</TD><TD>-3.14</TD><TD>HMG_box_dom</TD><TD>interpro domains</TD><TD>IPR009071</TD><TD>54</TD><TD>1</TD><TD>18293</TD><TD>15</TD>
<TD>TOX2</TD></TR>
<TR><TD>4.349e-02</TD><TD>-3.14</TD><TD>HNRNPA1 (heterogeneous nuclear ribonucleoprotein A1)</TD><TD>protein interactions</TD><TD>3178</TD><TD>495</TD><TD>2</TD><TD>16036</TD><TD>11</TD>
<TD>PLOD2,SYTL2</TD></TR>
<TR><TD>4.371e-02</TD><TD>-3.13</TD><TD>RPS6KA5 (ribosomal protein S6 kinase, 90kDa, polypeptide 5)</TD><TD>protein interactions</TD><TD>9252</TD><TD>65</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>NR4A1</TD></TR>
<TR><TD>4.386e-02</TD><TD>-3.13</TD><TD>WU_SILENCED_BY_METHYLATION_IN_BLADDER_CANCER</TD><TD>MSigDB lists</TD><TD>WU_SILENCED_BY_METHYLATION_IN_BLADDER_CANCER</TD><TD>53</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>NR4A1</TD></TR>
<TR><TD>4.386e-02</TD><TD>-3.13</TD><TD>VANTVEER_BREAST_CANCER_METASTASIS_UP</TD><TD>MSigDB lists</TD><TD>VANTVEER_BREAST_CANCER_METASTASIS_UP</TD><TD>53</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>MYRIP</TD></TR>
<TR><TD>4.386e-02</TD><TD>-3.13</TD><TD>PID_NFAT_3PATHWAY</TD><TD>MSigDB lists</TD><TD>PID_NFAT_3PATHWAY</TD><TD>53</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>NR4A1</TD></TR>
<TR><TD>4.386e-02</TD><TD>-3.13</TD><TD>TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_GRANULOCYTE_UP</TD><TD>MSigDB lists</TD><TD>TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_GRANULOCYTE_UP</TD><TD>53</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>MECOM</TD></TR>
<TR><TD>4.386e-02</TD><TD>-3.13</TD><TD>WATTEL_AUTONOMOUS_THYROID_ADENOMA_DN</TD><TD>MSigDB lists</TD><TD>WATTEL_AUTONOMOUS_THYROID_ADENOMA_DN</TD><TD>53</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>NR4A1</TD></TR>
<TR><TD>4.386e-02</TD><TD>-3.13</TD><TD>BOYLAN_MULTIPLE_MYELOMA_C_DN</TD><TD>MSigDB lists</TD><TD>BOYLAN_MULTIPLE_MYELOMA_C_DN</TD><TD>53</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>PLOD2</TD></TR>
<TR><TD>4.411e-02</TD><TD>-3.12</TD><TD>DNA binding</TD><TD>molecular function</TD><TD>GO:0003677</TD><TD>2437</TD><TD>5</TD><TD>16491</TD><TD>14</TD>
<TD>ZNF432,ASCL5,NR4A1,TOX2,MECOM</TD></TR>
<TR><TD>4.418e-02</TD><TD>-3.12</TD><TD>CUB_dom</TD><TD>interpro domains</TD><TD>IPR000859</TD><TD>55</TD><TD>1</TD><TD>18293</TD><TD>15</TD>
<TD>NETO2</TD></TR>
<TR><TD>4.421e-02</TD><TD>-3.12</TD><TD>alcohol catabolic process</TD><TD>biological process</TD><TD>GO:0046164</TD><TD>53</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>ALDH2</TD></TR>
<TR><TD>4.431e-02</TD><TD>-3.12</TD><TD>ankle</TD><TD>COSMIC cancer mutations</TD><TD>ankle</TD><TD>403</TD><TD>2</TD><TD>17775</TD><TD>15</TD>
<TD>ALDH2,CNTNAP2</TD></TR>
<TR><TD>4.437e-02</TD><TD>-3.12</TD><TD>NRG1 (neuregulin 1)</TD><TD>protein interactions</TD><TD>3084</TD><TD>66</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>NETO2</TD></TR>
<TR><TD>4.437e-02</TD><TD>-3.12</TD><TD>CHRNA9 (cholinergic receptor, nicotinic alpha 9)</TD><TD>protein interactions</TD><TD>55584</TD><TD>66</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>NETO2</TD></TR>
<TR><TD>4.444e-02</TD><TD>-3.11</TD><TD>membrane organization</TD><TD>biological process</TD><TD>GO:0061024</TD><TD>959</TD><TD>3</TD><TD>16441</TD><TD>14</TD>
<TD>SUN3,CNTNAP2,SYTL2</TD></TR>
<TR><TD>4.467e-02</TD><TD>-3.11</TD><TD>MODULE_175</TD><TD>MSigDB lists</TD><TD>MODULE_175</TD><TD>54</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>PLOD2</TD></TR>
<TR><TD>4.467e-02</TD><TD>-3.11</TD><TD>REACTOME_PI_3K_CASCADE</TD><TD>MSigDB lists</TD><TD>REACTOME_PI_3K_CASCADE</TD><TD>54</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>NR4A1</TD></TR>
<TR><TD>4.474e-02</TD><TD>-3.11</TD><TD>skin-scalp-carcinoma-squamous_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-scalp-carcinoma-squamous_cell_carcinoma</TD><TD>1659</TD><TD>4</TD><TD>17775</TD><TD>15</TD>
<TD>ZNF432,FAM198B,SYTL2,MECOM</TD></TR>
<TR><TD>4.499e-02</TD><TD>-3.10</TD><TD>YAGI_AML_WITH_INV_16_TRANSLOCATION</TD><TD>MSigDB lists</TD><TD>YAGI_AML_WITH_INV_16_TRANSLOCATION</TD><TD>406</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>MFI2,NR4A1</TD></TR>
<TR><TD>4.503e-02</TD><TD>-3.10</TD><TD>endothelial cell migration</TD><TD>biological process</TD><TD>GO:0043542</TD><TD>54</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>NR4A1</TD></TR>
<TR><TD>4.525e-02</TD><TD>-3.10</TD><TD>nuclear envelope</TD><TD>cellular component</TD><TD>GO:0005635</TD><TD>403</TD><TD>2</TD><TD>17570</TD><TD>15</TD>
<TD>SUN3,NR4A1</TD></TR>
<TR><TD>4.548e-02</TD><TD>-3.09</TD><TD>LIM_MAMMARY_LUMINAL_PROGENITOR_UP</TD><TD>MSigDB lists</TD><TD>LIM_MAMMARY_LUMINAL_PROGENITOR_UP</TD><TD>55</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>MFI2</TD></TR>
<TR><TD>4.568e-02</TD><TD>-3.09</TD><TD>GANAB (glucosidase, alpha; neutral AB)</TD><TD>protein interactions</TD><TD>23193</TD><TD>68</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>PLOD2</TD></TR>
<TR><TD>4.568e-02</TD><TD>-3.09</TD><TD>XPO7 (exportin 7)</TD><TD>protein interactions</TD><TD>23039</TD><TD>68</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>PLOD2</TD></TR>
<TR><TD>4.571e-02</TD><TD>-3.09</TD><TD>calcium-dependent phospholipid binding</TD><TD>molecular function</TD><TD>GO:0005544</TD><TD>55</TD><TD>1</TD><TD>16491</TD><TD>14</TD>
<TD>SYTL2</TD></TR>
<TR><TD>4.571e-02</TD><TD>-3.09</TD><TD>steroid hormone receptor activity</TD><TD>molecular function</TD><TD>GO:0003707</TD><TD>55</TD><TD>1</TD><TD>16491</TD><TD>14</TD>
<TD>NR4A1</TD></TR>
<TR><TD>4.575e-02</TD><TD>-3.08</TD><TD>Znf_NHR/GATA</TD><TD>interpro domains</TD><TD>IPR013088</TD><TD>57</TD><TD>1</TD><TD>18293</TD><TD>15</TD>
<TD>NR4A1</TD></TR>
<TR><TD>4.579e-02</TD><TD>-3.08</TD><TD>JOHNSTONE_PARVB_TARGETS_3_UP</TD><TD>MSigDB lists</TD><TD>JOHNSTONE_PARVB_TARGETS_3_UP</TD><TD>410</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>MFI2,TOX2</TD></TR>
<TR><TD>4.593e-02</TD><TD>-3.08</TD><TD>PKMTs methylate histone lysines</TD><TD>REACTOME pathways</TD><TD>R-HSA-3214841</TD><TD>64</TD><TD>1</TD><TD>8202</TD><TD>6</TD>
<TD>MECOM</TD></TR>
<TR><TD>4.629e-02</TD><TD>-3.07</TD><TD>MCCLUNG_CREB1_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>MCCLUNG_CREB1_TARGETS_DN</TD><TD>56</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>ALDH2</TD></TR>
<TR><TD>4.629e-02</TD><TD>-3.07</TD><TD>HUTTMANN_B_CLL_POOR_SURVIVAL_DN</TD><TD>MSigDB lists</TD><TD>HUTTMANN_B_CLL_POOR_SURVIVAL_DN</TD><TD>56</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>4.629e-02</TD><TD>-3.07</TD><TD>MORI_LARGE_PRE_BII_LYMPHOCYTE_DN</TD><TD>MSigDB lists</TD><TD>MORI_LARGE_PRE_BII_LYMPHOCYTE_DN</TD><TD>56</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>ALDH2</TD></TR>
<TR><TD>4.629e-02</TD><TD>-3.07</TD><TD>NAGASHIMA_EGF_SIGNALING_UP</TD><TD>MSigDB lists</TD><TD>NAGASHIMA_EGF_SIGNALING_UP</TD><TD>56</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>NR4A1</TD></TR>
<TR><TD>4.629e-02</TD><TD>-3.07</TD><TD>MODULE_350</TD><TD>MSigDB lists</TD><TD>MODULE_350</TD><TD>56</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>PLOD2</TD></TR>
<TR><TD>4.634e-02</TD><TD>-3.07</TD><TD>PON2 (paraoxonase 2)</TD><TD>protein interactions</TD><TD>5445</TD><TD>69</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>NETO2</TD></TR>
<TR><TD>4.634e-02</TD><TD>-3.07</TD><TD>CHEK2 (checkpoint kinase 2)</TD><TD>protein interactions</TD><TD>11200</TD><TD>69</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>NR4A1</TD></TR>
<TR><TD>4.634e-02</TD><TD>-3.07</TD><TD>MBD3 (methyl-CpG binding domain protein 3)</TD><TD>protein interactions</TD><TD>53615</TD><TD>69</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>MECOM</TD></TR>
<TR><TD>4.637e-02</TD><TD>-3.07</TD><TD>BENPORATH_SUZ12_TARGETS</TD><TD>MSigDB lists</TD><TD>BENPORATH_SUZ12_TARGETS</TD><TD>980</TD><TD>3</TD><TD>17758</TD><TD>15</TD>
<TD>COL4A5,TOX2,MECOM</TD></TR>
<TR><TD>4.654e-02</TD><TD>-3.07</TD><TD>Laminin_G</TD><TD>interpro domains</TD><TD>IPR001791</TD><TD>58</TD><TD>1</TD><TD>18293</TD><TD>15</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>4.654e-02</TD><TD>-3.07</TD><TD>urinary_tract-bladder-carcinoma-transitional_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>urinary_tract-bladder-carcinoma-transitional_cell_carcinoma</TD><TD>6320</TD><TD>9</TD><TD>17775</TD><TD>15</TD>
<TD>ZNF432,ALDH2,NR4A1,TOX2,COL4A5,CNTNAP2,MYRIP,SYTL2,MECOM</TD></TR>
<TR><TD>4.663e-02</TD><TD>-3.07</TD><TD>transitional_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>transitional_cell_carcinoma</TD><TD>6322</TD><TD>9</TD><TD>17775</TD><TD>15</TD>
<TD>ZNF432,ALDH2,NR4A1,TOX2,COL4A5,CNTNAP2,MYRIP,SYTL2,MECOM</TD></TR>
<TR><TD>4.677e-02</TD><TD>-3.06</TD><TD>main axon</TD><TD>cellular component</TD><TD>GO:0044304</TD><TD>56</TD><TD>1</TD><TD>17570</TD><TD>15</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>4.710e-02</TD><TD>-3.06</TD><TD>EXTRACELLULAR_MATRIX_PART</TD><TD>MSigDB lists</TD><TD>EXTRACELLULAR_MATRIX_PART</TD><TD>57</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>COL4A5</TD></TR>
<TR><TD>4.710e-02</TD><TD>-3.06</TD><TD>chr3q26</TD><TD>MSigDB lists</TD><TD>chr3q26</TD><TD>57</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>MECOM</TD></TR>
<TR><TD>4.710e-02</TD><TD>-3.06</TD><TD>GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_BLUE_DN</TD><TD>MSigDB lists</TD><TD>GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_BLUE_DN</TD><TD>57</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>MECOM</TD></TR>
<TR><TD>4.740e-02</TD><TD>-3.05</TD><TD>organelle</TD><TD>cellular component</TD><TD>GO:0043226</TD><TD>12606</TD><TD>14</TD><TD>17570</TD><TD>15</TD>
<TD>ZNF432,ALDH2,MFI2,PLOD2,ASCL5,NR4A1,TOX2,SUN3,COL4A5,CNTNAP2,FAM198B,MYRIP,SYTL2,MECOM</TD></TR>
<TR><TD>4.748e-02</TD><TD>-3.05</TD><TD>steroid hormone mediated signaling pathway</TD><TD>biological process</TD><TD>GO:0043401</TD><TD>57</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>NR4A1</TD></TR>
<TR><TD>4.748e-02</TD><TD>-3.05</TD><TD>iron ion transport</TD><TD>biological process</TD><TD>GO:0006826</TD><TD>57</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>MFI2</TD></TR>
<TR><TD>4.748e-02</TD><TD>-3.05</TD><TD>vesicle docking</TD><TD>biological process</TD><TD>GO:0048278</TD><TD>57</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>SYTL2</TD></TR>
<TR><TD>4.761e-02</TD><TD>-3.04</TD><TD>protein localization</TD><TD>biological process</TD><TD>GO:0008104</TD><TD>1685</TD><TD>4</TD><TD>16441</TD><TD>14</TD>
<TD>SUN3,CNTNAP2,MYRIP,SYTL2</TD></TR>
<TR><TD>4.782e-02</TD><TD>-3.04</TD><TD>HAN_SATB1_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>HAN_SATB1_TARGETS_DN</TD><TD>420</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>COL4A5,PLOD2</TD></TR>
<TR><TD>4.791e-02</TD><TD>-3.04</TD><TD>NAKAMURA_ADIPOGENESIS_EARLY_UP</TD><TD>MSigDB lists</TD><TD>NAKAMURA_ADIPOGENESIS_EARLY_UP</TD><TD>58</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>FAM198B</TD></TR>
<TR><TD>4.791e-02</TD><TD>-3.04</TD><TD>LEE_LIVER_CANCER_DENA_UP</TD><TD>MSigDB lists</TD><TD>LEE_LIVER_CANCER_DENA_UP</TD><TD>58</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>COL4A5</TD></TR>
<TR><TD>4.791e-02</TD><TD>-3.04</TD><TD>ACAWNRNSRCGG_UNKNOWN</TD><TD>MSigDB lists</TD><TD>ACAWNRNSRCGG_UNKNOWN</TD><TD>58</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>NR4A1</TD></TR>
<TR><TD>4.806e-02</TD><TD>-3.04</TD><TD>positive regulation of gene expression</TD><TD>biological process</TD><TD>GO:0010628</TD><TD>1690</TD><TD>4</TD><TD>16441</TD><TD>14</TD>
<TD>MFI2,NR4A1,TOX2,MECOM</TD></TR>
<TR><TD>4.815e-02</TD><TD>-3.03</TD><TD>modified amino acid binding</TD><TD>molecular function</TD><TD>GO:0072341</TD><TD>58</TD><TD>1</TD><TD>16491</TD><TD>14</TD>
<TD>SYTL2</TD></TR>
<TR><TD>4.823e-02</TD><TD>-3.03</TD><TD>MARTENS_BOUND_BY_PML_RARA_FUSION</TD><TD>MSigDB lists</TD><TD>MARTENS_BOUND_BY_PML_RARA_FUSION</TD><TD>422</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>ALDH2,TOX2</TD></TR>
<TR><TD>4.823e-02</TD><TD>-3.03</TD><TD>RGAANNTTC_V$HSF1_01</TD><TD>MSigDB lists</TD><TD>RGAANNTTC_V$HSF1_01</TD><TD>422</TD><TD>2</TD><TD>17758</TD><TD>15</TD>
<TD>COL4A5,NETO2</TD></TR>
<TR><TD>4.831e-02</TD><TD>-3.03</TD><TD>MED31 (mediator complex subunit 31)</TD><TD>protein interactions</TD><TD>51003</TD><TD>72</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>NR4A1</TD></TR>
<TR><TD>4.871e-02</TD><TD>-3.02</TD><TD>BROWNE_HCMV_INFECTION_1HR_UP</TD><TD>MSigDB lists</TD><TD>BROWNE_HCMV_INFECTION_1HR_UP</TD><TD>59</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>NR4A1</TD></TR>
<TR><TD>4.889e-02</TD><TD>-3.02</TD><TD>Znf_RING/FYVE/PHD</TD><TD>interpro domains</TD><TD>IPR013083</TD><TD>438</TD><TD>2</TD><TD>18293</TD><TD>15</TD>
<TD>MYRIP,SYTL2</TD></TR>
<TR><TD>4.897e-02</TD><TD>-3.02</TD><TD>SUGT1 (SGT1 homolog, MIS12 kinetochore complex assembly cochaperone)</TD><TD>protein interactions</TD><TD>10910</TD><TD>73</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>NR4A1</TD></TR>
<TR><TD>4.910e-02</TD><TD>-3.01</TD><TD>transmission of nerve impulse</TD><TD>biological process</TD><TD>GO:0019226</TD><TD>59</TD><TD>1</TD><TD>16441</TD><TD>14</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>4.922e-02</TD><TD>-3.01</TD><TD>histone deacetylase complex</TD><TD>cellular component</TD><TD>GO:0000118</TD><TD>59</TD><TD>1</TD><TD>17570</TD><TD>15</TD>
<TD>MECOM</TD></TR>
<TR><TD>4.952e-02</TD><TD>-3.01</TD><TD>RAMASWAMY_METASTASIS_DN</TD><TD>MSigDB lists</TD><TD>RAMASWAMY_METASTASIS_DN</TD><TD>60</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>NR4A1</TD></TR>
<TR><TD>4.952e-02</TD><TD>-3.01</TD><TD>KEGG_GLYCOLYSIS_GLUCONEOGENESIS</TD><TD>MSigDB lists</TD><TD>KEGG_GLYCOLYSIS_GLUCONEOGENESIS</TD><TD>60</TD><TD>1</TD><TD>17758</TD><TD>15</TD>
<TD>ALDH2</TD></TR>
<TR><TD>4.958e-02</TD><TD>-3.00</TD><TD>LDLRA_1</TD><TD>prosite domains</TD><TD>PS01209</TD><TD>43</TD><TD>1</TD><TD>11866</TD><TD>14</TD>
<TD>NETO2</TD></TR>
<TR><TD>4.962e-02</TD><TD>-3.00</TD><TD>KRTAP10-1 (keratin associated protein 10-1)</TD><TD>protein interactions</TD><TD>386677</TD><TD>74</TD><TD>1</TD><TD>16036</TD><TD>11</TD>
<TD>NR4A1</TD></TR>
<TR><TD>4.968e-02</TD><TD>-3.00</TD><TD>human chr1q32.1</TD><TD>chromosome location</TD><TD>human chr1q32.1</TD><TD>89</TD><TD>1</TD><TD>26250</TD><TD>15</TD>
<TD>ASCL5</TD></TR>
<TR><TD>4.973e-02</TD><TD>-3.00</TD><TD>response to hormone</TD><TD>biological process</TD><TD>GO:0009725</TD><TD>1003</TD><TD>3</TD><TD>16441</TD><TD>14</TD>
<TD>PLOD2,NR4A1,TOX2</TD></TR>
<TR><TD>4.985e-02</TD><TD>-3.00</TD><TD>single-organism catabolic process</TD><TD>biological process</TD><TD>GO:0044712</TD><TD>1004</TD><TD>3</TD><TD>16441</TD><TD>14</TD>
<TD>COL4A5,ALDH2,PLOD2</TD></TR>
</TABLE>
</BODY></HTML>
